Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 1 of 41 Page ID #2744

EXHIBIT B



Deposition of **Richard Cavalli**

Volume II

Date: August 23, 2022

Case: IN RE: PARAQUAT PRODUCTS LIABILITY LITIGATION

No. 3:21-md-3004-NJR

Court Reporter: Angela M. Taylor, RPR, IL-CSR, MO-CCR, LA-CCR, WA-CCR

Paszkiewicz Court Reporting Phone: 618-307-9320 Toll-Free: 855-595-3577 Fax: 618-855-9513

CONFIDE	
	TES DISTRICT COURT ISTRICT OF ILLINOIS
IN RE: PARAQUAT PRODUCTS LIABILITY LITIGATION)
))Case Number)3:21-md-3004-NJR
))MDL No. 3004)
THIS DOCUMENT RELATES TO ALL CASES.)))
* * HIGHLY CONFIDENTIAL	
30(b)(6) VIDEOTA	PED DEPOSIITON OF
30(b)(6) VIDEOTA CHEVRON BY: RICHAR	PED DEPOSIITON OF D CAVALLI, VOLUME II
30(b)(6) VIDEOTA CHEVRON BY: RICHAR	PED DEPOSIITON OF
30(b)(6) VIDEOTA CHEVRON BY: RICHAR	PED DEPOSIITON OF D CAVALLI, VOLUME II

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 4 of 41 Page ID #2747

Richard Cavalli August 23, 2022

ſ		
	Page 2	ENITIAI Page 4
1	PURSUANT TO WRITTEN NOTICE AND 26 AND	1 APPEARANCES (CONTINUED):
2	30(B)(6) OF THE FEDERAL RULES OF CIVIL PROCEDURE, the	2 Also Present: 3 Devin Williams
3	30(b)(6) videotaped deposition of CHEVRON BY:	Videographer
4	RICHARD CAVALLI, VOLUME II, called by Plaintiffs, was	4 Scott Sill
5	taken commencing at 8:41 a.m. Pacific Time Zone on	5 Audio-Video Tech Team Manager
6	August 23, 2022, at 14811 Kruse Oaks Drive, Lake	Paszkiewicz Reporting
7	Oswego, Oregon, 97035, before Angela M. Taylor, CSR,	7 APPEARANCES VIA VIDEOCONFERENCE:
8	CCR, RPR.	8 For the MDL Plaintiffs:
9		9
10		Sarah Shoemake Doles, Esq. 10 Alyson M. Petrick, Esq.
		Levin Papantonio Rafferty Proctor 11 Buchanan O'Brien Barr & Mougev P.A
11		11 Buchanan O'Brien Barr & Mougey P.A 316 South Baylen Street
12		12 Pensacola, Florida 32502 13 and
13		13 and 14 Chad Finley, Esq.
14		Tor Hoerman Law, LLC 15 210 South Main Street
15		Edwardsville, Illinois 62025
16		16
17		and 17
18		Khaldoun A. Baghdadi, Esq. 18 Walkup Melodia Kelly + Schoenberger
19		650 California Street
20		19 San Francisco California 94108 20
21		21 For the Defendant Chevron U.S.A. Inc.:
22		22 Jennifer Cecil, Esq. Husch Blackwell, LLP
23		23 190 Carondelet Plaza, Suite 600
24		St. Louis, MO 63105
25		and
25		and 25
25	Page 3	
25	Page 3	25 Page 5
1 2	APPEARANCES:	25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2
1	APPEARANCES: For the MDL Plaintiffs:	25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq.
1 2 3 4	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA	25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq. Debra R. Belott, Esq.
1 2 3	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor	 25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq. Debra R. Belott, Esq. 4 Jones Day 51 Louisiana Avenue, N.W.
1 2 3 4	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113	 25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq. 9 Debra R. Belott, Esq. 4 Jones Day 51 Louisiana Avenue, N.W. 5 Washington, D.C. 20001-2113
1 2 3 4 5	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor	 25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq. 9 Debra R. Belott, Esq. 4 Jones Day 51 Louisiana Avenue, N.W. 5 Washington, D.C. 20001-2113
1 2 3 4 5 6 7	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC:
1 2 3 4 5 6	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and	 25 Page 5 1 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: 2 3 Leon F. DeJulius, Esq. Debra R. Belott, Esq. 4 Jones Day 51 Louisiana Avenue, N.W. 5 Washington, D.C. 20001-2113 6 7 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: 8
1 2 3 4 5 6 7 8 9	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC:
1 2 3 4 5 6 7 8	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP
1 2 3 4 5 6 7 8 9 10 11	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 10 1301 Pennsylvania Avenue, N.W.
1 2 3 4 5 6 7 8 9 10	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP
1 2 3 4 5 6 7 8 9 10 11 12 12	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller:
1 2 3 4 5 6 7 8 9 10 11 12 13 14	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq.
1 2 3 4 5 6 7 8 9 10 11 12 12	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference):
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	APPEARANCES: For the MDL Plaintiffs: R. Fric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2000 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Myers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq. Jones Day 555 South Flowers Street, 50th Floor	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting Nicholas Campbell
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq. Jones Day 555 South Flowers Street, 50th Floor Los Angeles, California 90071	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting Nicholas Campbell Scheduling Manager Paszkiewicz Reporting Nicholas Campbell Scheduling Manager Paszkiewicz Reporting
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq. Jones Day 555 South Flowers Street, 50th Floor Los Angeles, California 90071 and Megan A. Scheiderer, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting Nicholas Campbell Scheduling Manager Paszkiewicz Reporting Paszkiewicz Reporting Paszkiewicz Reporting
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2000 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq. Jones Day 255 South Flowers Street, 50th Floor Los Angeles, California 90071 and Megan A. Scheiderer, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting Nicholas Campbell Scheduling Manager Paszkiewicz Reporting Paszkiewicz Reporting
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	APPEARANCES: For the MDL Plaintiffs: R. Eric Kennedy, Esq. Weisman Kennedy & Berris Co., LPA 2900 Detroit Avenue, 2nd Floor Cleveland, Ohio 44113 and Michael A. Kelly, Esq. Walkup, Melodia, Kelly & Schoenberger 650 California Street, 26th Floor San Francisco, California 94108 and Peter J. Flowers, Esq. Frank V. Cesarone, Esq. Meyers & Flowers, LLC 3 North Second Street, Suite 300 Saint Charles, Illinois 60174 For the Defendant Chevron U.S.A. Inc.: Sharyl A. Reisman, Esq. Jones Day 250 Vesey Street New York, NY 10281 and David J. DiMeglio, Esq. Jones Day 555 South Flowers Street, 50th Floor Los Angeles, California 90071 and Megan A. Scheiderer, Esq.	 25 Page 5 APPEARANCES (CONTINUED) VIA VIDEOCONFERENCE: Leon F. DeJulius, Esq. Debra R. Belott, Esq. Jones Day 51 Louisiana Avenue, N.W. Washington, D.C. 20001-2113 For the Defendant Syngenta AG and Syngenta Crop Protection LLC: Ragan Naresh, Esq. Grace C. Brier, Esq. Kirkland & Ellis LLP 1301 Pennsylvania Avenue, N.W. Washington, D.C. 20004 For the Plaintiff Keith Fuller: Leslie LaMacchia, Esq. LaMacchia Law, P.C. PO Box 131812 Houston, TX 77219 Also Present (via videoconference): Jodee Whitley Operations Manager Paszkiewicz Reporting Nicholas Campbell Scheduling Manager Paszkiewicz Reporting Paszkiewicz Reporting Paszkiewicz Reporting

2 (Pages 2 to 5)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 5 of 41 Page ID #2748

Richard Cavalli August 23, 2022

Page 6	
rage o	ENITTAT Page 8
1 INDEX OF EXAMINATION	\square And I'm going to continue this morning
2 QUESTIONS BY MR. KELLY	 talking about topics that were raised in the direct
QUESTIONS BY MR. KENNEDY	
3 QUESTIONS BY MS. REISMAN126 QUESTIONS BY MR. KENNEDY145	3 yesterday, and then as I mentioned yesterday, my
4	4 colleague has questions as well that may be different
5 INDEX OF EXHIBITS	5 and independent of that.
6 Exhibit 24, Neurotoxicology, Volume 19 by Roizin, et al.	6 MS. REISMAN: Mr. Kelly, I just have a
7 Exhibit 51, Letter by J.N. Ospenson29	7 question. You handed each of us a copy. Is one of
Exhibit 49, Notes on Meetings Held at	8 these intended for the court reporter or
8 CTL 6-9 October '75 Exhibit 48, 3/29/76 Memo from Cavalli to Ospenson 50	9 MR. KELLY: Oh, I thought the court reporter
9 Exhibit 50, 9/29/76 Letter from Cavalli	10 would get them. Sure. Why don't you give it to the
to Ospenson with Meeting Minutes	11 court reporter, please.
10 Exhibit 43, Paraquat Worker Safety63 Exhibit 45, 11/14/85 Letter to J.N. Sullivan68	12 MS. REISMAN: That's okay.
11 from J.N. Ospenson	13 MR. KELLY: Yeah. You have your own, I
Exhibit 111,A Study of the Health of Malaysian103	14 assume. Sorry.
12 Plantation Workers with Particular Reference to Paraquat Spraymen by J.K.	15 THE WITNESS: Am I supposed
13 Howard, et al	16 MS. REISMAN: Nothing you need to do.
Exhibit 40, The Toxicity of Paraquat	17 MR. KELLY: I have I have a third one.
14 by D.G. Clark, et al.	18 You don't have to do anything with it, sir.
16 (Exhibits are attached to transcript.)	19 THE WITNESS: Excellent.
17	20 Q (By Mr. Kelly) Okay. In the direct
18 19	 examination yesterday when you were asked what you did
20	22 to learn about what other scientists and researchers
21 22	were doing and learning about paraquat, you mentioned
22 23	 that you had access to the toxicology literature and
24	24 that you had access to the toxicology interature and 25 the medical literature from all over the world; is that
25	2.5 the medical metature from an over the world, is that
Page 7	Page 9
1 TUESDAY, AUGUST 23, 2022	1 true?
2 8:41 A.M. PACIFIC TIME	2 A I did have access to that.
3	3 Q And then that you had a system that would
4	4 flag papers and publications about paraquat, and your
5 VIDEOGRAPHER: Stand by. Good morning. We	5 library would get copies of those?
6 are now on the record. This is Volume II of the	6 A Yes.
1 1 5	
	 8 not a good question. Let me back up. 9 Was the purpose for doing that so that you
	was the purpose for doing that so that you
9 8:41 a.m.	· · · · · · · · · · · · · · · · · · ·
10 The witness has been previously sworn. You	10 could keep abreast of the relevant scholarly
10 The witness has been previously sworn. You 11 may begin.	 could keep abreast of the relevant scholarly literature that dealt with, among other things, the
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. 	 could keep abreast of the relevant scholarly literature that dealt with, among other things, the risk to human health of exposure to paraquat?
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. [EXAMINATION] 	 could keep abreast of the relevant scholarly literature that dealt with, among other things, the risk to human health of exposure to paraquat? MS. REISMAN: Objection to form.
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. [EXAMINATION] QUESTIONS BY MR. KELLY: 	 could keep abreast of the relevant scholarly literature that dealt with, among other things, the risk to human health of exposure to paraquat? MS. REISMAN: Objection to form. A Yes.
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. [EXAMINATION] QUESTIONS BY MR. KELLY: Q Good morning, Mr. Cavalli. 	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. [EXAMINATION] QUESTIONS BY MR. KELLY: Q Good morning, Mr. Cavalli. A Good morning. 	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've 16 marked as Exhibit 24.
 The witness has been previously sworn. You may begin. MR. KELLY: Thank you. [EXAMINATION] QUESTIONS BY MR. KELLY: Q Good morning, Mr. Cavalli. 	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am.	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've 16 marked as Exhibit 24.
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning?	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've 16 marked as Exhibit 24. 17 MS. REISMAN: Can we go off the record for
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am.	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've 16 marked as Exhibit 24. 17 MS. REISMAN: Can we go off the record for 18 one minute?
 10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am. 19 Q Terrific. 	 10 could keep abreast of the relevant scholarly 11 literature that dealt with, among other things, the 12 risk to human health of exposure to paraquat? 13 MS. REISMAN: Objection to form. 14 A Yes. 15 Q (By Mr. Kelly) Let me show you what we've 16 marked as Exhibit 24. 17 MS. REISMAN: Can we go off the record for 18 one minute? 19 VIDEOGRAPHER: Going off the record at
10The witness has been previously sworn. You11may begin.12MR. KELLY: Thank you.13[EXAMINATION]14QUESTIONS BY MR. KELLY:15Q16AAGood morning.17Q18A19Q20MR. KELLY: Let me just small piece of	10could keep abreast of the relevant scholarly11literature that dealt with, among other things, the12risk to human health of exposure to paraquat?13MS. REISMAN: Objection to form.14A Yes.15Q (By Mr. Kelly) Let me show you what we've16marked as Exhibit 24.17MS. REISMAN: Can we go off the record for18one minute?19VIDEOGRAPHER: Going off the record at208:43 a.m.21(A break was taken.)
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am. 19 Q Terrific. 20 MR. KELLY: Let me just small piece of 21 housekeeping from yesterday I intended to do but 22 didn't. Let me mark and attach the disclosure of	10could keep abreast of the relevant scholarly11literature that dealt with, among other things, the12risk to human health of exposure to paraquat?13MS. REISMAN: Objection to form.14A Yes.15Q (By Mr. Kelly) Let me show you what we've16marked as Exhibit 24.17MS. REISMAN: Can we go off the record for18one minute?19VIDEOGRAPHER: Going off the record at208:43 a.m.21(A break was taken.)
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am. 19 Q Terrific. 20 MR. KELLY: Let me just small piece of 21 housekeeping from yesterday I intended to do but 22 didn't. Let me mark and attach the disclosure of 23 nonretained expert that was served in the case for use	 could keep abreast of the relevant scholarly literature that dealt with, among other things, the risk to human health of exposure to paraquat? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Let me show you what we've marked as Exhibit 24. MS. REISMAN: Can we go off the record for one minute? VIDEOGRAPHER: Going off the record at 8:43 a.m. (A break was taken.) VIDEOGRAPHER: Okay. We're back on the record at 8:44 a.m.
10 The witness has been previously sworn. You 11 may begin. 12 MR. KELLY: Thank you. 13 [EXAMINATION] 14 QUESTIONS BY MR. KELLY: 15 Q Good morning, Mr. Cavalli. 16 A Good morning. 17 Q Are you good to go this morning? 18 A Yes, I am. 19 Q Terrific. 20 MR. KELLY: Let me just small piece of 21 housekeeping from yesterday I intended to do but 22 didn't. Let me mark and attach the disclosure of 23 nonretained expert that was served in the case for use	10could keep abreast of the relevant scholarly11literature that dealt with, among other things, the12risk to human health of exposure to paraquat?13MS. REISMAN: Objection to form.14A Yes.15Q (By Mr. Kelly) Let me show you what we've16marked as Exhibit 24.17MS. REISMAN: Can we go off the record for18one minute?19VIDEOGRAPHER: Going off the record at208:43 a.m.21(A break was taken.)22VIDEOGRAPHER: Okay. We're back on the

3 (Pages 6 to 9)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 6 of 41 Page ID #2749

Richard Cavalli August 23, 2022

-		Ì
	Page 10	ENITIAI Page 12
1	Q (By Mr. Kelly) And I've handed you Exhibit 24	direct or indirect neurotoxicity of this compound, we
2	and a couple of questions just about the front page of	2 considered them interesting for presentation and
3	Exhibit 24.	3 discussion."
4	Do you recognize any of these authors, most	4 Have I read that correctly?
5	particularly Leon Roizin, R-O-I-Z-I-N, MD, by name?	5 A That's what it says on the page.
6	A I do not.	6 Q As you sit here now, do you remember in '73,
7	Q And did you were you excuse me were	7 '74 reading scholarly texts or treatises or monographs
8	you in this '73 through '86 time frame familiar with	8 or textbook chapters that had as their subject matter
9	who the most prominent specialists were in the field	9 the pathological changes that might indicate the
10	of neurotoxicology?	10 direct or indirect neurotoxicity of paraquat?
11	MS. REISMAN: Objection to form.	10 anect of maneet neurotoxicity of paraquati 11 A I can't say one way or the other.
12	A I don't. I can't say one way or the other.	11AI can t say one way of the other.12QWould that, given the nature of your work,
12	Q (By Mr. Kelly) Okay. As you sit here now, do	12 Q would that, given the nature of your work, 13 have been a topic in which you would have been
	you have recollection of actually having gotten this	13 nave been a topic in which you would have been 14 interested?
14 15		
	article which begins on the next page through the	, ,
16	process of having your librarian pull relevant	16 A In general, yes.
17	toxicology literature from the worldwide literature	17 Q (By Mr. Kelly) As of 1977, had Chevron shared
18	base?	18 with any pathologists anywhere what it believed was an
19	A You know, I don't remember one way or the	19 appropriate pathological examination to be conducted in
20	other.	20 a postmortem exam to identify brain changes in humans
21	Q Would cerebral changes in human beings	21 thought to be due to paraquat?
22	secondary to paraquat paraquat poisoning have been	22 MS. REISMAN: Objection to form.
23	a topic in which you were interested in at 1977?	23 Foundation.
24	MS. REISMAN: Objection to form.	A Could you repeat that?
25	A Long time ago. I don't remember one way or	25 MS. REISMAN: And the only thing, I would
	Page 11	Page 13
1		
1	the other.	1 remind you, Mr. Kelly, and the witness is he's here in
2	the other. Q (By Mr. Kelly) Just to refresh, in '73,	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his
2 3	the other.Q (By Mr. Kelly) Just to refresh, in '73,'74 when you were asked to focus in the area through	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of
2 3 4	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of
2 3 4 5	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6).
2 3 4 5 6	the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure?	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so
2 3 4 5 6 7	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity.
2 3 4 5 6 7 8	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as
2 3 4 5 6 7 8 9	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries,
2 3 4 5 6 7 8 9 10	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any
2 3 4 5 6 7 8 9 10 11	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever
2 3 4 5 6 7 8 9 10 11 12	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group
2 3 4 5 6 7 8 9 10 11 12 13	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a
2 3 4 5 6 7 8 9 10 11 12 13 14	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a histopathological point of view to identify brain
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a histopathological point of view to identify brain changes in human beings thought to be related to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a histopathological point of view to identify brain changes in human beings thought to be related to paraquat exposure?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title 'Cerebral Changes in Paraquat Poisoning,' you can see up in the right-hand corner this is 1977. Are you with me? A I am. 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A Iam. Q Come down the right-hand side and the 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a histopathological point of view to identify brain changes in human beings thought to be related to paraquat exposure? MS. REISMAN: Objection to form. A II'm sorry. I just don't remember one
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word "we." Do you see 	 remind you, Mr. Kelly, and the witness is he's here in his individual capacity and can testify to his recollection. He's not here testifying on behalf of Chevron Corporation. That's a corporation in terms of its person most knowledgeable of 30(b)(6). MR. KELLY: Then let me rephrase that so there's no ambiguity. Q (By Mr. Kelly) As of 1977, Mr. Cavalli, as the person who was directing paraquat inquiries, research in toxicology from '77 to 1980 had you and any members of the team that you identified yesterday ever shared with pathologists what you and your group thought should be an appropriate postmortem exam from a histopathological point of view to identify brain changes in human beings thought to be related to paraquat exposure? MS. REISMAN: Objection to form. A II'm sorry. I just don't remember one way or the other.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word "we." Do you see that? 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.18AI I'm sorry. I just don't remember one19way or the other.20Q(By Mr. Kelly) Okay. Did your group and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word "we." Do you see 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9(By Mr. Kelly) As of 1977, Mr. Cavalli, as9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.18AI I'm sorry. I just don't remember one19way or the other.20Q(By Mr. Kelly) Okay. Did your group and21again, the group is the persons you identified for me
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word "we." Do you see that? 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.18AI I'm sorry. I just don't remember one19way or the other.20Q(By Mr. Kelly) Okay. Did your group and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title "Cerebral Changes in Paraquat Poisoning," you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word "we." Do you see that? 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9(By Mr. Kelly) As of 1977, Mr. Cavalli, as9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.18A19way or the other.20Q21again, the group is the persons you identified for me
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title ''Cerebral Changes in Paraquat Poisoning,'' you can see up in the right-hand corner this is 1977. Are you with me? A I am. Q Come down the right-hand side and the paragraph that begins with the word ''we.'' Do you see that? Q All right. It says: ''We have had the 	1 remind you, Mr. Kelly, and the witness is he's here in 2 his individual capacity and can testify to his 3 recollection. He's not here testifying on behalf of 4 Chevron Corporation. That's a corporation in terms of 5 its person most knowledgeable of 30(b)(6). 6 MR. KELLY: Then let me rephrase that so 7 there's no ambiguity. 8 Q 9 the person who was directing paraquat inquiries, 10 research in toxicology from '77 to 1980 had you and any 11 members of the team that you identified yesterday ever 12 shared with pathologists what you and your group 13 thought should be an appropriate postmortem exam from a 14 histopathological point of view to identify brain 15 changes in human beings thought to be related to 16 paraquat exposure? 17 MS. REISMAN: Objection to form. 18 A I I'm sorry. I just don't remember one 19 way or the other. 20 20 Q (By Mr. Kelly) Okay. Did your group and 21 again, the group is the persons you identified for me
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 the other. Q (By Mr. Kelly) Just to refresh, in '73, '74 when you were asked to focus in the area through '86, was it your custom and practice to read relevant literature about the health effects on the human brain of paraquat exposure? A Yes. Q Okay. Were there any topics in the toxicology literature relating to human health effects of paraquat exposure that you asked the librarian not to pull and share with you? A No. Q If we go just to the front page, the title ''Cerebral Changes in Paraquat Poisoning,'' you can see up in the right-hand corner this is 1977. Are you with me? A Iam. Q Come down the right-hand side and the paragraph that begins with the word ''we.'' Do you see that? A I think so, yes. Q All right. It says: ''We have had the opportunity to examine the brain of two patients who 	1remind you, Mr. Kelly, and the witness is he's here in2his individual capacity and can testify to his3recollection. He's not here testifying on behalf of4Chevron Corporation. That's a corporation in terms of5its person most knowledgeable of 30(b)(6).6MR. KELLY: Then let me rephrase that so7there's no ambiguity.8Q9(By Mr. Kelly) As of 1977, Mr. Cavalli, as9the person who was directing paraquat inquiries,10research in toxicology from '77 to 1980 had you and any11members of the team that you identified yesterday ever12shared with pathologists what you and your group13thought should be an appropriate postmortem exam from a14histopathological point of view to identify brain15changes in human beings thought to be related to16paraquat exposure?17MS. REISMAN: Objection to form.18A14I I'm sorry. I just don't remember one19way or the other.20Q21again, the group is the persons you identified for me22yesterday and yourself at any time author in writing23any kind of an outline or template intended to be read

Paszkiewicz Court Reporting (618) 307-9320 / Toll-Free (855) 595-3577

4 (Pages 10 to 13)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 7 of 41 Page ID #2750

Richard Cavalli August 23, 2022

	_	
	Page 14	Page 16
1	what the brain examination should consist of?	asking him about his current recollection
2	MS. REISMAN: Objection to form.	2 MR. KELLY: Counsel Counsel, let me
3	A No. I don't think we did.	3 just
4		5
	Q (By Mr. Kelly) Did you ever discuss whether	57
5	that would be helpful or of assistance to you and your	55,55
6	group in trying to identify whether or not there was on	, , , , , , , , , , , , , , , , , , ,
7	postmortem examinations changes in the human brain that	7 No.
8	were thought to be paraquat-related?	8 MS. REISMAN: For the record, I think we
9	MS. REISMAN: Objection to form.	9 should make it clear as to whether you're asking for
10	A Could you repeat? I'm sorry.	10 current understanding or his understanding back then.
11	Q (By Mr. Kelly) Yes, sir.	11 MR. KELLY: Fine. I'm going to proceed with
12	A Long question.	12 my questions, and if there's confusion, I'll depend on
13	Q Yeah, yeah.	13 the witness to ask me.
14	Did you and your group ever discuss whether	14 Q (By Mr. Kelly) Sir, the next sentence says:
15	you thought it would be helpful or of assistance to	15 "The most striking was a very pronounced accumulation
16	you in trying to identify whether or not there was on	16 of lipofuscin-like material in the ganglion cells
17	postmortem examination changes in human beings that	17 throughout the brain but most marked in the pallidum
18	were thought to be due to paraquat exposure to give	18 intralaminar nuclei of the thalamus, corpus geniculatum
19	pathologists doing postmortems a template or outline	19 laterale, substantia nigra, dentate and fastigial
20	of what should be done?	20 nuclei of the cerebellum."
21	MS. REISMAN: Objection to form.	21 Did I get that right? Maybe not so much
22	A I don't recall one way or the other.	22 with the Latin.
23	Q (By Mr. Kelly) Okay. I'm lower right-hand	A It's what it says on the page.
24	corner, there was some numbers. I'm all the way over	24 Q I want to ask you a couple questions about
25	to page 4700.	25 this sentence, sir. Do you know what lipofuscin
	Page 15	Page 17
1	_	Page 17 1 L-I-P-O-F-U-S-C-I-N like material is?
1 2	Page 15 Do you see that, sir? A 4700?	1 L-I-P-O-F-U-S-C-I-N like material is?
	Do you see that, sir? A 4700?	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form.
2	Do you see that, sir? A 4700? Q Yes, sir.	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know.
2 3 4	Do you see that, sir? A 4700? Q Yes, sir. A Yes.	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you
2 3 4 5	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No.
2 3 4	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results."	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you
2 3 4 5 6 7	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that?	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No. Q Have you ever known what lipofuscin-like material is?
2 3 4 5 6	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do.	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No. Q Have you ever known what lipofuscin-like material is? A Can't say one way or the other.
2 3 4 5 6 7 8 9	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No. Q Have you ever known what lipofuscin-like material is? A Can't say one way or the other. Q Do you know whether lipofuscin is caused by
2 3 4 5 6 7 8 9 10	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress?
2 3 4 5 6 7 8 9 10 11	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination."	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay?	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word
2 3 4 5 6 7 8 9 10 11 12 13	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it
2 3 4 5 6 7 8 9 10 11 12 13 14	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes."	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No. Q Have you ever known what lipofuscin-like material is? A Can't say one way or the other. Q Do you know whether lipofuscin is caused by oxidative stress? MS. REISMAN: Objection to form. A Since I sit here, I'm not sure what the word means. I have no opinion as to whether where it C (By Mr. Kelly) Does paraquat kill human cells
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have	 L-I-P-O-F-U-S-C-I-N like material is? MS. REISMAN: Objection. Form. A As I sit here, I don't know. Q (By Mr. Kelly) Do you A I mean, I don't know. No. Q Have you ever known what lipofuscin-like material is? A Can't say one way or the other. Q Do you know whether lipofuscin is caused by oxidative stress? MS. REISMAN: Objection to form. A Since I sit here, I'm not sure what the word means. I have no opinion as to whether where it Comes from. Q (By Mr. Kelly) Does paraquat kill human cells by oxidative stress?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir?	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form.	1L-I-P-O-F-U-S-C-I-N like material is?2MS. REISMAN: Objection. Form.3A As I sit here, I don't know.4Q (By Mr. Kelly) Do you5A I mean, I don't know. No.6Q Have you ever known what lipofuscin-like7material is?8A Can't say one way or the other.9Q Do you know whether lipofuscin is caused by10oxidative stress?11MS. REISMAN: Objection to form.12A Since I sit here, I'm not sure what the word13means. I have no opinion as to whether where it14comes from.15Q (By Mr. Kelly) Does paraquat kill human cells16by oxidative stress?17MS. REISMAN: Objection to form.18A I'm not exactly sure what that term means.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does.	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological change in your mind?	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human 21 cells by oxidative stress?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological change in your mind? A Change in structure of something.	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human 21 cells by oxidative stress? 22 MS. REISMAN: Objection. Form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological change in your mind? A Change in structure of something. Q Okay.	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human 21 MS. REISMAN: Objection. Form. 23 A I'm not sure what oxidative stress means.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological change in your mind? A Change in structure of something. Q Okay. MS. REISMAN: Again, Mr. Kelly, I'd ask	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human 21 cells by oxidative stress? 22 MS. REISMAN: Objection. Form. 23 A I'm not sure what oxidative stress means. 24 Q (By Mr. Kelly)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Do you see that, sir? A 4700? Q Yes, sir. A Yes. Q And I'm in the left-hand column under the heading "Results." Do you see that? A I do. Q And then it says: "Light Microscopic Examination, Case 1." And I'm in the paragraph that begins with the word "histological examination." Okay? "Histological examination, in addition to severe edema and congestion showed a number of quite marked morphological changes." Does the phrase "morphological changes" have significance to you, sir? MS. REISMAN: Objection to form. A I think it does. Q (By Mr. Kelly) Okay. What is a morphological change in your mind? A Change in structure of something. Q Okay.	1 L-I-P-O-F-U-S-C-I-N like material is? 2 MS. REISMAN: Objection. Form. 3 A As I sit here, I don't know. 4 Q (By Mr. Kelly) Do you 5 A I mean, I don't know. No. 6 Q Have you ever known what lipofuscin-like 7 material is? 8 A Can't say one way or the other. 9 Q Do you know whether lipofuscin is caused by 10 oxidative stress? 11 MS. REISMAN: Objection to form. 12 A Since I sit here, I'm not sure what the word 13 means. I have no opinion as to whether where it 14 comes from. 15 Q (By Mr. Kelly) Does paraquat kill human cells 16 by oxidative stress? 17 MS. REISMAN: Objection to form. 18 A I'm not exactly sure what that term means. 19 Q (By Mr. Kelly) All right. Have you ever 20 known whether or not paraquat kills plant or human 21 MS. REISMAN: Objection. Form. 23 A I'm not sure what oxidative stress means.

5 (Pages 14 to 17)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 8 of 41 Page ID #2751

Richard Cavalli August 23, 2022

	Page 18	FNTIAI Page 20
1	what oxidative stress means?	through 1986 have a person on your staff who educated
2	MS. REISMAN: Objection to form.	2 you about the course of development to end stage of
3	A Specifically as oxidative stress, no, I	3 Parkinson's disease in human beings?
4	don't.	4 MS. REISMAN: Objection to form.
5	Q (By Mr. Kelly) In your study of paraquat from	5 A I don't recall either way.
6	'73 through '86, have did you ever learn that the	6 Q (By Mr. Kelly) Okay. Did you at any time
7	process of oxidative stress was in any way related to	7 undertake to educate yourself on how Parkinson's
8	how paraquat operated as a nonselective herbicide?	8 disease begins and how it ends in human beings?
9	MS. REISMAN: Objection. Form.	9 MS. REISMAN: Objection to form.
10 11	A I'm having trouble I'm sorry with oxidative stress.	10AI didn't.11Q(By Mr. Kelly) Do you know what the
11		12 relationship is, if any, between the substantia nigra
12	Q (By Mr. Kelly) Okay.A You have another name for it?	12 relationship is, if any, between the substantia higha 13 and Parkinson's disease?
14		13and Farkinson's disease?14AI do have a vague understanding of that.
14 15	Q Do you know what a reactive oxygen species is?	14AI do have a vague understanding of that.15QAnd did you have a vague understanding of
16	A Yes, I do.	16 what that was in the period 1973 to 1986?
17	Q Is a paraquat a reactive oxygen species	10what that was in the period 1975 to 1980.17AI can't pin it down by date either way.
18	MS. REISMAN: Objection. Form.	17AI can't pin it down by date enter way.18QDuring the period of time during which you
19	Q (By Mr. Kelly) or does it produce a	19 were charged with making an assessment as to whether
20	reactive oxygen species?	20 or not there was a risk to human health in terms of
21	MS. REISMAN: Objection. Form.	21 injury in the brain between 1973 and 1986, did you
22	A Which question?	22 have any understanding of the role of the substantia
23	Q (By Mr. Kelly) And how about we do it in	23 nigra in Parkinson's disease?
24	order. Is paraquat an oxidative species?	24 MS. REISMAN: Objection to form.
25	MS. REISMAN: Objection to form.	25 A Only vaguely in a general way.
	-	
	Page 19	Page 21
1	Page 19 A No.	1 Q (By Mr. Kelly) And what was the vague general
1 2	A No.Q (By Mr. Kelly) Does paraquat produce a	
	A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species?	1 Q (By Mr. Kelly) And what was the vague general
2 3 4	A No.Q (By Mr. Kelly) Does paraquat produce a	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease?
2 3 4 5	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. 	1Q (By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.
2 3 4 5 6	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read
2 3 4 5 6 7	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read 7 this paragraph again. "Histological examination, in
2 3 4 5 6 7 8	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a
2 3 4 5 6 7 8 9	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The
2 3 4 5 6 7 8 9 10	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of
2 3 4 5 6 7 8 9 10 11	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells
2 3 4 5 6 7 8 9 10 11 12	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a 9 number of quite marked morphological changes. The 10 most striking was a very pronounced accumulation of 11 lipofuscin-like material in the ganglion cells 12 throughout the brain but most marked in the pallidum
2 3 4 5 6 7 8 9 10 11 12 13	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5AI can't say for certain.6QOkay. So we go back, and I want to read7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus
2 3 4 5 6 7 8 9 10 11 12 13 14	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5AI can't say for certain.6QOkay. So we go back, and I want to read7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a 9 number of quite marked morphological changes. The 10 most striking was a very pronounced accumulation of 11 lipofuscin-like material in the ganglion cells 12 throughout the brain but most marked in the pallidum 13 intralaminar nuclei of the thalamus, the corpus 14 geniculatum laterale, substantia nigra excuse me 15 substantia nigra, dentate and fastigial nuclei of the 16 cerebellum."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the16cerebellum."17Having that paragraph in mind, do you know
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the16cerebellum."17Having that paragraph in mind, do you know18whether any part of those brain structures articulated
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5A I can't say for certain.6Q7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the16cerebellum."17Having that paragraph in mind, do you know18whether any part of those brain structures articulated19by the authors have anything to do with Parkinson's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. A very much about Parkinson's disease. 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a 9 number of quite marked morphological changes. The 10 most striking was a very pronounced accumulation of 11 lipofuscin-like material in the ganglion cells 12 throughout the brain but most marked in the pallidum 13 intralaminar nuclei of the thalamus, the corpus 14 geniculatum laterale, substantia nigra excuse me 15 substantia nigra, dentate and fastigial nuclei of the 16 cerebellum." 17 Having that paragraph in mind, do you know 18 whether any part of those brain structures articulated 19 by the authors have anything to do with Parkinson's 20 disease?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. A very much about Parkinson's disease. Q When in did you at any time in the 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a 9 number of quite marked morphological changes. The 10 most striking was a very pronounced accumulation of 11 lipofuscin-like material in the ganglion cells 12 throughout the brain but most marked in the pallidum 13 intralaminar nuclei of the thalamus, the corpus 14 geniculatum laterale, substantia nigra excuse me 15 substantia nigra, dentate and fastigial nuclei of the 16 cerebellum." 17 Having that paragraph in mind, do you know 18 whether any part of those brain structures articulated 19 by the authors have anything to do with Parkinson's 20 disease? 21 MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. A very much about Parkinson's disease. Q When in did you at any time in the '73 through 1986 period educate yourself on how 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5AI can't say for certain.6QOkay. So we go back, and I want to read7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the16cerebellum."17Having that paragraph in mind, do you know18whether any part of those brain structures articulated19by the authors have anything to do with Parkinson's20disease?21MS. REISMAN: Objection to form.22AAAgain, the only one that stands out is a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. A very much about Parkinson's disease. Q When in did you at any time in the 	1 Q (By Mr. Kelly) And what was the vague general 2 way that you had some understanding about the 3 relationship of the substantia nigra to Parkinson's 4 disease? 5 A I can't say for certain. 6 Q Okay. So we go back, and I want to read 7 this paragraph again. "Histological examination, in 8 addition to severe edema and congestion, showed a 9 number of quite marked morphological changes. The 10 most striking was a very pronounced accumulation of 11 lipofuscin-like material in the ganglion cells 12 throughout the brain but most marked in the pallidum 13 intralaminar nuclei of the thalamus, the corpus 14 geniculatum laterale, substantia nigra excuse me 15 substantia nigra, dentate and fastigial nuclei of the 16 cerebellum." 17 Having that paragraph in mind, do you know 18 whether any part of those brain structures articulated 19 by the authors have anything to do with Parkinson's 20 disease? 21 MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A No. Q (By Mr. Kelly) Does paraquat produce a reactive oxygen species? MS. REISMAN: Objection to form. A I believe it does. Q (By Mr. Kelly) Does a reactive oxygen species contribute to the production of lipofuscin? MS. REISMAN: Objection to form. A I don't know the definition of that word, so I can't say. Q (By Mr. Kelly) Is the pathological accumulation of lipofuscin implicated in Parkinson's disease? A I have MS. REISMAN: Objection. Form. Lack of foundation. Q (By Mr. Kelly) Go ahead, sir. A I don't know Q All right. A very much about Parkinson's disease. Q When in did you at any time in the '73 through 1986 period educate yourself on how Parkinson's disease was thought to begin? 	1Q(By Mr. Kelly) And what was the vague general2way that you had some understanding about the3relationship of the substantia nigra to Parkinson's4disease?5AI can't say for certain.6QOkay. So we go back, and I want to read7this paragraph again. "Histological examination, in8addition to severe edema and congestion, showed a9number of quite marked morphological changes. The10most striking was a very pronounced accumulation of11lipofuscin-like material in the ganglion cells12throughout the brain but most marked in the pallidum13intralaminar nuclei of the thalamus, the corpus14geniculatum laterale, substantia nigra excuse me15substantia nigra, dentate and fastigial nuclei of the16cerebellum."17Having that paragraph in mind, do you know18whether any part of those brain structures articulated19by the authors have anything to do with Parkinson's20disease?21MS. REISMAN: Objection to form.22A23vague memory of the substantia nigra have something to

6 (Pages 18 to 21)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 9 of 41 Page ID #2752

Richard Cavalli August 23, 2022

	Page 22	IH'I	NTIAI Page 24
1	did your group under your direction at any time		Q- (By Mr. Kelly) All right. And does addition
2	commission any consultation with a neurotoxicologist to	2	of this modifying language "PAS positive, mostly
3	evaluate whether or not a substantia nigra was or was	3	granular, partly brownish lipo lipofuscin-like
4	not something that would be affected negatively by	4	material," does that bring any more clarity to mind as
5	exposure to paraquat?	5	to what lipofuscin is?
6	MS. REISMAN: Objection to form.	6	MS. REISMAN: Objection to form.
7	A I don't recall any such discussion.	7	A No, it doesn't.
8	MS. REISMAN: One way or the other, or you	8	Q (By Mr. Kelly) Okay. Let's just go to
9	don't recall a discussion?	9	page 4711. And on on the left-hand column, sir,
10	THE WITNESS: Well, one way or the other.	10	60 percent of the way down, a sentence begins
11	MR. KELLY: Excuse me. Counsel, that's not	11	"Hypoxia"
12	appropriate to coach the witness.	12	Do you see that? "Hypoxia has also"?
13	MS. REISMAN: I was not Mr. Kelly, I am	13	A Not yet.
14	not coaching the witness. I've sat here as you've	14	Q Okay. Take take your time, sir.
15	asked question after question, some very unclear that	15	A You said on the left side?
16	the witness is confused about. I was making sure that	16	Q Yes, sir. On the column on the left just
17	the record was clear as to whether he didn't recall it	17	down here.
18	happening or whether he didn't recall it whether he	18	A Okay. Second yeah. First the far
19	didn't recall it either way, that it happened or not.	19	left word is "system"?
20	You can continue with your questioning. I	20	Q Yes, sir.
21	was not coaching the witness. I was making sure that	21	A Okay. I see.
22	his answer was clear.	22	Q "Hypoxia has also been indicated by some
23	MR. KELLY: May I just say that the process	23	authors as a possible cause of excessive production of
24	of exam and redirect is for the benefit of	24	lipofuscin. Pathological changes in the lungs of our
25	clarification, and to the extent that this is	25	cases, as well as in many cases from the literature,
	Page 23		Page 25
			Tage 20
1	testimony to potentially be played in court, I don't	1	seemed to have developed rather late in the course of
1 2	testimony to potentially be played in court, I don't believe it is appropriate for you to interject your	1 2	-
			seemed to have developed rather late in the course of
2	believe it is appropriate for you to interject your	2	seemed to have developed rather late in the course of the disease with blockage of alveolar space being
2 3	believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in	2 3	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline
2 3 4	believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying.	2 3 4	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes."
2 3 4 5	believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly.	2 3 4 5	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are
2 3 4 5 6	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you 	2 3 4 5 6	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there?
2 3 4 5 6 7	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, 	2 3 4 5 6 7	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form.
2 3 4 5 6 7 8	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you 	2 3 4 5 6 7 8	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A Ido.
2 3 4 5 7 8 9	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first 	2 3 4 5 6 7 8 9	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you
2 3 6 7 8 9 10	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page 	2 3 4 5 6 7 8 9 10	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute
2 3 6 7 8 9 10 11	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first 	2 3 4 5 6 7 8 9 10 11	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat?
2 3 4 5 6 7 8 9 10 11 12	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page 	2 3 4 5 6 7 8 9 10 11 12	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone
2 3 4 5 6 7 8 9 10 11 12 13	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of 	2 3 4 5 6 7 8 9 10 11 12 13	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat?
2 3 4 5 6 7 8 9 10 11 12 13 14	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that 	2 3 4 5 6 7 8 9 10 11 12 13 14	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A Ido. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, lipofuscin-like material in the ganglion cells with 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir? A I have no I mean, I don't know what
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, lipofuscin-like material in the ganglion cells with the same pattern of predilection as in the previous case." 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir? A I have no I mean, I don't know what "late" means in this context. Q All right. And that's true
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, lipofuscin-like material in the ganglion cells with the same pattern of predilection as in the previous case." 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir? A I have no I mean, I don't know what "late" means in this context. Q All right. And that's true
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, lipofuscin-like material in the ganglion cells with the same pattern of predilection as in the previous case." 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir? A I have no I mean, I don't know what "late" means in this context. Q All right. And that's true A Perhaps it's elsewhere in the paper. Q Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 believe it is appropriate for you to interject your thoughts or comments. They wouldn't be permitted in court. That's all I'm saying. MS. REISMAN: Thank you, Mr. Kelly. Q (By Mr. Kelly) Mr. Cavalli, turn, if you will, for me to in the lower right-hand corner, page 4702. And on the left-hand side at the top, you see it's the heading "Case 2"? A Yes, I see it. Q All right. I'm just going to read the first paragraph to make sure you and I are on the same page here. It says: "Gross and histological examination of the brain showed a strikingly similar picture of that of Case 1. Here also, the most pronounced pathological change was an accumulation of PAS positive, mostly granular, partly brownish, lipofuscin-like material in the ganglion cells with the same pattern of predilection as in the previous case." 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 seemed to have developed rather late in the course of the disease with blockage of alveolar space being produced mostly by acute hemorrhages and hyaline membranes." Do you understand what the authors are talking about there? MS. REISMAN: Objection. Form. A I do. Q (By Mr. Kelly) All right. And do you understand that hypoxic changes causing acute hemorrhage and hyaline membranes is something that these authors say happens late in the course of someone poisoned by paraquat? MS. REISMAN: Objection to form. A That's what's on the page. Q (By Mr. Kelly) Okay. Do you agree with that, sir? A I have no I mean, I don't know what "late" means in this context. Q All right. And that's true A Perhaps it's elsewhere in the paper.

7 (Pages 22 to 25)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 10 of 41 Page ID #2753

Richard Cavalli August 23, 2022

	Page 26		Page 28
1	Q (By Mr. Kelly) So the next sentence begins:	A More know	ledgeable in neurotoxicity than I,
2	"Clinically, both of our patients developed breathing	2 likely.	reugeable in neurotoxicity than 1,
3	difficulties quite terminally."		lly) And not just limiting to you,
4	You understand what that means?		your group of five and in the
5	MS. REISMAN: Objection to form.		nteracted with at ICI, was there a
6	A Yes, I do.		ho regularly participated in the
7	Q (By Mr. Kelly) "Quite terminally" means at or	7 meetings you had w	
8	near the end of life, correct?	8 A I don't reca	all that one way or the other.
9	A Yes.		d 1973, '74, through 1986, did
10	Q And then the authors conclude "Thus, one	10 you yourself or any	members of your group that we
11	would presume that hypoxia of respiratory origin could	11 talked about yester	lay ever suggest that you should
12	not have played a decisive role in influencing	12 get a board-certified	d neurotoxicologist involved with
13	formulation of lipofuscin-like material in our cases."	13 your team?	
14	Do you understand what that means?	14 MS. REISMA	AN: Objection. Form.
15	MS. REISMAN: Objection to form.	15 A No, we did	
16	A I understand that's what's on the page.	~ ` •	lly) Did 1973 to 1986, did
17	Q (By Mr. Kelly) Well, do you understand what		up or yourself suggest that you
18	these authors are saying is the lipofuscin-like		y underwrite research on the
19	materials they saw were not in any way produced by	-	jury as a result of paraquat
20	terminal hypoxia?		a neurotoxicologist to research and
21	MS. REISMAN: Objection to form.	write on the topic?	
22	A The sentence reads "Thus, one would		AN: Objection to form.
23	presume"	23 A I I don't	
24	Q (By Mr. Kelly) Yes, sir.		lly) As a person who had attended
25	A So that that's	three classes at UC	SF, did you at any point think
	Page 27		Page 29
1	-	1 putting aside the of	_
1	Q This is the presumption of the authors,		her five people in the group it
2	Q This is the presumption of the authors, correct?	2 would be helpful to	her five people in the group it you to have a better understanding
2 3	Q This is the presumption of the authors, correct?A It it is their presumption. Not not	2 would be helpful to3 of the potential neuronal	her five people in the group it you to have a better understanding protoxicity of paraquat on human
2 3 4	Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You	 2 would be helpful to 3 of the potential neu 4 beings to have some 	her five people in the group it you to have a better understanding protoxicity of paraquat on human bebody from the UCSF
2 3 4 5	Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions.	 2 would be helpful to 3 of the potential neu 4 beings to have som 5 neurotoxicological 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you?
2 3 4 5 6	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. 	her five people in the group it you to have a better understanding protoxicity of paraquat on human bebody from the UCSF
2 3 4 5	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form.
2 3 4 5 6 7	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form.
2 3 4 5 6 7 8 9	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of 	 2 would be helpful to 3 of the potential neu 4 beings to have som 5 neurotoxicological 6 MS. REISM. 7 A No. 8 Q (By Mr. Ke 9 topics, change subj 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can.
2 3 4 5 6 7 8	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find
2 3 4 5 6 7 8 9 10	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find e had to do with your interaction
2 3 4 5 6 7 8 9 10 11	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find e had to do with your interaction
2 3 4 5 6 7 8 9 10 11 12	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction ICI. period of time that came
2 3 4 5 6 7 8 9 10 11 12 13	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I Was there a p actually, let me wit 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction ICI. period of time that came
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I Was there a p actually, let me wit When you w 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction ICI. period of time that came hdraw that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I Was there a p actually, let me wit When you w efforts on paraquat 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I Was there a p actually, let me wit When you w efforts on paraquat 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human ebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers 	 would be helpful to of the potential neu beings to have som neurotoxicological MS. REISM. A No. Q (By Mr. Ke topics, change subj Yesterday there we the right place here with the people at I Was there a p actually, let me wit When you w efforts on paraquat which you became 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human ebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers in the medical profession are learning in the treatment 	 would be helpful to of the potential neurol beings to have som neurotoxicological MS. REISMA A No. Q (By Mr. Ke) topics, change subj Yesterday there weight the right place here with the people at I Was there a plat actually, let me with When you weight efforts on paraquat which you became team? A Yes. 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human ebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. are questions asked that had find e had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers in the medical profession are learning in the treatment of a given disease? 	 would be helpful to of the potential neurol beings to have som neurotoxicological MS. REISMA A No. Q (By Mr. Ke) topics, change subj Yesterday there weight the right place here with the people at I Was there a plat actually, let me with When you weight efforts on paraquat which you became team? A Yes. 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find e had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in involved interacting with the ICI
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers in the medical profession are learning in the treatment of a given disease? MS. REISMAN: Objection. Form. A Yes. Q (By Mr. Kelly) And would you expect these 	 would be helpful to of the potential neurol beings to have some neurotoxicological MS. REISM. A No. Q (By Mr. Ke) topics, change subj Yesterday there weight the right place here with the people at I Was there and actually, let me with When you weight efforts on paraquat which you became team? A Yes. Q Okay. Let point Exhibit 51. (Exhibit 51. 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in involved interacting with the ICI me show you what we'll mark as 51 has been marked and now
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers in the medical profession are learning in the treatment of a given disease? MS. REISMAN: Objection. Form. A Yes. Q (By Mr. Kelly) And would you expect these physicians publishing in neurotoxicology to be not more 	2would be helpful to3of the potential neu4beings to have som5neurotoxicological6MS. REISM.7ANo.8Q(By Mr. Ke)9topics, change subj10Yesterday there wei11the right place here12with the people at I13Was there a p14actually, let me witi15When you w16efforts on paraquat17which you became18team?19A20Q21Exhibit 51.22(Exhibit 52.23identified	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in involved interacting with the ICI me show you what we'll mark as 61 has been marked and now for the record.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q This is the presumption of the authors, correct? A It it is their presumption. Not not having the case histories, the I don't know. You ask the questions. Q You yourself have never published in a journal of neurology or neurotoxicology, correct? A That is correct. Q And do you understand that the purpose of journal publications and peer-reviewed journals is to educate other members of the profession? MS. REISMAN: Objection to form. A I would have said to share experiences. Q (By Mr. Kelly) Is the purpose of sharing experiences in medical journals so that all members of the medical community in a particular discipline have a better understanding of what their sisters and brothers in the medical profession are learning in the treatment of a given disease? MS. REISMAN: Objection. Form. A Yes. Q (By Mr. Kelly) And would you expect these 	 would be helpful to of the potential neurol beings to have some neurotoxicological MS. REISM. A No. Q (By Mr. Ke) topics, change subj Yesterday there weight the right place here with the people at I Was there and actually, let me with When you weight efforts on paraquat which you became team? A Yes. Q Okay. Let and Exhibit 51. (Exhibit 51. (Exhibit 51. (Exhibit 52. identified Q (By Mr. Ke) 	her five people in the group it o you to have a better understanding protoxicity of paraquat on human bebody from the UCSF department consult with you? AN: Objection to form. Ily) Let me change change ects here for a minute, if we can. re questions asked that had find had to do with your interaction (CI. period of time that came hdraw that. ere asked to focus more of your issues, was that the point in involved interacting with the ICI me show you what we'll mark as 51 has been marked and now

8 (Pages 26 to 29)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 11 of 41 Page ID #2754

Richard Cavalli August 23, 2022

1 2 3			
2	Page 30	T	Page 32
2	orienting us.		lower right-hand corner, 1061, under the heading
	Do you see the last page, sir?	2	"Toxicology," this is one of the topics you're listed
- J	A I think I do, yes.	3	on for the addenda, correct?
4	Q Okay. And this is written by J.N. Ospenson?	4	A Yes.
5	MS. REISMAN: This being the last page is	5	Q It begins and says: "It was felt that the
6	written by J.N. Ospenson?	6	lack of chronic inhalation toxicity information and
7	MR. KELLY: Yes.	7	epidemiological surveys were a definite weakness in
8	Q (By Mr. Kelly) So it's a letter, correct?	8	properly evaluating the safety of paraquat use or
9	A Yes.	9	properly defending the safety of paraquat."
10	Q And it contains an agenda, if we believe the	10	Did I read that correctly?
11	top, for a March 27, 1974, paraquat conference ICI and	11	A You did. That's what's on the page.
12	Chevron Chemical Company, correct?	12	Q And were those opinions that you shared with
13	A That's what it says.	13	all of the people in attendance at this conference?
14	MS. REISMAN: Object to the form.	14	MS. REISMAN: Objection to form.
15	Q (By Mr. Kelly) And this is to be held at	15	A I have to say I do not have a specific
16	555 Market Street. Was that at the time a Chevron	16	recollection of this conference.
10	Chemical Company address?	17	Q (By Mr. Kelly) Okay. Were those your
18	A It was a Chevron address.		
10 19	Q Okay. And among the addressees, you are	18 19	opinions in 1974? MS. REISMAN: Objection to form.
20	listed as Number 1?	20	A I would not consider I mean, again, I
20	A I see that.	20	can't can't go back to '74. The no, I I
21		21	can't say one way or another.
22	Q And under the agenda topics, 2-B,	23	
23	toxicological aspects, you are listed with looks	23	Q (By Mr. Kelly) In your history of attending
24	like Dr. Kinoshita, K-I-N-O-S-H-I-T-A. Right? A That's correct.	24	these meetings, was it your understanding that the purpose of generating minutes or a meeting report was
2.5	A That's correct.	2.5	purpose of generating minutes of a meeting report was
	Page 31		Page 33
1	MS. REISMAN: Mr. Kelly, just a correction	1	to accurately document what had happened?
2	so the record's clear. You noted that this agenda was	2	MS. REISMAN: Objection to form.
3	for a meeting taking place on March 27. I believe	3	A Yes.
4	that last page	4	Q (By Mr. Kelly) And would you yourself keep a
5	MR. KELLY: No.	5	binder or a collection of meeting reports or minutes so
6	MS. REISMAN: indicates that it's an	6	that you could keep track of what happened
7	agenda for meetings being held on March 28 and 29.	7	historically?
8	MR. KELLY: Yeah. I'm sorry. I should have	8	MS. REISMAN: Objection to form.
9	said "it's dated."	9	A No.
10	Q (By Mr. Kelly) This letter is dated March 27,	10	Q (By Mr. Kelly) Do you have reason to believe
11	1974. And when we go to the front page, we see the	11	that these minutes are inaccurate in documenting what
12	meeting report, correct?	12	your thoughts were toxicologically in 1974?
13	A I'm sorry.	13	MS. REISMAN: Objection to form.
	Q Let's go to the front page of the exhibit	14	A I can't say one way or the other.
14	A Yes.	15	Q (By Mr. Kelly) In 1974, was there, in your
	Q which is page 10 1060?	16	opinion, a lack of chronic inhalation toxicity
14	A Yes.	17	information?
14 15	Q Okay. And you are listed here in the second	18	MS. REISMAN: Objection to form.
14 15 16	Q Okay. And you are listed here in the second		
14 15 16 17	line from the bottom, says "SOCAL-R.D. Cavalli." Do	19	A There was not a specific study, but we have
14 15 16 17 18		19 20	
14 15 16 17 18 19	line from the bottom, says "SOCAL-R.D. Cavalli." Do		large collection of studies and data that supported a
14 15 16 17 18 19 20	line from the bottom, says "SOCAL-R.D. Cavalli." Do you know what the "SOCAL" stands for? A Standard Oil California.	20	large collection of studies and data that supported a view that chronic inhalation was not a significant
14 15 16 17 18 19 20 21	line from the bottom, says "SOCAL-R.D. Cavalli." Do you know what the "SOCAL" stands for? A Standard Oil California. Q This is, as counsel was discussing	20 21	large collection of studies and data that supported a view that chronic inhalation was not a significant risk in the field if the product was used according to
14 15 16 17 18 19 20 21 22	 line from the bottom, says "SOCAL-R.D. Cavalli." Do you know what the "SOCAL" stands for? A Standard Oil California. Q This is, as counsel was discussing yesterday, before the name changed? Is that right? 	20 21 22	large collection of studies and data that supported a view that chronic inhalation was not a significant risk in the field if the product was used according to the precautionary label.
14 15 16 17 18 19 20 21 22 23	 line from the bottom, says "SOCAL-R.D. Cavalli." Do you know what the "SOCAL" stands for? A Standard Oil California. Q This is, as counsel was discussing yesterday, before the name changed? Is that right? 	20 21 22 23	large collection of studies and data that supported a view that chronic inhalation was not a significant risk in the field if the product was used according to

9 (Pages 30 to 33)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 12 of 41 Page ID #2755

Richard Cavalli August 23, 2022

	Page 34		TTTAT Page 36
1			
1	lack of chronic inhalation toxicity information?		felt that the lack of chronic inhalation toxicity
2	MS. REISMAN: Objection to form. Asked and	2	information and epidemiological surveys were a definite
3	answered.	3	weakness in properly evaluating the safety of paraquat
4	A Not information, no.	4	use or properly defending the safety of paraquat."
5	Q (By Mr. Kelly) Yesterday you told us you	5	My question to you is, was it part of your
6	would be you were in favor of doing an inhalation	6	job at any time between 1973 and 1986 to properly
7	study.	7	defend the safety of paraquat?
8	Do you recall that?	8	MS. REISMAN: Objection to form.
9	A I do.	9	A Again, those aren't my words, but I
10	Q And were you in favor of doing an inhalation	10	certainly believed at the time that it would be useful
11	study because there was a lack of chronic inhalation	11	in understanding the toxicity of paraquat to have
12	toxicity information?	12	several different kinds of studies, among the two
13	MS. REISMAN: Objection to form. Asked and	13	mentioned here.
14	answered.	14	Q (By Mr. Kelly) But with reference to the
15	A I have to give you the same answer. There	15	specific phrase "defending the safety of paraquat," did
16	wasn't a study, but there was information.	16	you understand that that was part of your job between
17	Q (By Mr. Kelly) In 1974, was it your opinion	17	1973 and 1986?
18	that the lack of epidemiological surveys were a	18	MS. REISMAN: Objection to form. Asked and
19	definite weakness in properly evaluating the safety of	19	answered.
20	paraquat use or properly defending the safety of	20	A Part of my job in those years, as I recall,
21	paraquat?	21	was to study the toxicity of paraquat, make
22	MS. REISMAN: Objection to form.	22	recommendations for its safe use, and review the world
23	A Once again, I don't recall what I said.	23	of of others. I I personally don't think of
24	Those are not my words.	24	that as defending.
25	Q (By Mr. Kelly) In 1974, did you believe that	25	Q (By Mr. Kelly) Was it any part of your work
	Page 35		Page 37
1 2	Page 35 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat	1 2	Page 37 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of
	the lack of epidemiological surveys were a definite		in 1973 through 1986 or the work of anybody in your
2	the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat	2	in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of
2 3	the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use?	2 3	in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California?
2 3 4	the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form.	2 3 4	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it
2 3 4 5	the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of	2 3 4 5	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it
2 3 4 5 6	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study 	2 3 4 5 6	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it
2 3 4 5 6 7	the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we	2 3 4 5 6 7 8 9	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your
2 4 5 7 8 9	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. 	2 3 4 5 6 7 8	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's
2 3 5 6 7 8 9	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at 	2 3 4 5 6 7 8 9 10 11	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers'
2 3 4 5 6 7 8 9 10 11	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more 	2 3 4 5 6 7 8 9 10 11 12	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through
2 3 4 5 6 7 8 9 10 11	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate 	2 3 4 5 6 7 8 9 10 11 12 13	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986?
2 3 4 5 7 8 9 10 11 12 13	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? 	2 3 4 5 6 7 8 9 10 11 12	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through
2 3 4 5 6 7 8 9 10 11 12 13 14	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at that phrase, do you look at that with the connotation
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or together commission one or more epidemiological surveys 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at that phrase, do you look at that with the connotation of defending the safety of paraquat in legal
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or together commission one or more epidemiological surveys in order to properly evaluate 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at that phrase, do you look at that with the connotation of defending the safety of paraquat in legal proceedings?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or together commission one or more epidemiological surveys in order to praquat use; 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at that phrase, do you look at that with the connotation of defending the safety of paraquat in legal proceedings? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the lack of epidemiological surveys were a definite weakness in properly evaluating the safety of paraquat use? MS. REISMAN: Objection to form. A As I say, there was a large body of information in supporting that an epidemiology study would have been a good thing to do but not because of any weakness on on my part. Again, I don't recall the discussions we had, and I didn't write this. Q (By Mr. Kelly) From 1974 to 1986, did you at any point personally commission one or more epidemiological surveys in order to properly evaluate the safety of paraquat use? MS. REISMAN: Objection to form. A If I understood your question, no. Q (By Mr. Kelly) Okay. From 1974 to 1986, did any member of your group either individually or together commission one or more epidemiological surveys in order to properly evaluate use in the United States? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 in 1973 through 1986 or the work of anybody in your group to defend paraquat's safety to the state of California? MS. REISMAN: Objection to form. Asked and answered. A To share to the extent that we did that, it would have been a sharing of data and information, and I mean, that's what we did. Q (By Mr. Kelly) Okay. Was it any part of your job or other members of the group to defend paraquat's safety in lawsuits against Chevron or workers' compensation claims against Chevron from 1973 through 1986? MS. REISMAN: Objection to form. A Yes, it was. Q (By Mr. Kelly) Okay. When the phrase "defending the safety of paraquat" when you look at that phrase, do you look at that with the connotation of defending the safety of paraquat in legal proceedings? MS. REISMAN: Objection to form. A You know, I don't have a specific

10 (Pages 34 to 37)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 13 of 41 Page ID #2756

Richard Cavalli August 23, 2022

	Page 38	יח	VTTAT Page 40
1	the 1973 through 1986 period, were there any persons	Lil	- A- I'm not there yet.
2	besides yourself who had as part of their job defending	2	Q Oh, I'm sorry. At the top of the page to
3	the safety of paraquat in either lawsuits against	3	make it easier for you.
4	Chevron or workers' compensation claims?	4	A Page 4 of the document.
5	MS. REISMAN: Objection to form.	5	Q Yes. And way up at the top,
6	A We did provide assistance in in those	6	Roman Numeral II, it says "Meetings With"?
7	cases from a factual standpoint.	7	A Yes.
8	Q (By Mr. Kelly) And when you say "we," which	8	Q Can you see that you are present with
9	persons in your group are you referring to?	9	Dr. Ospenson?
10	A Myself, John Ford. I think it was just the	10	A I am. I was.
11	two of us.	11	Q And is it also correct that the other folks
12	MR. KELLY: I want to move to the next	12	on the list Swan, Fletcher, and Waitt were ICI people?
13	thing. Exhibit 49.	13	MS. REISMAN: Objection to form.
14	(Exhibit 49 has been marked and now	14	A Yes.
15	identified for the record.	15	
16		16	Q (By Mr. Kelly) Do you recognize PPD next to Mr. Waitt's name as the plant protection division of
10 17	MS. REISMAN: When you get to a convenient	17	ICI?
	stopping point, Mike, it's probably a good time for a		
18	break. I think we've been going a bit over an hour.	18	A I I think that's what PPD was.
19	MR. KELLY: Okay. We can stop.	19	Q Okay. If you'll turn to the next page,
20	VIDEOGRAPHER: Okay. We're going off the	20	No. 5, heading "Chronic Toxicity."
21	record at 9:26 a.m.	21	Do you see that?
22	(A break was taken.)	22	A Not yet.
23	VIDEOGRAPHER: We're back on the record at	23	Q Okay.
24	9:42 a.m.	24	A Yes, I do.
25	Q (By Mr. Kelly) Mr. Cavalli, we're back on the	25	Q It says: "Chevron are concerned on the
		i	
	Page 39		Page 41
1	_	1	_
1 2	Page 39 record here. Are you good to continue forward? A Yes, I am.	1	chronic effects of paraquat sprays resulting from
	record here. Are you good to continue forward? A Yes, I am.	2	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The
2 3	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I 	2 3	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS,
2 3 4	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? 	2 3 4	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury."
2 3 4 5	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. 	2 3 4 5	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a
2 3 4 5 6	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 	2 3 4 5 6	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or
2 3 4 5 6 7	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are 	2 3 4 5 6 7	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting?
2 3 4 5 6 7 8	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." 	2 3 4 5 6 7 8	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? 	2 3 4 5 6 7 8 9	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't
2 3 4 5 6 7 8 9	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. 	2 3 4 5 6 7 8 9 10	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document.
2 3 4 5 6 7 8 9 10 11	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? 	2 3 4 5 6 7 8 9 10 11	chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay.
2 3 4 5 6 7 8 9 10 11 12	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. 	2 3 4 5 6 7 8 9 10 11 12	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other.
2 3 4 5 6 7 8 9 10 11 12 13	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central 	2 3 4 5 6 7 8 9 10 11 12 13	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job
2 3 4 5 6 7 8 9 10 11 12 13 14	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern on behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the bottom of that paragraph, do you see the sentence that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the bottom of that paragraph, do you see the sentence that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that correct? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the bottom of that paragraph, do you see the sentence that begins: "Refutation of this claim"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 record here. Are you good to continue forward? A Yes, I am. Q Okay. Just before we took this break, I think I handed you Exhibit 49; is that right? A Yes, you did. Q Okay. This has a date stamped on it of 24 November 1975, but I think that's these are "Notes on Meetings Held at CTL 6-9 October '75." Do you see that on the front page? A Yes, I do. Q And do you know that CTL is part of ICI? A Yes. Q That's the Central is it the Central Toxicology Laboratory? A Yes. Q And during this period of time '73, '74 through '86, you had more than one opportunity to go and meet on this biannual program with folks at ICI? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that correct? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 chronic effects of paraquat sprays resulting from four cases reported to the state of California. The syndrome is reported as injury to the CNS, nonspecific liver/kidney injury." Just stopping right there, do you have a memory of in 1975 in the fall carrying that concern or behalf of Chevron to this meeting? MS. REISMAN: Objection to form. A No. I don't remember the meeting. I don't remember the document. Q (By Mr. Kelly) Okay. A I can't say one way or the other. Q And in 1975, it was still part of your job to assist in the defense of lawsuits against Chevron alleging injury from paraquat exposure? MS. REISMAN: Objection to form. Q (By Mr. Kelly) Is that right? A It was. Q Okay. If you just come down towards the bottom of that paragraph, do you see the sentence that begins: "Refutation of this claim" Do you see that sentence?

11 (Pages 38 to 41)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 14 of 41 Page ID #2757

Richard Cavalli August 23, 2022

1		1	
	Page 42	TN	Page 44
1	positive data to use in litigation cases."	\mathbf{L}_{1}	MS. REISMAN: Objection to form.
2	Did you on behalf of Chevron reach out to	2	A The we did not do such a study.
3	ICI for information, witnesses, or data to use in	3	Q (By Mr. Kelly) Going down to the next
4	defending litigation cases?	4	paragraph there, it says: "Activity of paraquat on
5	MS. REISMAN: Objection to form.	5	CNS."
6		6	
7	A I don't recall one way or the other. Q (By Mr. Kelly) In 19 November of	7	Do you understand that CNS in this context
8	excuse me.	8	refers to the nervous system? MS. REISMAN: Objection to form.
9		9	A Yes.
10	In October of 1975 and I'm looking at the next sentence it says: "It is suggested that a	10	Q (By Mr. Kelly) Did you or your team at any
10	critical epidemiology study is carried out and a	10	time investigate central nervous system effects on
12	long-term toxicity study using sprays on animals."	12	human beings as reflected in autopsy data that you
12	Was it your belief in the fall of 1975 that	13	collected?
13	-	14	MS. REISMAN: Objection to form.
14	both an epidemiology study and a long-term toxicity	15	A You lost me somewhere.
15 16	study using sprays on animals was necessary to assist in defending lawsuits against Chevron?	16	
16		17	· · · · · · · · ·
17	MS. REISMAN: Objection to form.		you at and we have I think we'll get to some
	A Specifically with regard to lawsuits, I I	18	autopsies here before we finish.
19 20	don't know one way or the other. Q (By Mr. Kelly) The question of a critical	19 20	Over time you, Mr. Ford, and others
20			collected autopsies from victims of paraquat
21	epidemiology study actually, let me rephrase it.	21 22	poisoning, correct?
	Was there any time in 1975 that you		MS. REISMAN: Objection to form.
23	suggested to ICI an epidemiology study should be	23	Q (By Mr. Kelly) Is that right?
24	carried out as well as a long-term study using sprays	24	A Yes.
25	on animals?	25	Q All right. Was discussion of the autopsies,
		i	
	Page 43		Page 45
1	_	1	
1 2	MS. REISMAN: Objection to form.	1	of paraquat poisoning autopsies done in the
	MS. REISMAN: Objection to form. A There were such discussions.		of paraquat poisoning autopsies done in the United States, something that was ever discussed at
2	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a	2	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings?
2 3	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a	2 3	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way
2 3 4	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology	2 3 4	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other.
2 3 4 5	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a	2 3 4 5	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in
2 3 4 5 6	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on	2 3 4 5 6	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other.
2 3 4 5 6 7	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"?	2 3 4 5 6 7	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the
2 3 4 5 6 7 8	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form.	2 3 4 5 6 7 8	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on
2 3 4 5 6 7 8 9	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please.	2 3 4 5 6 7 8 9	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning?
2 3 4 5 6 7 8 9 10	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir.	2 3 4 5 6 7 8 9 10	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would	2 3 4 5 6 7 8 9 10 11	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information.
2 3 4 5 6 7 8 9 10 11 12	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study	2 3 4 5 6 7 8 9 10 11 12	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this
2 3 4 5 6 7 8 9 10 11 12 13	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using	2 3 4 5 6 7 8 9 10 11 12 13	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent
2 3 4 5 6 7 8 9 10 11 12 13 14	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals?	2 3 4 5 7 8 9 10 11 12 13 14	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist
2 3 4 5 6 7 8 9 10 11 12 13 14 15	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending lawsuits?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were sufficient to cause debilitation." Do you see that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending lawsuits? MS. REISMAN: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were sufficient to cause debilitation." Do you see that sentence?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending lawsuits? MS. REISMAN: Objection to form. A We didn't Chevron did not do an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were sufficient to cause debilitation." Do you see that sentence? A I do.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending lawsuits? MS. REISMAN: Objection to form. A We didn't Chevron did not do an epidemiology study. That's all I can say.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were sufficient to cause debilitation." Do you see that sentence? A I do. Q Does that refresh your memory at all as to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MS. REISMAN: Objection to form. A There were such discussions. Q (By Mr. Kelly) Okay. And was there a decision made that ICI would provide Chevron with a using the phraseology here "critical epidemiology study and a long-term toxicity study using sprays on animals"? MS. REISMAN: Objection to form. A One more time for me, please. Q (By Mr. Kelly) Yes, sir. Was there a decision made that ICI would provide Chevron with a critical epidemiological study and a long-term toxicity toxicity study using sprays on animals? MS. REISMAN: Objection to form. A I don't recall one way or the other. Q (By Mr. Kelly) Did Chevron itself ever do an epidemiology study for the purpose of defending lawsuits? MS. REISMAN: Objection to form. A We didn't Chevron did not do an epidemiology study. That's all I can say. Q (By Mr. Kelly) All right. Did Chevron at any	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of paraquat poisoning autopsies done in the United States, something that was ever discussed at the Chevron ICI meetings? A Again, specifically I don't recall one way or the other. Q Do you generally remember whether you set in place a protocol or process for exchanging all of the autopsies that you obtained between you and ICI on victims of paraquat poisoning? MS. REISMAN: Objection to form. A We did exchange information. Q (By Mr. Kelly) Okay. Going back to this paragraph just for a second. It says: "In a recent autopsy on a paraquat poisoning, the pathologist discovered lesions on the motor neurons." Do you remember discussing that with ICI? A I do not one way or another. Q It goes on to say: "The lesions were sufficient to cause debilitation." Do you see that sentence? A I do. Q Does that refresh your memory at all as to whether or not the discussion of autopsy-discovered

12 (Pages 42 to 45)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 15 of 41 Page ID #2758

Richard Cavalli August 23, 2022

	Page 46		Page 48
1	MS. REISMAN: Objection to form.	$ \mathbf{L}_{1} $	didn't support involvement of the central nervous
2	A You know, again, I don't remember the	2	system.
3	specific meeting.	3	Q (By Mr. Kelly) Okay. My question,
4	Q (By Mr. Kelly) Okay.	4	Mr. Cavalli, was a little bit different. It's a
5	A So	5	little just a discreet question.
6	Q I'm wondering more generally in the '73 to	6	With reference to studying the CNS effect of
7	'86 period, do you have a memory of discussing that	7	ataxia in people exposed to paraquat, did you or your
8	topic?	8	group ever endeavor to study that focused topic?
9	MS. REISMAN: Objection to form.	9	MS. REISMAN: Objection to form. Asked and
10	A We discussed numerous topics, this may or	10	answered.
11	may not have been among them. I just that was a	11	A In human beings?
12	long time ago.	12	Q (By Mr. Kelly) Yes, sir.
13	Q (By Mr. Kelly) Well, I understand it was a	13	A Don't believe so.
14	long time ago, sir, but was potential central nervous	14	Q Okay. And then the sentence continues:
15	system effects of paraquat on human beings a topic of	15	"And Fletcher has received a few inquiries on
16	importance for the ICI Chevron group?	16	peripheral neurites."
17	MS. REISMAN: Objection to form.	17	Do you see that part of the sentence?
18	A Yes.	18	A Yes, I do.
19	Q (By Mr. Kelly) Okay. If we continue down	19	Q Do you know Dr. Fletcher?
20	this paragraph, do you see I'm starting with the	20	A I do.
21	sentence that begins with "Fisher"	21	Q He was your primary contact at ICI?
22	Do you see that?	22	A Yes.
23	A Uh-huh.	23	MS. REISMAN: Objection to the form.
24	Q Just the word "Fisher." That's someone's	24	Q (By Mr. Kelly) And did you and Dr. Fletcher
25	name?	25	at any time investigate or commission any analysis of
	D 47		
	Page 47		Page 49
1	A I see that, yes.	1	the link between paraquat exposure and the development
2	A I see that, yes.Q And do you know who that refers to where it	2	the link between paraquat exposure and the development of peripheral neuritis?
2 3	A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"?	2 3	the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form.
2 3 4	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? 	2 3 4	the link between paraquat exposure and the development of peripheral neuritis?MS. REISMAN: Objection to form.A Don't recall one way or the other.
2 3 4 5	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? 	2 3 4 5	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says:
2 3 4 5 6	A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if	2 3 4 5 6	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check,
2 3 4 5 6 7	A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is.	2 3 4 5 6 7	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological
2 3 4 5 6 7 8	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't 	2 3 4 5 6 7 8	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study."
2 3 4 5 6 7 8 9	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. 	2 3 4 5 6 7 8 9	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that?
2 3 4 5 6 7 8 9 10	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence 	2 3 4 5 6 7 8 9 10	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes.
2 3 4 5 6 7 8 9 10 11	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat 	2 3 4 5 6 7 8 9 10 11	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study
2 3 4 5 6 7 8 9 10 11 12	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part 	2 3 4 5 6 7 8 9 10 11 12	the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a
2 3 4 5 6 7 8 9 10 11 12 13	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. 	2 3 4 5 6 7 8 9 10 11 12 13	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the
2 3 4 5 6 7 8 9 10 11 12 13 14	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying the CNS effect of ataxia in people exposed to paraquat, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're talking about the one you also referenced yesterday in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying the CNS effect of ataxia in people exposed to paraquat, did you or your group ever endeavor to study that 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're talking about the one you also referenced yesterday in your direct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying the CNS effect of ataxia in people exposed to paraquat, did you or your group ever endeavor to study that focused topic? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're talking about the one you also referenced yesterday in your direct? MS. REISMAN: Objection. Form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying the CNS effect of ataxia in people exposed to paraquat, did you or your group ever endeavor to study that focused topic? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're talking about the one you also referenced yesterday in your direct? MS. REISMAN: Objection. Form. A I probably, yeah.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A I see that, yes. Q And do you know who that refers to where it says "Fisher has also reported ataxia"? MS. REISMAN: Wait. What's the question? Are you asking if he sees that? MR. KELLY: I'm ask no. I'm asking if he knows who Fisher is. A Well, I may have at one point, but I don't recall. Q (By Mr. Kelly) All right. The full sentence says: "Fisher has also reported ataxia from paraquat administered by any route." Just focusing on that part of it. Do you know what ataxia is? A Yes, I do. Q Is that a CNS effect? MS. REISMAN: Objection to form. A It can be. Q (By Mr. Kelly) And with reference to studying the CNS effect of ataxia in people exposed to paraquat, did you or your group ever endeavor to study that focused topic? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 the link between paraquat exposure and the development of peripheral neuritis? MS. REISMAN: Objection to form. A Don't recall one way or the other. Q (By Mr. Kelly) And the next sentence says: "It was agreed that this effect was difficult to check, but evidence might be obtained from an epidemiological study." Do you see that? A Yes. Q Did anyone ever do an epidemiological study to investigate the relationship or lack of a relationship between paraquat exposure and the development of peripheral neuritis in human beings? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kelly) Who did that study? A Dr. Howard of ICI and a Dr. Sabapathy. Q Is the the Howard-Sabapathy study you're talking about the one you also referenced yesterday in your direct? MS. REISMAN: Objection. Form.

13 (Pages 46 to 49)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 16 of 41 Page ID #2759

Richard Cavalli August 23, 2022

	Page 50	171	TTIAT Page 52
1	MS. REISMAN: Objection to form. Asked and	$ \mathbf{L}_{\mathbf{I}} $	wrote on it was something you authored for review by
2	answered.	2	the person who was your superior, correct?
3		3	A Yes.
	A It would have included their examination		
4	would have found peripheral neuritis neuritis	4	Q All right. I just want to focus on two
5	excuse me had it been there.	5	things. First the first sentence says: "The
6	Q (By Mr. Kelly) Okay. I'm going to try and	6	following is a summary of the meetings held between
7	move with some dispatch. I'm moving to my next	7	myself and Ken Fletcher of CTL on February 17 and 18
8	exhibit. Mr. Cavalli, if you would put that aside.	8	1976."
9	Thank you, sir.	9	Did I read that correctly?
10	(Exhibit 48 has been marked and now	10	A That's what's on the page.
11	identified for the record.	11	Q And in this context, "myself" was you,
12	Q (By Mr. Kelly) This particular exhibit is	12	Mr. Richard Cavalli, right?
13	marked No. 48. This as you can see on the on the	13	A Yes.
14	first page, appears to be directed to Mr. J.N. Osperson	14	Q Okay. And and this would have been
15	[as pronounced]?	15	consistent with the arrangement that was struck where
16	MS. REISMAN: Ospenson.	16	Fletcher would be the primary contact for ICI, you
17	Q (By Mr. Kelly) Ospenson.	17	would be the primary contact for Chevron; is that
18	This is an internal Chevron document; is	18	true?
19	that right?	19	MS. REISMAN: Objection to form.
20	A Yes, it is.	20	A In matters pertaining to health effects,
21	MS. REISMAN: Now, I'm just going to object	21	yes.
22	because the copy that you've put in front of the	22	Q (By Mr. Kelly) Okay. I'm looking exclusively
23	witness, Mr. Kelly, is a Syngenta document. So I	23	here at Paragraph 3. This is in 1976. It begins: "We
24		24	
	don't know what your question is actually asking		discussed at some length the gaps in our knowledge of
25	but	25	the chronic effects of paraquat exposure."
	Page 51		Page 53
1	MR. KELLY: My question is you'll find	1	Did I read that correctly?
2	out if you wait.	2	A Yes, you did.
3	MS. REISMAN: No, no, no. My point is	3	Q And so in 1976, were both you and
4	you you said that this document, this particular	4	Dr. Fletcher acknowledging there were gaps in your
5	document is not a Chevron document. It is so I	5	knowledge regarding the effects of paraquat exposure?
6	just wanted to make that clear. You can go on with	6	MS. REISMAN: Objection to form.
7	your questions.	7	A You know, I I I don't recall this
8	Q (By Mr. Kelly) Do you see the last page, sir,	8	specific document. I don't recall what Ken and I
9	and where you are the signature on this document?	9	discussed, and I don't know we may have discusse
10	A Yes, I do.	10	gaps, but it doesn't say that we found gaps. But I
11	MS. REISMAN: Just so there's no	11	have very poor recollection of this.
12	Mr. Kelly, I'm objecting because this is not from	12	Q (By Mr. Kelly) Well, you do recall that at
13	Syngenta and are handwritten notes I mean, this is	13	this particular time in history, it would have both
14	not from Chevron files, and there are handwritten	14	been part of your personal practice and your job
15	notes on it. So at least on mine. So go ahead.	15	responsibilities to accurately report to Dr. Ospenson
16	Q (By Mr. Kelly) Let's focus on Exhibit 48	16	what transpired between you and Dr. Fletcher, correct?
17	here. You see it bears the date March 29, 1976,	17	MS. REISMAN: Objection. Objection to form.
18	directed to Mr. J.N. Ospenson.	18	A Yes. It would have been.
19	You know who that is, correct?	19	Q (By Mr. Kelly) There would be no incentive,
	A Yes.	20	purpose, or reason to mislead Dr. Ospenson, would
	Q And do you see the last page says: "Original	21	there?
20	Q And do you see the last page says. Original		A No.
20 21	Signed R.D. Cavalli Cavalli." Excuse me.	22	A 110.
20 21 22	Signed R.D. Cavalli Cavalli." Excuse me.		
20 21 22 23	Signed R.D. Cavalli Cavalli." Excuse me. A Yes, I see that.	23	Q The second sentence says: "The animal
20 21 22	Signed R.D. Cavalli Cavalli." Excuse me.		

14 (Pages 50 to 53)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 17 of 41 Page ID #2760

Richard Cavalli August 23, 2022

	Page 54		Page 5
1		$ E_1 $	Q "in which he states that he has reviewed
1	That was a statement that you made here as	2	
2	of 1976, correct?	1	this area with Allen Calderbank and Arthur Waitt, an
3	A Correct.	3	they do not believe it warranted to repeat any of this
4	Q And you go on to say: "Some are poorly	4	work."
5	done." Right?	5	Did I say that correctly?
6	MS. REISMAN: Objection to form.	6	A You did.
7	What are you asking him?	7	Q And to repeat any of this work was asking
8	Q (By Mr. Kelly) You report here that with	8	them to repeat the animal studies to bring them up to
9	reference to the animal studies that are available,	9	date and to make sure they were not poorly done,
10	"some are poorly done." Correct?	10	right?
11	A That's what it says.	11	MS. REISMAN: Objection to form.
12	Q And are "poorly done studies" studies that	12	A Again, I don't remember the meeting.
13	you regularly rely on?	13	Q (By Mr. Kelly) And you are unable to
14	MS. REISMAN: Objection to form.	14	ascertain actually, I'll withdraw that.
15	A Could you	15	You then write as follows: "I agree with
16	Q (By Mr. Kelly) Yes, sir. My question was,	16	this" and this that phrase, "I agree with this"
17	are "poorly done studies" studies that you regularly	17	references not redoing the studies, correct?
18	rely on?	18	MS. REISMAN: Objection to form.
19	MS. REISMAN: Objection to form.	19	A I believe so.
20	A That's you know, I I I don't	20	Q (By Mr. Kelly) Okay. "I agree with this only
21	remember what studies I had in mind at that time. It	21	if we can do the proposed epidemiology study. If no
22	says "some," not "all," on the paper. I just don't	22	our only recourse will be to have good animal studies
23	remember one way or the other.	23	in this area."
24	Q (By Mr. Kelly) The next sentence says: "In	24	Did I read that correctly?
25	fact, the cause of death from chronic exposure to	25	A Yes, you did.
	Page 55		Page 5
1	paraquat could not be determined from these studies."	1	Q What is the proposed epidemiology study to
2	Do you see that sentence?	2	which you reference in the March 29, 1976
3	A Ido.	3	correspondence to Ospenson?
4	Q And it would be important to have current,	4	A The it would have been the study that was
5	valid, reliable studies from which the cause of death	5	ultimately conducted in Malaysia by Dr. Howard an
6	from chronic exposure to paraquat could be determined;	6	Dr. Sabapathy.
7	isn't that correct?	7	Q And so were you for Chevron proposing an
8	MS. REISMAN: Objection to form.	8	epidemiology study in Malaysia rather than a study in
9	A Yes.	9	the United States to substitute for the poorly done
10	Q (By Mr. Kelly) Then you go on to say:	10	animal studies referred to here?
11	"Dr. Fletcher agreed to review those and to consider	11	MS. REISMAN: Objection to form.
12	repeating certain of the studies."	12	A There – there were – I mean, basically,
13	Did I get that right?	13	yes.
14	A You did.	14	Q (By Mr. Kelly) Okay. Okay.
14	Q And does this reflect that you, in fact,	15	I'm going to next my exhibit, sir, which is
	asked ICI to get current studies that were not poorly	16	Exhibit 50.
		17	A Thank you.
16	done?	1	A Thank you. (Exhibit 50 has been marked and now
16 17	done? MS_REISMAN: Objection to form	1 19	селиния зу наз веен шагкей ани ной
16 17 18	MS. REISMAN: Objection to form.	18	
16 17 18 19	MS. REISMAN: Objection to form. A You know, I don't recall one way or the	19	identified for the record.
16 17 18 19 20	MS. REISMAN: Objection to form. A You know, I don't recall one way or the other.	19 20	identified for the record. Q (By Mr. Kelly) This Exhibit 50 at the top
16 17 18 19 20 21	MS. REISMAN: Objection to form. A You know, I don't recall one way or the other. Q (By Mr. Kelly) The next sentence says then:	19 20 21	identified for the record. Q (By Mr. Kelly) This Exhibit 50 at the top says September of 1976, and on the second page, it is
16 17 18 19 20 21 22	MS. REISMAN: Objection to form. A You know, I don't recall one way or the other. Q (By Mr. Kelly) The next sentence says then: "I have recently received a letter from him,	19 20 21 22	identified for the record. Q (By Mr. Kelly) This Exhibit 50 at the top says September of 1976, and on the second page, it is headed: "Minutes of Chevron/CTL Liaison Meeting 8-5
16 17 18 19 20 21 22 23	MS. REISMAN: Objection to form. A You know, I don't recall one way or the other. Q (By Mr. Kelly) The next sentence says then: "I have recently received a letter from him, enclosed" and here you're referencing Dr. Fletcher,	19 20 21 22 23	identified for the record. Q (By Mr. Kelly) This Exhibit 50 at the top says September of 1976, and on the second page, it is headed: "Minutes of Chevron/CTL Liaison Meeting 8-9 September 1976." Correct?
16 17 18 19 20 21 22	MS. REISMAN: Objection to form. A You know, I don't recall one way or the other. Q (By Mr. Kelly) The next sentence says then: "I have recently received a letter from him,	19 20 21 22	identified for the record. Q (By Mr. Kelly) This Exhibit 50 at the top says September of 1976, and on the second page, it is headed: "Minutes of Chevron/CTL Liaison Meeting 8-5

15 (Pages 54 to 57)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 18 of 41 Page ID #2761

Richard Cavalli August 23, 2022

		_	Page 60
	Page 58		
1	think I was clear enough.	1_1	damage. Chevron believe that more work should be
2	Was it correct that there were twice yearly	2	carried out on the effects of chronic exposure to
3	meetings, once in the US in California and once in	3	paraquat to help in the defense of these actions.
4	London with the ICI people?	4	Two approaches were seen to be possible - experimental
5	MS. REISMAN: Objection to form.	5	and epidemiological."
6	A Minor point, the meetings were held in	6	Now, this was the report you gave, right?
7	Manchester.	7	MS. REISMAN: Objection to form.
8	Q (By Mr. Kelly) Once a year in Manchester,	8	A No. Again, I don't specifically recall the
9	once a year in California?	9	document or the meeting, but that's what's written on
10	MS. REISMAN: Objection to form.	10	the page.
11	Q (By Mr. Kelly) Is that right?	11	Q (By Mr. Kelly) Okay. In the September of
12	A Yes.	12	1976 which is ten years plus or minus since Chevron had
13	Q And beginning in 1973? Or had they already	13	been selling paraquat, did you and your group have in
14	begun before you were tasked with your paraquat	14	mind experimental or epidemiological work to assist in
15	responsibilities?	15	the defense of litigation?
16	A My recollection is that those meetings were	16	MS. REISMAN: Objection to form.
17	held before I got involved.	17	A One more time, please.
18	Q And for how long did they continue? Did	18	Q (By Mr. Kelly) Sure.
19	they continue all the way until 1986 when Chevron	19	Did you and your group in 1976 ten years
20	withdrew from the business?	20	
20	MS. REISMAN: Objection to form.	1	after you had started or not you but Chevron had
22	-	21	started selling paraquat in the US have in mind what
22	A I believe they did.	22	kind of experimental or epidemiological reach would be
	Q (By Mr. Kelly) Okay. I just have one small	23	necessary to assist in the defense of litigation
24	piece of this that involves you that I wanted to speak	24	alleging injury from paraquat exposure?
0 E	-1	0.5	
25	about, and so if you will turn to the one, two,	25	MS. REISMAN: Objection to form.
25	about, and so if you will turn to the one, two, Page 59	25	MS. REISMAN: Objection to form. Page 61
25	· · · · · · · · · · · · · · · · · · ·	25	
	Page 59		Page 61
1	Page 59 third page of text. In the lower right-hand corner,	1	Page 61 A Specifically to defend litigation?
1 2	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay.	1 2	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall.
1 2 3	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says:	1 2 3	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is
1 2 3 4	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA."	1 2 3 4	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more
1 2 3 4 5	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says:	1 2 3 4 5	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic
1 2 3 4 5 6	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do.	1 2 3 4 5 6	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more
1 2 3 4 5 6 7	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving	1 2 3 4 5 6 7	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these
1 2 3 4 5 6 7 8	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do.	1 2 3 4 5 6 7 8	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly?
1 2 3 4 5 6 7 8 9	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by	1 2 3 4 5 6 7 8 9	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form.
1 2 3 4 5 6 7 8 9 10	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from	1 2 3 4 5 6 7 8 9 10	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly.
1 2 3 4 5 6 7 8 9 10 11	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of	1 2 3 4 5 6 7 8 9 10 11	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately
1 2 3 4 5 6 7 8 9 10 11 12	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to
1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings?	1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against
1 2 3 4 5 6 7 8 9 10 11 12 13	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall one way or the other whether we did work to defend
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation against Chevron?	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further understand the toxicity of paraquat and its use.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation against Chevron? MS. REISMAN: Objection to form.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further understand the toxicity of paraquat and its use. Q (By Mr. Kelly) This particular little piece
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation against Chevron? MS. REISMAN: Objection to form. A Not to my knowledge.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To - you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further understand the toxicity of paraquat and its use. Q (By Mr. Kelly) This particular little piece of the report says: "There are four cases involving
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation against Chevron? MS. REISMAN: Objection to form. A Not to my knowledge. Q (By Mr. Kelly) Continuing with that	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further understand the toxicity of paraquat and its use. Q (By Mr. Kelly) This particular little piece of the report says: "There are four cases involving hematological disorders."
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 59 third page of text. In the lower right-hand corner, the number is 1160. A Okay. Q And at the very bottom, it says: "Litigation USA." Do you see that? A I do. Q It says: "The four cases involving litigation against paraquat were summarized by Dr. Cavalli." Stop there. Was it a regular part of these meetings from '73 forward for you to report on the status of litigation between Chevron and American litigants at the joint meetings? MS. REISMAN: Objection to form. A I don't know if it was regular, but I think it was among the things we talked about. Q (By Mr. Kelly) Did the ICI scientists and professionals assist in the defense of the litigation against Chevron? MS. REISMAN: Objection to form. A Not to my knowledge.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 61 A Specifically to defend litigation? Q (By Mr. Kelly) Yes. A I don't recall. Q Okay. The your presentation here is reported as you saying: "Chevron believe that more work should be carried out on the effects of chronic exposure to paraquat to help in the defense of these actions." Did I read that correctly? MS. REISMAN: Objection to form. A You did read it correctly. Q (By Mr. Kelly) And did Chevron ultimately undertake work on the effects of chronic exposure to paraquat to help in the defense of litigation against it? MS. REISMAN: Objection to form. A To - you know, I don't I don't recall one way or the other whether we did work to defend litigation as opposed to doing work to further understand the toxicity of paraquat and its use. Q (By Mr. Kelly) This particular little piece of the report says: "There are four cases involving

16 (Pages 58 to 61)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 19 of 41 Page ID #2762

Richard Cavalli August 23, 2022

	Page 62	FNITTAI Page 64
1	A Ido.	Q (By Mr. Kelly) And this I will tell you,
2	Q This would be some blood-related injury,	2 it's not on here, Mr. Cavalli, but the computer says
3	disease, or ailment; is that right?	3 this is from December 12 of 1978, if it makes any
4	A Yes.	4 difference, the way these documents are produced.
5	Q And/or some organ damage of some kind. We	5 And this is simply headed: "Paraquat Worker
6	don't know which organ, correct?	6 Safety." If we go to the end of it, is this your name
7	A Doesn't say that here.	7 with your initials?
8	Q Which organ?	8 A Yes.
9	A No, it doesn't.	9 Q All right. And can we, therefore, be
10	Q Okay. Focusing just on that, do you have a	10 assured that this is something that you authored,
11	memory of Chevron undertaking work that had as its	11 read, and then initialed as accurate?
12	focus hematological disorders or organ damage where it	12 A It would have been.
13	studied the effect of chronic exposure to help defend	13 Q If you would just go to the page in the
14	those lawsuits?	14 lower, the third the second page, I'm sorry. 3320.
15	MS. REISMAN: Objection to form. Asked and	15 MS. REISMAN: I don't have a 3320.
16	answered.	16 MR. KELLY: 2320. I'm sorry. I need to get
17	A Again, the work would have been done for the	17 my lenses refracted.
18	overall assessment of paraquat and its risks but as	18 Q (By Mr. Kelly) The last paragraph on
19	opposed to being done for litigation purposes.	19 page 32320.
20	Q (By Mr. Kelly) Was that done?	20 A Oh, okay. Looking at the wrong number.
21	MS. REISMAN: Objection to form.	21 Q Oh, yeah. I'm sorry. I see there's another
22	A I lost the paragraph. Oh, there it is.	22 one at the bottom.
23	MS. REISMAN: Objection to form.	23 The paragraph begins: "Due to paraquat's
24	Do you know what he's asking?	24 extremely low vapor pressure" Do you see that?
25	MR. KELLY: No. You don't have to ask him.	25 A Yes.
	Page 63	Page 65
1	_	
1	He can tell me. It's not your job, Counsel. This is	1 Q Okay. I'm focused on the sentence that
2	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face
2 3	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator"
2 3 4	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there?
2 3	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am.
2 3 4 5	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please.
2 3 4 5 6 7	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator"
2 3 4 5 6	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions
2 3 4 5 6 7 8 9	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be
2 3 4 5 6 7 8	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn."
2 3 4 5 6 7 8 9 10	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn."
2 3 4 5 6 7 8 9 10 11	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worm." 11 Do you have in mind what that refers to, 12 sir?
2 3 4 5 6 7 8 9 10 11 12	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning.	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worm." 11 Do you have in mind what that refers to, 12 sir?
2 3 4 5 6 7 8 9 10 11 12 13	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I
2 3 4 5 6 7 8 9 10 11 12 13 14	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this
2 3 4 5 6 7 8 9 10 11 12 13 14 15	He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders?	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worm." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worm." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q 17 A 14 Just know what it says.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A 6 Q 9 Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q 17 A 18 Q 19 All right. Well, in 1978, sir, did you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more things. Then I'm going to pass this. Let me 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q Okay. 17 A I just know what it says. 18 Q All right. Well, in 1978, sir, did you 19 oppose the utilization of a full-face respirator
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more things. Then I'm going to pass this. Let me apparently, I had two of these. So giving one to 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q Okay. 17 A I just know what it says. 18 Q All right. Well, in 1978, sir, did you 19 oppose the utilization of a full-face respirator 20 because it would lessen the effectiveness of the use
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more things. Then I'm going to pass this. Let me apparently, I had two of these. So giving one to counsel and one to the witness. 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q Okay. 17 A I just know what it says. 18 Q All right. Well, in 1978, sir, did you 19 oppose the utilization of a full-face respirator 20 because it would lessen the effectiveness of the use 21 of full-face respirators for other chemicals for which
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more things. Then I'm going to pass this. Let me apparently, I had two of these. So giving one to counsel and one to the witness. 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worn." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q Okay. 17 A I just know what it says. 18 Q All right. Well, in 1978, sir, did you 19 oppose the utilization of a full-face respirator 20 because it would lessen the effectiveness of the use 21 of full-face respirators for other chemicals for which 22 they should be worn?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 He can tell me. It's not your job, Counsel. This is trial this is trial testimony. Stop pretending it's not. Please. MS. REISMAN: Mr. Kelly, please. The witness looks confused to you and me. MR. KELLY: The witness does not look confused. The witness looks no more confused than he's been for two days which is not confused. MS. REISMAN: Well, the record will is what it is. Why don't you continue with your questioning. MR. KELLY: Goodness gracious. Q (By Mr. Kelly) Did your group at any time do studies or analysis on the effect of paraquat exposure in causing hematological or organ disorders? A Those end points would have been would have been part of any subchronic or chronic study. MR. KELLY: Okay. I have just a couple more things. Then I'm going to pass this. Let me apparently, I had two of these. So giving one to counsel and one to the witness. This is Exhibit 43. Oh, I do have one more. Here you go, Counsel. 	1 Q Okay. I'm focused on the sentence that 2 begins: "A requirement to use a full-face 3 respirator" 4 Are you there? 5 A I am. 6 Q Okay. Let me read this, please. 7 "A requirement to use a full-face respirator 8 will only lessen the effectiveness of these directions 9 with regard to chemicals for which they should be 10 worm." 11 Do you have in mind what that refers to, 12 sir? 13 A You know, I don't remember the meeting. I 14 don't remember what this as I sit here, what this 15 inspired that. 16 Q Okay. 17 A I just know what it says. 18 Q All right. Well, in 1978, sir, did you 19 oppose the utilization of a full-face respirator 20 because it would lessen the effectiveness of the use 21 of full-face respirators for other chemicals for which 22 MS. REISMAN: Objection the form. Objection

17 (Pages 62 to 65)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 20 of 41 Page ID #2763

Richard Cavalli August 23, 2022

	Page 66	ריד	Page 68
1	whether that was my view or a view I carried for	$ \mathbf{L}_{l} $	Q- (By Mr. Kelly) And was it part of your job to
2	others.	2	respond on behalf of Chevron to the State of California
3	Q (By Mr. Kelly) All right. Did you ever carry	3	Worker Health and Safety Unit regarding what was
4	the view for others or for yourself that workers	4	appropriate protective gear in 1978?
5	utilizing paraquat sold by Chevron should be wearing	5	MS. REISMAN: Objection to form.
6	full-face respirators?	6	A I I may have done so. I just don't
7	MS. REISMAN: Objection to form.	7	recall.
8	A I don't recall one way or the other.	8	Q (By Mr. Kelly) And would that have been a
9	Q (By Mr. Kelly) Continuing in that paragraph,	9	task that would have been within the job description of
10	sir. You go on to say in this document you wrote	10	the position you held at that time?
11	and initialed "Likewise, there is no reason to	11	MS. REISMAN: Objection to form.
12	protect the entire body with waterproof gear since	12	A Yes, it would have been.
13	there is no evidence which indicates that the	13	Q (By Mr. Kelly) I have one last thing, sir,
14	incidental exposure to skin from dilute paraquat is	14	and then we're going to take a break and Mr. Kennedy is
15	detrimental."	15	going to conclude our work for the day.
16	Did I read that correctly?	16	MR. KELLY: I'm going to mark Exhibit 45, if
17	A Yes, you did.	17	I can.
18	Q Was that the opinion that you held or	18	(Exhibit 45 has been marked and now
19	carried or both in December of 1978?	19	identified for the record.
20	MS. REISMAN: Object to form.	20	Q (By Mr. Kelly) Yesterday in the questioning,
20	A Again, I I don't have a specific	21	there were questions for you about an article in
22	recollection of this. It just – long ago.	22	ScienceDirect linking proposing that there was a
23	Q (By Mr. Kelly) Okay. Sir, at any time	23	link between Parkinson's and exposure to paraquat.
24	between 1973 and 1986, did you, the sig signature	24	Do you remember that?
25	of this document, R.D. Cavalli, ever hold the opinion	25	MS. REISMAN: Give me one second. Go ahead.
	, , , 1		
	Page 67		Page 69
1	that there is no reason to protect the entire body with	1	Q (By Mr. Kelly) Do you remember that?
2	waterproof gear since there is no evidence which	2	A Yes, I do.
3			
	indicates that the incidental exposure to skin from	3	Q Okay. And and I think you talked about a
4	indicates that the incidental exposure to skin from dilute paraquat is detrimental?	3 4	
4 5	-		Q Okay. And and I think you talked about a
	dilute paraquat is detrimental?	4	Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that?A Yes, I do.
5	dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and	4 5	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a
5 6	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. 	4 5 6	Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that?A Yes, I do.
5 6 7 8 9	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of 	4 5 6 7 8 9	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here.
5 6 7 8 9 10	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job 	4 5 6 7 8 9	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N.
5 6 7 8 9 10 11	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's 	4 5 7 8 9 10 11	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do.
5 6 7 8 9 10 11 12	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face 	4 5 7 8 9 10 11 12	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go
5 6 7 8 9 10 11 12 13	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with 	4 5 7 8 9 10 11	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the
5 6 7 8 9 10 11 12 13 14	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? 	4 5 7 8 9 10 11 12	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go
5 6 7 8 9 10 11 12 13 14 15	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. 	4 5 6 7 8 9 10 11 12 13	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes.
5 6 7 8 9 10 11 12 13 14 15 16	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. 	4 5 6 7 8 9 10 11 12 13 14 15 16	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I
5 6 7 8 9 10 11 12 13 14 15 16 17	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person 	4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I
5 6 7 8 9 10 11 12 13 14 15 16 17 18	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect from paraquat exposure? 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it. Do you see that box of folks?
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect from paraquat exposure? MS. REISMAN: Objection to form. 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it. Do you see that box of folks? A Yes, I do.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect from paraquat exposure? MS. REISMAN: Objection to form. A There was an industrial hygiene group 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it. Do you see that box of folks? A Yes, I do. Q And your name is on there?
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect from paraquat exposure? MS. REISMAN: Objection to form. A There was an industrial hygiene group that whose business it was to recommend protective 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it. Do you see that box of folks? A Yes, I do. Q And your name is on there? MS. REISMAN: Objection to form.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 dilute paraquat is detrimental? MS. REISMAN: Objection to form. Asked and answered. A You know, again, I just don't remember one way or the other. Q (By Mr. Kelly) Sir, was there a period of time in 1978 where you had it as part of your job responsibilities to articulate what the company's position was with reference to wearing either full-face respirators or protecting the entire body with waterproof gear? MS. REISMAN: Objection to form. A You know, I just can't say. Q (By Mr. Kelly) Was there in 1978 any person other than yourself who was a spokesperson for the company on what the appropriate use was of either full-face respirators or waterproof gear to protect from paraquat exposure? MS. REISMAN: Objection to form. A There was an industrial hygiene group 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q Okay. And and I think you talked about a study by somebody named Barbeau. Do you remember talk talking about that? A Yes, I do. Q So I've handed you Exhibit 45, and this is a piece of correspondence from J.N. Ospenson to J.N. Sullivan where you are copied here. Do you see that? A I do. Q And as you look at this and you go to go two pages in, if you will. The Bates number in the corner is 3004. A Yes. Q And in the upper right-hand portion, I don't know what you call these. I do recall when I started practice we had these where you stamped everybody's name on something and you circulated and you read it. Do you see that box of folks? A Yes, I do. Q And your name is on there?

18 (Pages 66 to 69)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 21 of 41 Page ID #2764

Richard Cavalli August 23, 2022

	Page 70	17	VTTAT Page 72
1	so.	Lil	of the attachments is the article you discussed
2	Q (By Mr. Kelly) Great. And that's what my	2	yesterday; is that correct?
3	next question. Are these the folks in your department?	3	A What was the number page number?
4	MS. REISMAN: Objection to form.	4	Q Yes, sir.
5	A Yes.	5	A 6?
6	Q (By Mr. Kelly) Okay. Do you know who R. Gwin	6	Q Yeah. 006 in the lower right-hand corner.
7	Follis is?	7	A Yes.
8	А Не	8	Q This is the article you were discussing
9	Q Was I think is the correct way to say it.	9	yesterday with counsel, right?
.0	A He was chairman of the board of Chevron for	10	MS. REISMAN: Objection to form.
1	many years.	11	A I believe it is.
2	Q And in 1985, who was Mr. Keller?	12	Q (By Mr. Kelly) Does this refresh your memory
.3	A George Keller was the chairman of the board	13	that this is how you saw this article, you saw it when
4	at that time.	14	it was forwarded to the company by the former chairman
.5	Q And Mr. Follis, after his retirement, did he	15	MS. REISMAN: Objection to form.
.6	remain in contact with the executives there at	16	A No. I saw this article that other people
.7	Chevron?	17	sent to me. I – I just – I have no memory of
8	MS. REISMAN: Objection to form.	18	letters between chairman and vice chairmans and all
.9	Foundation.	19	that.
0	A I have no idea.	20	Q (By Mr. Kelly) And when you say I have a
1	Q (By Mr. Kelly) On on this page 3004,	21	memory of it from other people sending it to me, are
2	Mr. Follis's letter to Mr. Keller talks about an	22	you referring to people within the company?
3	article about paraquat. And the second paragraph says:	23	A You know, I can't say one way or the other.
4	"Since we don't want to take any chance of facing an	24	Q Okay. Okay.
5	asbestos situation down the road, I am sure your people	25	MR. KELLY: Mr. Cavalli, thank you for your
	Page 71		Page 73
1	_	1	_
1 2	are following this aspect of the matter most closely."	2	courtesy. I don't have additional questions at this time. And I think we'll take a break and let
2	Do you actually remember seeing this letter,	1	
3 4	sir?	3	Mr. Kennedy change chairs here.
	A I do not. Q Okay. Do you remember being consulted with	4	VIDEOGRAPHER: Okay. We're going off the record at 10:28 a.m.
			record at 10:28 a.m.
5			
5 6	respect to the response to Mr. Follis?	6	(A break was taken.)
5 6 7	respect to the response to Mr. Follis? A I don't.	6 7	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th
5 6 7 8	respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this	6 7 8	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m.
5 6 7 8 9	respect to the response to Mr. Follis?A I don't.Q Do you remember any discussion about this correspondence and this article and the question of a	6 7 8 9	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION]
5 6 7 8 9	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat 	6 7 8 9 10	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY:
5 6 7 8 9 0 1	respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem?	6 7 8 9 10 11	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I
5 7 8 9 0 1 2	respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form.	6 7 8 9 10 11 12	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought
5 7 8 9 0 1 2 3	respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen	6 7 8 9 10 11 12 13	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right?
5 7 8 9 0 1 2 3 4	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. 	6 7 8 9 10 11 12 13 14	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right.
5 6 7 8 9 0 1 2 3 4 5	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front 	6 7 8 9 10 11 12 13 14 15	(A break was taken.) VIDEOGRAPHER: Stand by. We're back on th record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on
5 6 7 8 9 0 1 2 3 4 5 6	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to 	6 7 8 9 10 11 12 13 14 15 16	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions
5 6 7 8 9 0 1 2 3 4 5 6 7	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. 	6 7 8 9 10 11 12 13 14 15 16 17	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right?
5 6 7 8 9 0 1 2 .3 .4 .5 .6 .7 .8	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological 	6 7 8 9 10 11 12 13 14 15 16 17 18	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right.
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of 	6 7 8 9 10 11 12 13 14 15 16 17 18 19	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an
5 6 7 8 9 .0 1 2 .3 4 5 .6 7 8 9 .0 1 2 .3 4 5 .6 7 8 9 .0	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of correspondence that you necessarily would have 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an understanding of of just how toxic paraquat is,
5 6 7 8 9 0 1 2 .3 4 5 .6 .7 8 .9 0 1 2 .3 4 .5 .6 .7 8 .9 0 1 2 .3 4 .5 .6 .7 8 .9 0 1 2 .3 .4 .5 .6 .7 8 .9 0 .1 2 .3 .4 .5 .7 8 .9 0 .1 2 .3 .4 .5 .7 8 .5 .5 .5 .5 .5 .5 .5 .5 .5 .5 .5 .5 .5	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of correspondence that you necessarily would have received copies of in your position? 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an understanding of of just how toxic paraquat is, just how dangerous it is, would I be correct in saying
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 9 0 1 2 3 4 5 6 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 7 8 9 0 1 2 3 4 5 7 8 9 0 1 2 3 7 8 9 0 1 2 3 7 8 9 1 2 3 1 2 3 7 8 9 1 2 3 7 8 9 1 2 3 7 8 9 1 2 3 7 7 8 9 1 2 3 7 7 8 9 1 2 3 7 7 8 9 7 8 9 1 2 3 2 3 7 7 7 8 9 10 1 2 3 7 7 8 9 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 2 1 2 1 2 1 2 2 1 1 2 2 2 1 2 1 2 2 1 2 2 2 1 2 1 2 2 2 1 2 2 2 2 1 2	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of correspondence that you necessarily would have received copies of in your position? MS. REISMAN: Objection to form. 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an understanding of of just how toxic paraquat is, just how dangerous it is, would I be correct in saying that if an applicator were to get as little as an
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of correspondence that you necessarily would have received copies of in your position? MS. REISMAN: Objection to form. A I don't recall any discussion of asbestos. 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an understanding of of just how toxic paraquat is, just how dangerous it is, would I be correct in saying that if an applicator were to get as little as an ounce of paraquat on their skin and not wash it off
5 6 7 8 9 .0 1 2 .3 4 5 .6 7 8 9 .0 1 2 .3 4 5 .6 7 8 9 .0	 respect to the response to Mr. Follis? A I don't. Q Do you remember any discussion about this correspondence and this article and the question of a long period of latency after exposure to paraquat resulting in a "asbestos"-like problem? MS. REISMAN: Objection to form. A No. I have no recollection of having seen this at the time. Q (By Mr. Kelly) And the back to the front page for a moment, the transmittal from Ospenson to Sullivan. Would a response regarding the toxicological effects of asbestos exposure in 1985 been the kind of correspondence that you necessarily would have received copies of in your position? MS. REISMAN: Objection to form. 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 (A break was taken.) VIDEOGRAPHER: Stand by. We're back on the record at 10:33 a.m. [EXAMINATION] QUESTIONS BY MR. KENNEDY: Q Mr. Cavalli, my name's Eric Kennedy, and I represent the plaintiffs in various lawsuits brought against Chevron. All right? A All right. Q And I want to focus my questioning today on your testimony given in response to the questions asked to you by the Chevron attorney. All right? A All right. Q Before I do that, though, so the jury has an understanding of of just how toxic paraquat is, just how dangerous it is, would I be correct in saying that if an applicator were to get as little as an

19 (Pages 70 to 73)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 22 of 41 Page ID #2765

Richard Cavalli August 23, 2022

	1	
Page 74	L J	Page 76
A That would depend on the circumstances.		Q This was 1982 when you were still working at
-	2	Chevron, true?
		A Uh-huh. Yes.
		Q Before you gave testimony yesterday in
		response to the questioning of the Chevron attorney,
		can you tell me about what meetings to prepare you for
		your testimony you had with the Chevron attorneys?
-		MS. REISMAN: Objection to form.
	1	A In this in this matter?
		Q (By Mr. Kennedy) Yes, sir.
	1	A Okay.
		MS. REISMAN: What are you asking?
-		MR. KENNEDY: Let him answer.
-		MS. REISMAN: Are you asking for the number
		of times? I'm not going to allow him to testify with
*		respect to the content of those minutes.
		Q (By Mr. Kennedy) Sir, if you can please
		answer my question.
-		MS. REISMAN: Could you answer it without
		revealing any of the content of your meetings and
		conversations with counsel.
-		THE WITNESS: Okay.
-		Could you repeat your question?
		Q (By Mr. Kennedy) Can you tell me about the
		preparation that you had by the attorneys for Chevron
please. And if you	25	preparation that you had by the attorneys for chevron
Page 75		Page 77
MS. REISMAN: Let me just have a standing	1	prior to your testimony here today?
objection to the use of this testimony without a hard	2	MS. REISMAN: And again, you can answer
copy or a full transcript and having directing this	3	other than with respect to the content of the meetings
witness to one single response.	4	that you have had with counsel.
With that objection, please proceed.	5	MR. KENNEDY: Do we have a Special Master
Q (By Mr. Kennedy) If you go to line 17, this	6	available?
was sworn testimony in the Ferebee case, was it not?	7	MR. FLOWERS: We can try.
A If you say so.	8	MR. KENNEDY: Check it out.
Q Question asked you	9	Q (By Mr. Kennedy) Please answer my question,
MS. REISMAN: Do you know whether it was	10	sir.
sworn testimony?	11	MS. REISMAN: You can you can answer
THE WITNESS: Well, looks like it.	12	without revealing the content of the conversations.
MS. REISMAN: Okay.	13	MR. KENNEDY: That's the third time. Once
Q (By Mr. Kennedy) "QUESTION: Doctor, can you	14	is enough. No?
answer my question once again, or can you answer it	15	MS. REISMAN: Well, I just I'm directing
once?	16	him not to answer with the respect to the content of
"If you put an ounce of paraquat on your	17	conversation.
skin, it will kill you, won't it, if you leave it on,	18	MR. KENNEDY: You've don't it three times.
if you don't wash it off?"	19	MS. REISMAN: You've asked the question
Your answer: "If you leave it on and if the	20	three times in an unclear way.
-	21	Q (By Mr. Kennedy) Go ahead, sir.
sufficient amount."	22	A I did meet with attorneys representing
Do you recall that testimony under oath?	23	Chevron on several occasions.
	1	
A I don't specifically recall it, but I see it	24	Q How many occasions?
	MS. REISMAN: Let me just have a standing objection to the use of this testimony without a hard copy or a full transcript and having directing this witness to one single response. With that objection, please proceed. Q (By Mr. Kennedy) If you go to line 17, this was sworn testimony in the Ferebee case, was it not? A If you say so. Q Question asked you MS. REISMAN: Do you know whether it was sworn testimony? THE WITNESS: Well, looks like it. MS. REISMAN: Okay. Q (By Mr. Kennedy) "QUESTION: Doctor, can you answer my question once again, or can you answer it once? "If you put an ounce of paraquat on your skin, it will kill you, won't it, if you leave it on, if you don't wash it off?" Your answer: "If you leave it on and if the skin breaks down, I would guess that might be a sufficient amount."	Q(By Mr. Kennedy) Sir, you remember and I2know it's a long time ago giving testimony all the3way back in in 1982 directly addressing the toxicity4of - of paraquat.5Do you ave cell that back in 1982?6A Do you have the name of the7QI'm going to let me bring that up.8MR. KENNEDY: If you can bring up9Mr. Cavalli's testimony from 4/29/1982, please.10Q(By Mr. Kennedy) This was the case ofFerebec. Do you recall that, sir?12A Yes. Thank you.13MS. REISMAN: Mr. Kennedy, do you have hardcopies of this?15MR. KENNEDY: Pardon me?16MS. REISMAN: Do you have hard copies ofyour exhibits?18MR. KENNEDY: I do not.19MS. REISMAN: Can we does anybody havehard copies?21MR. KENNEDY: This is transcript. This isnot23Q(By Mr. Kennedy) If you can go to page 1545,please. And if you25Page 75MS. REISMAN: Let me just have a standingobjection to the use of this testimony without a hardcopy or a full transcript and having directing thiswitness to one single response.With that objection, please proceed.QQ(By Mr. Kennedy) If you go to line 17, thiswas sworn testimony in the Ferebee case, was it not?AIf you say so.QQQMS

20 (Pages 74 to 77)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 23 of 41 Page ID #2766

Richard Cavalli August 23, 2022

1	O More than once? ONF178	Page 80
2	A Several implies more than once, yes.	2 A I am being paid for my time.
3	Q Where did those meetings take place?	3 Q (By Mr. Kennedy) And how much are you being
4	A They took place at my residence.	
5		1 /
6		31
6 7	your residence?	6 Q Today how many hours have you billed Chevron 7 for your time to testify?
	A Last week, I believe, was.	
8	Q And prior to last week, did you have a	8 MS. REISMAN: Objection to form.
9	meeting at your residence with the attorneys from	9 A I don't have that number in mind.
10	Chevron?	10 Q (By Mr. Kennedy) And last evening after the
11	A Prior to that, yes.	11 questioning by Mr. Kelly and before the commencement of
12	Q And more than one occasion?	12 his questioning today, did you meet with the Chevron
13	A On more than one occasion.	13 lawyers to discuss this case?
14	Q On more than two occasions prior to last	14 MS. REISMAN: Objection to form.
15	week?	15 A I did.
16	A More than two occasions.	16 Q (By Mr. Kennedy) And did you meet again
17	Q Would you say that you met with the	17 between Mr. Kelly's questioning last night and the
18	attorneys from Chevron more or less than	18beginning of his questioning today? Did you meet this
19	five occasions?	19 morning in talking to Chevron lawyers about this case?
20	A I couldn't say.	20 MS. REISMAN: Objection to form.
21	Q At each of those meetings, how long did	21 A Yes.
22	those meetings last at your home?	22 Q (By Mr. Kennedy) Let's talk about some of the
23	MS. REISMAN: Objection to form.	23 testimony of let's talk about some of the testimony
24	A They varied from couple of hours to four or	24 that you gave in response to the to the Chevron
25	five hours.	25 questioning.
	Page 79	Page 81
1	Page 79 Q (By Mr. Kennedy) And were you shown any	Page 81 1 You testified, sir, that that the
1 2	Q (By Mr. Kennedy) And were you shown any	1 You testified, sir, that that the
	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these	1 You testified, sir, that that the 2 scientific studies that you have reviewed led you to
2	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings?	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of
2 3	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators.
2 3 4 5	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that?
2 3 4	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection.	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah.
2 3 4 5 6	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your
2 3 4 5 6 7	Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection.	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat
2 3 4 5 6 7 8	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1 – I don't remember specifically. 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat A Yes. That was my belief at the time.
2 3 4 5 6 7 8 9 10	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I – I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat
2 3 4 5 6 7 8 9 10 11	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators,
2 3 4 5 6 7 8 9 10 11 12	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for
2 3 4 5 6 7 8 9 10 11 12 13	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1 I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents idin't refresh your 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators.
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents didn't refresh your recollection. 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1 I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents didn't refresh your recollection. 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents didn't refresh your recollection. If any of the documents refreshed your recollection. A None of the documents that I looked at 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form. A I believe that paraquat was safe for use if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I - I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection. 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form. A I believe that paraquat was safe for use if the label precautions were followed.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat? A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form. A I believe that paraquat was safe for use if the label precautions were followed. Q (By Mr. Kennedy) And, sir, you told us
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents didn't refresh your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form. A I believe that paraquat was safe for use if the label precautions were followed. Q (By Mr. Kennedy) And, sir, you told us yesterday that you believe that paraquat did not get
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A I I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents didn't refresh your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you by the lawyers from Chevron? 	 You testified, sir, that that the scientific studies that you have reviewed led you to believe that paraquat does not get into the brains of paraquat applicators. Do you remember stating that? A I probably did, yeah. Q And that's your your belief and was your belief when you were at Chevron in studying paraquat A Yes. That was my belief at the time. Q And because it was your belief that paraquat did not get into the brains of paraquat applicators, you concluded that paraquat was a safe for applicators. Is that what you believed? MS. REISMAN: Objection to form. A I believe that paraquat was safe for use if the label precautions were followed. Q (By Mr. Kennedy) And, sir, you told us yesterday that you believe that paraquat did not get into the brains of applicators, number one, because of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1-I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you by the lawyers from Chevron? 	1You testified, sir, that that the2scientific studies that you have reviewed led you to3believe that paraquat does not get into the brains of4paraquat applicators.5Do you remember stating that?6A I probably did, yeah.7Q And that's your your belief and was your8belief when you were at Chevron in studying paraquat?9A Yes. That was my belief at the time.10Q And because it was your belief that paraquat11did not get into the brains of paraquat applicators,12you concluded that paraquat was a safe for13applicators.14Is that what you believed?15MS. REISMAN: Objection to form.16A I believe that paraquat was safe for use if17the label precautions were followed.18Q (By Mr. Kennedy) And, sir, you told us19yesterday that you believe that paraquat did not get20into the brains of applicators, number one, because of21the animal studies that you reviewed, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1-I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you by the lawyers from Chevron? A Yes. 	1You testified, sir, that that the2scientific studies that you have reviewed led you to3believe that paraquat does not get into the brains of4paraquat applicators.5Do you remember stating that?6A I probably did, yeah.7Q And that's your your belief and was your8belief when you were at Chevron in studying paraquat?9A Yes. That was my belief at the time.10Q And because it was your belief that paraquat11did not get into the brains of paraquat applicators,12you concluded that paraquat was a safe for13applicators.14Is that what you believed?15MS. REISMAN: Objection to form.16A I believe that paraquat was safe for use if17the label precautions were followed.18Q (By Mr. Kennedy) And, sir, you told us19yesterday that you believe that paraquat did not get20into the brains of applicators, number one, because of21the animal studies that you reviewed, correct?22A That that's correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you by the lawyers from Chevron? MS. REISMAN: You can answer yes or no. A Yes. Q (By Mr. Kennedy) You're being paid for your 	1You testified, sir, that that the2scientific studies that you have reviewed led you to3believe that paraquat does not get into the brains of4paraquat applicators.5Do you remember stating that?6A I probably did, yeah.7Q And that's your your belief and was your8belief when you were at Chevron in studying paraquat'9A Yes. That was my belief at the time.10Q And because it was your belief that paraquat11did not get into the brains of paraquat applicators,12you concluded that paraquat was a safe for13applicators.14Is that what you believed?15MS. REISMAN: Objection to form.16A I believe that paraquat was safe for use if17the label precautions were followed.18Q (By Mr. Kennedy) And, sir, you told us19yesterday that you believe that paraquat did not get20into the brains of applicators, number one, because of21the animal studies that you reviewed, correct?22A That that's correct.23Q Back at the time that you were were at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q (By Mr. Kennedy) And were you shown any medical literature, published articles, in any of these meetings? MS. REISMAN: I'm going to object to you asking him what he was shown until you establish that those documents refreshed his recollection. You can answer to the extent any of the documents refreshed your recollection. A 1-I don't remember specifically. Q (By Mr. Kennedy) Were you shown any Chevron documents during those those meetings? MS. REISMAN: Same objection. And object to the extent that those documents refreshed your recollection. If any of the documents refreshed your recollection, please do testify. A None of the documents that I looked at refreshed my memory. Q (By Mr. Kennedy) That wasn't my question. My question was, did you review any documents provided you by the lawyers from Chevron? A Yes. 	1You testified, sir, that that the2scientific studies that you have reviewed led you to3believe that paraquat does not get into the brains of4paraquat applicators.5Do you remember stating that?6A I probably did, yeah.7Q And that's your your belief and was your8belief when you were at Chevron in studying paraquat?9A Yes. That was my belief at the time.10Q And because it was your belief that paraquat11did not get into the brains of paraquat applicators,12you concluded that paraquat was a safe for13applicators.14Is that what you believed?15MS. REISMAN: Objection to form.16A I believe that paraquat was safe for use if17the label precautions were followed.18Q (By Mr. Kennedy) And, sir, you told us19yesterday that you believe that paraquat did not get20into the brains of applicators, number one, because of21the animal studies that you reviewed, correct?22A That that's correct.

21 (Pages 78 to 81)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 24 of 41 Page ID #2767

Richard Cavalli August 23, 2022

	Page 82	EN	Page 84
1	and and the IBT laboratory in ICI, correct?		Q- And when I say "rat studies," I'm talking
2	A Yes.	2	about either Chevron, or ICI, or the independent
3	Q And based upon those animal studies you came	3	laboratory exposing or intoxicating rats with
4	to the belief that paraquat did not get into the	4	paraquat, correct?
5	brains of applicators, correct?	5	MS. REISMAN: Objection to form.
6	MS. REISMAN: Objection to form.	6	A Exposing them to it, yes.
7	A That paraquat appeared to have no effect on	7	Q (By Mr. Kennedy) Okay. So they're either
8	the central nervous system.	8	intraperitoneal exposure; there's dermal exposure;
9	Q (By Mr. Kennedy) Well, we're talking about	9	there's inhalation exposure; there's feeding studies.
10	paraquat getting into the brain. That's what we're	10	Correct?
11	focused on. And yesterday you testified that you	11	A Yes.
12	believe paraquat did not get into the brains of	12	Q And the rat studies that were done, when you
13	applicators, correct?	13	
			looked, you found paraquat in the brain, correct?
14	A I do. I do remember, and I do believe that.	14	MS. REISMAN: Objection to form.
15	Q And the second thing beside the animal	15	A You know, I don't specifically recall.
16	studies that you you were relying upon were the	16	Q (By Mr. Kennedy) When you did mice studies,
17	autopsies, correct?	17	you found paraquat in the brain, correct?
18	MS. REISMAN: Objection to form.	18	MS. REISMAN: Objection to form.
19	Q (By Mr. Kennedy) You reviewed the autopsies	19	A Again, I don't recall one way or the other.
20	while you were at Chevron, did you not, sir? Autopsies	20	Q (By Mr. Kennedy) When you studied hens in
21	of folks that had been poisoned by paraquat and died?	21	paraquat, you found paraquat in the brain, correct?
22	A Okay. I didn't catch the jump from animals	22	MS. REISMAN: Objection to form.
23	to people. Sorry.	23	A Same thing. I don't remember one way or th
24	Yes. I did review those.	24	other.
25	Q And the third thing that you based this	25	Q (By Mr. Kennedy) When you studied monkeys,
	Page 83		Dage 9
	200000		Page 85
1		1	
1 2	opinion on that paraquat was not getting into the	1	you found paraquat in the brain, true?
2	opinion on that paraquat was not getting into the brains of applicators were the human applicator		you found paraquat in the brain, true? MS. REISMAN: Objection. Form.
	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today,	2	you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other.
2 3 4	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct?	2 3 4	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you
2 3 4 5	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form.	2 3 4 5	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not?
2 3 4 5 6	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something.	2 3 4 5 6	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, yo found paraquat in the brain, did you not? MS. REISMAN: Objection. Form.
2 3 4 5 6 7	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human	2 3 4 5 6 7	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, yo found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific
2 3 4 5 6 7 8	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in	2 3 4 5 6 7 8	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, yo found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection.
2 3 4 5 6 7 8 9	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct?	2 3 4 5 6 7 8 9	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you
2 3 4 5 6 7 8 9	opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes.	2 3 4 5 6 7 8 9 10	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not?
2 3 4 5 6 7 8 9 10 11	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that 	2 3 4 5 6 7 8 9 10 11	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that 	2 3 4 5 6 7 8 9 10 11 12	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall.
2 3 4 5 6 7 8 9 10 11 12 13	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, 	2 3 4 5 6 7 8 9 10 11 12 13	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found you found the provided dogs, you found the provided dogs.
2 3 4 5 6 7 8 9 10 11 12 13 14	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A I missed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat does not get into the brains of applicators. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you Exhibit 135, if we could. Sir, this the testimony of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you Exhibit 135, if we could. Sir, this the testimony of Dr. Philip Botham. Dr. Botham gave testimony in this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat does not get into the brains of applicators. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you Exhibit 135, if we could. Sir, this the testimony of Dr. Philip Botham. Dr. Botham gave testimony in this case as the representative of ICI. All right? Have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat does not get into the brains of applicators. Can we do that? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you Exhibit 135, if we could. Sir, this the testimony of Dr. Philip Botham. Dr. Botham gave testimony in this case as the representative of ICI. All right? Have you ever reviewed this?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 opinion on that paraquat was not getting into the brains of applicators were the human applicator studies which you talked about yesterday and today, correct? MS. REISMAN: Objection to form. A Imissed something. Q (By Mr. Kennedy) You also looked at the human studies, the applicator human studies, particularly in Malaysia, correct? A Yes. Q And that was the third body of evidence that you told us that you looked at to conclude that paraquat does not get into the brains of applicators, correct? A Yes. Q All right. What I want to do with you is look at those three bodies of studies, the animals, brain tissue, and the human studies, and try to understand how those led you to conclude that paraquat does not get into the brains of applicators. Can we do that? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 you found paraquat in the brain, true? MS. REISMAN: Objection. Form. A I don't recall one way or the other. Q (By Mr. Kennedy) When you studied goats, you found paraquat in the brain, did you not? MS. REISMAN: Objection. Form. A Same answer. I don't have specific recollection. Q (By Mr. Kennedy) When you studied pigs, you found paraquat in the brain, did you not? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A I don't recall. Q (By Mr. Kennedy) When you studied dogs, you found paraquat in the brain, did you not, sir? MS. REISMAN: Objection to form. A You know, I don't I don't have a recollection of that either way. If you have documents Q (By Mr. Kennedy) I'm going to show you Exhibit 135, if we could. Sir, this the testimony of Dr. Philip Botham. Dr. Botham gave testimony in this case as the representative of ICI. All right? Have

22 (Pages 82 to 85)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 25 of 41 Page ID #2768

Richard Cavalli August 23, 2022

	Page 86	ENITIAI Page	88
1	that was manufacturing paraquat, correct?	1 looked, they found paraquat in the brain?	
2	A Yes.	2 MS. REISMAN: Objection to form.	
3	MS. REISMAN: During the time that	3 Foundation.	
4	A During during	4 A Again, if I could see the studies again, it	
5	Q (By Mr. Kennedy) During the time that you	5 might refresh my memory, but I don't recall one wa	ay or
6	folks were selling it from 1965 to '86, correct?	6 the other.	
7	A Yes.	7 Q (By Mr. Kennedy) Sir, can we agree that in	
8	Q Okay. And you understand Mr. Botham was	8 every animal study where they looked showed paraqua	at in
9	chosen by ICI to represent them and make statements of	9 the brain? Can we agree that that doesn't support the	
10	their behalf in this case. All right?	10 conclusion that paraquat can never get into the brain	
11	MS. REISMAN: Objection.	11 of an applicator, true?	
12	Q (By Mr. Kennedy) And assume that. All right?	12 MS. REISMAN: Objection to form.	
13	MS. REISMAN: Object object to form and	13 Foundation.	
14	foundation.	14 A You know, it it it depends on the	
15	Q (By Mr. Kennedy) All right. Again, ICI was	15 the circumstances under which these animals were	
16	the company that Chevron was working with to understand	16 exposed, and I just don't have that in my mind.	
17	the risks of paraquat, correct?	17 Q (By Mr. Kennedy) Well, you told us yesterday	
18	MS. REISMAN: Objection to form.	18 that a lot of these studies were high-dose studies,	
19	A Yes.	19 correct?	
20	Q (By Mr. Kennedy) And when they did a study,	20 MS. REISMAN: Objection. Form.	
21	they would share it with you, true?	21 Q (By Mr. Kennedy) Is that correct?	
22	MS. REISMAN: Objection to form.	22 MS. REISMAN: Objection to form.	
23	Foundation.	A Oh.	
24	A They shared with us. I I have no idea	24 MS. REISMAN: Objection to form.	
25	how complete that sharing was.	25 Q (By Mr. Kennedy) Is that correct, sir?	
	Page 87	Page	89
1	_		89
1	Q (By Mr. Kennedy) Go to page 239. It's the	1 A Could you repeat that?	89
2	Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony.	1ACould you repeat that?2QA lot of these studies were high-dose	89
2 3	Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony.A Where are the numbers?	 A Could you repeat that? Q A lot of these studies were high-dose studies, correct? 	89
2 3 4	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last 	 A Could you repeat that? Q A lot of these studies were high-dose studies, correct? MS. REISMAN: Objection to form. 	
2 3 4 5	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. 	 A Could you repeat that? Q A lot of these studies were high-dose studies, correct? MS. REISMAN: Objection to form. A These studies generally included at lease 	
2 3 4	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? 	 A Could you repeat that? Q A lot of these studies were high-dose studies, correct? MS. REISMAN: Objection to form. A These studies generally included at least one high dose. 	t
2 3 4 5 6	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at least6one high dose.7Q (By Mr. Kennedy) And if high-dose paraque	t uat
2 3 4 5 6 7	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at lease6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly	t uat
2 3 4 5 6 7 8	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at least6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly	t uat
2 3 4 5 6 7 8 9	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who 	 A Could you repeat that? Q A lot of these studies were high-dose studies, correct? MS. REISMAN: Objection to form. A These studies generally included at least one high dose. Q (By Mr. Kennedy) And if high-dose paraq study leads to paraquat in the brain, that certainly doesn't prove that a lesser dose will not get in the 	t uat
2 3 4 5 6 7 8 9 10	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at least6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly9doesn't prove that a lesser dose will not get in the10brain, correct?	t uat
2 3 4 5 6 7 8 9 10 11	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at lease6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly9doesn't prove that a lesser dose will not get in the10brain, correct?11MS. REISMAN: Objection to form.	t uat
2 3 4 5 6 7 8 9 10 11 12	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A 1 I don't follow you.	t uat
2 3 4 5 6 7 8 9 10 11 12 13	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of doesed	t uat
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a	t uat
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at lease 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose.	t uat ose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at least6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly9doesn't prove that a lesser dose will not get in the10brain, correct?11MS. REISMAN: Objection to form.12A I I don't follow you.13Q (By Mr. Kennedy) Sir, the the type of do14that that an applicator gets is is probably a15low-dose, long-term chronic, correct?16MS. REISMAN: Objection to form.17A I would agree with low dose.18Q (By Mr. Kennedy) Okay. And they can be	t uat ose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 	1A Could you repeat that?2Q A lot of these studies were high-dose3studies, correct?4MS. REISMAN: Objection to form.5A These studies generally included at least6one high dose.7Q (By Mr. Kennedy) And if high-dose paraq8study leads to paraquat in the brain, that certainly9doesn't prove that a lesser dose will not get in the10brain, correct?11MS. REISMAN: Objection to form.12A I I don't follow you.13Q (By Mr. Kennedy) Sir, the the type of do14that that an applicator gets is is probably a15low-dose, long-term chronic, correct?16MS. REISMAN: Objection to form.17A I would agree with low dose.18Q (By Mr. Kennedy) Okay. And they can be19exposed over years, correct?	t uat ose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form.	t uat ose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" "ANSWER: I think they can, yes." 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form. 21 A Yeah. Yes. Possible.	t uat ose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" "ANSWER: I think they can, yes." Did you have any memory that that 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form. 21 A Yeah. Yes. Possible. 22 Q (By Mr. Kennedy) And if they're exposed	t uat ose e
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" "ANSWER: I think they can, yes." Did you have any memory that that disagrees with the testimony here of of Dr. Botham 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form. 21 A Yeah. Yes. Possible. 22 Q (By Mr. Kennedy) And if they're exposed 23 years, that would fit the definition of a chronic lor	t uat ose e
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" "ANSWER: I think they can, yes." Did you have any memory that that disagrees with the testimony here of of Dr. Botham on behalf of ICI that every single one of these animal 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form. 21 A Yeah. Yes. Possible. 22 Q (By Mr. Kennedy) And if they're exposed 23 years, that would fit the definition of a chronic low 24	t uat ose e
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q (By Mr. Kennedy) Go to page 239. It's the last page of of Dr. Botham from ICI, his testimony. A Where are the numbers? Q 239 up in the top right. The very last page, sir. A Okay. This page 239 of the report? Q Yes, sir. A Yes. Q Go to starting at line 3, Dr. Botham, who gave testimony on behalf of ICI, he was asked: "So can I add pigs to that list I gave you before, rats, mice, hens, monkeys, man, goats, pigs, all found after either injection or feeding studies where they were slaughtered to have accumulated residual paraquat in the brain?" "ANSWER: Yes. Very low levels of paraquat found in the brain, yes." "QUESTION: And although I don't have the study here, can dogs also be added to that list by 1976?" "ANSWER: I think they can, yes." Did you have any memory that that disagrees with the testimony here of of Dr. Botham 	1 A Could you repeat that? 2 Q A lot of these studies were high-dose 3 studies, correct? 4 MS. REISMAN: Objection to form. 5 A These studies generally included at least 6 one high dose. 7 Q (By Mr. Kennedy) And if high-dose paraq 8 study leads to paraquat in the brain, that certainly 9 doesn't prove that a lesser dose will not get in the 10 brain, correct? 11 MS. REISMAN: Objection to form. 12 A I I don't follow you. 13 Q (By Mr. Kennedy) Sir, the the type of do 14 that that an applicator gets is is probably a 15 low-dose, long-term chronic, correct? 16 MS. REISMAN: Objection to form. 17 A I would agree with low dose. 18 Q (By Mr. Kennedy) Okay. And they can be 19 exposed over years, correct? 20 MS. REISMAN: Objection to form. 21 A Yeah. Yes. Possible. 22 Q (By Mr. Kennedy) And if they're exposed 23 years, that would fit the definition of a chronic lor	t uat ose e

23 (Pages 86 to 89)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 26 of 41 Page ID #2769

Richard Cavalli August 23, 2022

	Page 90		Page 92
		ΗÌ	
1	A It could, yes.		- their brains because that would mean you would have to
2	Q (By Mr. Kennedy) And if you if you wanted	2	do an autopsy, correct?
3	to know if you wanted to know whether or not	3	MS. REISMAN: Objection to form.
4	paraquat could get into the brain of an applicator, the	4	Q (By Mr. Kennedy) Is that true, sir?
5	best study to do would be a low-dose, long-term chronic	5	A Yes. That's correct.
6	study, correct?	6	Q So with the animal studies with the
7	MS. REISMAN: Objection to form. I assume	7	animal studies it would be true that Chevron never did
8	you're asking about his recollections from back then.	8	a long-term study to look to see whether or not
9	He's not identified as an expert today.	9	paraquat got into the brain, true?
10	A I mean, there were chronic studies on on	10	MS. REISMAN: Objection to form.
11	paraquat.	11	A We did not, as I recall, any studies that
12	Q (By Mr. Kennedy) Sir, my question is: If you	12	in which the paraquat level in the brain was measured.
13	want to try to understand through animal studies	13	The chronic studies we did did look at behavioral
14	whether paraquat is going to get into the brain of an	14	effects and any pathology in the brain.
15	applicator, the best studies to do would be low-dose,	15	Q (By Mr. Kennedy) So the best study to
16	long-term chronic studies, true?	16	determine whether paraquat would actually get into the
17	MS. REISMAN: Objection to form and	17	brain was never done with respect to animals, true?
18	foundation.	18	MS. REISMAN: Objection to form. Asked and
19	A I think that's what was done.	19	answered.
20	Q (By Mr. Kennedy) Sir, the fact of the matter	20	Q (By Mr. Kennedy) Is that true, sir?
21	is neither Chevron nor ICI ever, ever did a long-term	21	MS. REISMAN: Objection to form. Asked and
22	chronic study to determine whether or not paraquat got	22	answered.
23	into the brain. That's the truth, correct?	23	A That study wasn't done.
24	MS. REISMAN: Objection to form.	24	Q (By Mr. Kennedy) Sir, you also testified
25	A We we had body of data that suggested	25	with with respect to these animal studies that the
	Page 91		Page 93
1	Page 91 that it didn't, and we didn't do such a study.	1	primary target of paraquat seemed to be the lung.
1 2	that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what	1 2	_
	that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not		primary target of paraquat seemed to be the lung.
2	that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what	2	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just
2 3	that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not	2 3	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that
2 3 4	that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator,	2 3 4	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just
2 3 4 5	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies 	2 3 4 5	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct?
2 3 4 5 6	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. 	2 3 4 5 6	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form.
2 3 4 5 6 7	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies 	2 3 4 5 6 7	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct?
2 3 4 5 6 7 8	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was 	2 3 4 5 6 7 8	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the 	2 3 4 5 6 7 8 9	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the
2 3 4 5 6 7 8 9 10 11 12	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. 	2 3 4 5 6 7 8 9 10 11 12	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true?
2 3 4 5 6 7 8 9 10 11	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to 	2 3 4 5 6 7 8 9 10 11	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the
2 3 4 5 6 7 8 9 10 11 12	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group 	2 3 4 5 6 7 8 9 10 11 12	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true?
2 3 4 5 6 7 8 9 10 11 12 13	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to 	2 3 4 5 6 7 8 9 10 11 12 13	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group 	2 3 4 5 6 7 8 9 10 11 12 13 14	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal studies is try to determine what happens in human 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal studies is try to determine what happens in human beings, true? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal studies is try to determine what happens in human beings, true? MS. REISMAN: Objection. Form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal studies is try to determine what happens in human beings, true? MS. REISMAN: Objection. Form. Q (By Mr. Kennedy) That's the purpose? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies right now. And the purpose of doing animal studies is try to determine what happens in human beings, true? MS. REISMAN: Objection. Form. Q (By Mr. Kennedy) That's the purpose? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A Yeah. As I said, the damage to the lung
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies right now. And the purpose of doing animal studies is try to determine what happens in human beings, true? MS. REISMAN: Objection. Form. Q (By Mr. Kennedy) That's the purpose? A Yes. Q Because you can't do an applicator study and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A Yeah. As I said, the damage to the lung does not preclude consideration of other organs.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 that it didn't, and we didn't do such a study. Q (By Mr. Kennedy) Never. You never did what would be the best study to determine whether or not paraquat would get into the brain of an applicator, correct? MS. REISMAN: Objection to form. A You know, again, there were so many studies on paraquat, exposure studies in the field that was the evaluation of the health of the Malaysian sprayers, and at the time I was of the opinion that there was a very low risk to applicators in the United States following the labeled precautions. Q (By Mr. Kennedy) Sir, we're we're going to talk about the Malaysia study. We're going one group of studies at a time. We're talking about the animal studies is try to determine what happens in human beings, true? MS. REISMAN: Objection. Form. Q (By Mr. Kennedy) That's the purpose? A Yes. Q Because you can't do an applicator study and look into their brain to determine whether or not 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 primary target of paraquat seemed to be the lung. Do you remember that? A Yes. Q And so we could be clear for the jury, just because the lung was the primary target, that certainly doesn't mean that the brain can't also be damaged by paraquat, correct? MS. REISMAN: Objection to form. A No. No, it doesn't exclude any other organ from Q (By Mr. Kennedy) If we look at alcohol, the primary target of alcohol would be the brain, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A It certainly affects neuro function, yes. Q (By Mr. Kennedy) But that certainly doesn't mean that the liver in the long term can't be damaged by alcohol, true? MS. REISMAN: Objection to form. Foundation. A Yeah. As I said, the damage to the lung does not preclude consideration of other organs. Q (By Mr. Kennedy) You needed to consider other

24 (Pages 90 to 93)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 27 of 41 Page ID #2770

Richard Cavalli August 23, 2022

	Page 94		Page 96
1	MS. REISMAN: Objection. Form.		were involved with warnings and education of
2	A And I believe we did.	2	applicators?
3	Q (By Mr. Kennedy) Stereology. Was stereology	3	MS. REISMAN: Objection to form.
4	available in the 1970s and the 1980s?	4	A One more time, please.
5	MS. REISMAN: Objection to form.	5	Q (By Mr. Kennedy) Your belief that paraquat
6	A What was the word?	6	could not get into the brains of applicators, did you
7	Q (By Mr. Kennedy) Stereology. Was that	7	share that belief with anyone at Chevron that was
8	available in in examining tissues of animal or human	8	involved with communicating with applicators by way of
9	beings? Was stereology available in the 1970s or '80s?	9	labels, warnings?
10	MS. REISMAN: Objection object to form.	10	MS. REISMAN: Objection to form.
11	A I'm not sure	11	A We shared the data that we had that was the
12	MS. REISMAN: Hold on. Let me just I'm	12	basis of my opinion that paraquat would not harm the
13	sorry let me just get an objection. Objection to	13	brain.
14	form.	14	Q (By Mr. Kennedy) And that's not my question.
15	Go ahead.	15	My question: Did you share your belief that paraquat
16	A I'm not sure I understand what you mean.	16	could not get into the brain of an applicator?
17	Q (By Mr. Kennedy) Was cell counting available?	17	Did you share that belief with any of the
18	Could you could you count the cells in tissue in the	18	folks at Chevron that had responsibility for creating
19	1970s and '80s to evaluate in animal studies? Could	19	labels and warnings and communicating with workers?
20	you count cells?	20	MS. REISMAN: Objection to form. Asked and
21	MS. REISMAN: Objection to form.	21	answered.
22	A You you could count red cells and white	22	A I don't have a recollection of specific
23	cells and mass cells and any other kind of cell in the	23	discussions about paraquat getting into the brain.
24	blood. I don't I don't know about counting	24	The discussions were on whether paraquat affected
25	cells – cells of the organ.	25	various organs including the brain.
-	cons cons or the organi	2.5	various of gans including the of ani.
	Page 95		Page 97
		1	I age 57
1	MS. REISMAN: Mr. Kennedy, when you get to a	1	Q (By Mr. Kennedy) We looked at animal studies
1 2	MS. REISMAN: Mr. Kennedy, when you get to a good stopping point, we've been going about	1	
			Q (By Mr. Kennedy) We looked at animal studies
2	good stopping point, we've been going about	2	Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did
2 3	good stopping point, we've been going about MR. KENNEDY: Fine's right now.	2 3	Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask
2 3 4	good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now?	2 3 4	Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right?
2 3 4 5	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 	2 3 4 5	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay.
2 3 4 5 6	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. 	2 3 4 5 6	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or
2 3 4 5 6 7	good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.)	2 3 4 5 6 7	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them
2 3 4 5 6 7 8	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 	2 3 4 5 6 7 8	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks,
2 3 4 5 6 7 8 9	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. 	2 3 4 5 6 7 8 9	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right?
2 3 4 5 6 7 8 9 10	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are 	2 3 4 5 6 7 8 9 10	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were.
2 3 6 7 8 9 10 11	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did 	2 3 4 5 6 7 8 9 10 11	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain
2 3 4 5 6 7 8 9 10 11 12	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we 	2 3 4 5 6 7 8 9 10 11 12	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true?
2 3 4 5 6 7 8 9 10 11 12 13	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: 	2 3 4 5 6 7 8 9 10 11 12 13	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared 	2 3 4 5 6 7 8 9 10 11 12 13 14	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. Foundation. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kennedy) And Chevron, when they would receive tissue from the brain of a patient that died
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. Foundation. A Yes, there were. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kennedy) And Chevron, when they would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. Foundation. A Yes, there were. Q (By Mr. Kennedy) And who was that? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kennedy) And Chevron, when they would receive tissue from the brain of a patient that died
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. Foundation. A Yes, there were. Q (By Mr. Kennedy) And who was that? A Dr. Ford, Dr. White. I I'm sorry. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kennedy) And Chevron, when they would receive tissue from the brain of a patient that died from paraquat poisoning, Chevron at times would do its
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 good stopping point, we've been going about MR. KENNEDY: Fine's right now. MS. REISMAN: You want to stop now? VIDEOGRAPHER: We're going off the record at 11:01 a.m. (A break was taken.) VIDEOGRAPHER: We're back on the record at 11:22 a.m. Q (By Mr. Kennedy) So, Mr. Cavalli, we are we had been talking about your belief that paraquat did not get into the brain of applicators, and before we let me ask you this: Was there anybody else at Chevron who shared your opinion and your belief that paraquat could not get into the brains of applicators? MS. REISMAN: Objection to form. Foundation. A Yes, there were. Q (By Mr. Kennedy) And who was that? A Dr. Ford, Dr. White. I I'm sorry. Q And did you communicate your your belief 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q (By Mr. Kennedy) We looked at animal studies as to how you got to this conclusion that paraquat did not get into the brain of applicators. I want to ask you about autopsies. All right? A Okay. Q When someone would intentionally or unintentionally drink paraquat and it would cause them to die, autopsies were done on some of these folks, right? A Yes, they were. Q And that information and sometimes brain tissue would be sent to Chevron, true? A Yes. Q And you were aware of of those autopsies and that brain tissue while you were at Chevron; would that be accurate? MS. REISMAN: Objection to form. A Yes. Q (By Mr. Kennedy) And Chevron, when they would receive tissue from the brain of a patient that died from paraquat poisoning, Chevron at times would do its own analysis of that tissue, true?

25 (Pages 94 to 97)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 28 of 41 Page ID #2771

Richard Cavalli August 23, 2022

		1	-
	Page 98	Page 10	0
1	man and in the basic of the second should be	A It supported that there were no neurological	
1	was paraquat in the brains of these people that had	- It supported that there were no near orogical	
2	been poisoned with paraquat, true?	2 effects.	
3	A Yes.	3 Q Again, I'm focused on paraquat in the brains	
4	Q Now, Chevron and and ICI have sent us	4 of workers. One of the things that you told us	
5	lawyers for for these applicators have sent us	5 supports your opinion and belief back in the '80s that	
6	26 reports.	6 paraquat did not get into the brain of applicators was	
7	MS. REISMAN: I'm sorry. You said the	7 these worker studies, true?	
8	lawyers of the applicators?	8 MS. REISMAN: Objection to form.	
9	MR. KENNEDY: Let me repeat my question.	9 A Yes. It was supportive of that.	
10	Q (By Mr. Kennedy) Chevron and ICI have sent us	10 Q (By Mr. Kennedy) And the worker study you	
11	reports, 26 reports, showing paraquat in the brains of	11 talked about was the Malaysian study, right, by Howard	1?
12	poison victims.	12 A Yes. Excuse me. Yes.	
13	Can you explain to me how does that support	13 Q And in that study, they found paraquat in	
14	your conclusion that paraquat cannot get into the	14 the urine of these workers, did they not?	
15	brain of a human applicator?	15 MS. REISMAN: Objection to form.	
16	MS. REISMAN: Objection to form.	16 A In the paper by Howard and Sabapathy, I	
17	A All of those persons died from pulmonary	17 don't recall.	
18	complications, pulmonary congestion, pulmonary	18 Q (By Mr. Kennedy) Well, the Chester paper that	
19	fibrosis. They were all in a state of hypoxia. The	19 dealt with the same group of Malaysian workers	
20	gross findings in the brain were suggestive and	20 evaluated as to whether or not they had paraquat in	
21	supportive of the kind of damage that occurs in a	21 their urine, did it not?	
22	hypoxic person or animal.	22 MS. REISMAN: Objection to form.	
23	In all of the studies done at lower doses	23 A Yes.	
24	where animals were not in extremis, people not	24 Q (By Mr. Kennedy) That's the same Malaysian	
25	people. I'm sorry.	25 study we've been talking about, but this is by Chester	
		i de la companya de l	
	Page 99	Page 10	1
1	_	Page 10	
1	The animals that were not in extremis did	1 who's looking to see whether or not they have paraqua	
2	The animals that were not in extremis did not show damage to the brain.	 who's looking to see whether or not they have paraqua in their urine? 	
2 3	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. 	
2 3 4	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? 	
2 3 4 5	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. 	
2 3 4 5 6	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. 	
2 3 4 5 6 7	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct?	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found 	
2 3 4 5 6 7 8	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form.	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they 	
2 3 4 5 6 7 8 9	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did?	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? 	
2 3 4 5 6 7 8 9 10	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No.	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. 	
2 3 4 5 6 7 8 9 10 11	The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. 	at
2 3 4 5 6 7 8 9 10 11 12	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue 	 who's looking to see whether or not they have paraqua in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out 	at
2 3 4 5 6 7 8 9 10 11 12 13	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the sumple is greater than the amount of paraquat in the 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquating the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? 	at
2 3 4 5 6 7 8 9 10 11 12 13 14	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the bisoue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquating the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. 	at
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the bisoud sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? 	 who's looking to see whether or not they have paraquation in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. MS. REISMAN: Objection to form. 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquatin the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. 	 who's looking to see whether or not they have paraquation in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. 	 who's looking to see whether or not they have paraquation in their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. Q Let's look to worker studies. Again, it is 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they mot? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire body, does it not? 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. Q Let's look to worker studies. Again, it is your belief that the worker studies and the one you 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire body, does it not? A It does. 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. Q Let's look to worker studies. Again, it is your belief that the worker studies and the one you talked about was the Malaysian study it was your 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire body, does it not? A It does. Q And it circulates through the entire body 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. Q Let's look to worker studies. Again, it is your belief that the walaysian study it was your belief that the Malaysian study it was your 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire body, does it not? Q And it circulates through the entire body including the brain, true? 	at t
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 The animals that were not in extremis did not show damage to the brain. Q (By Mr. Kennedy) I'm asking you about the presence of paraquat in the brain. And, sir, the fact of the matter is, as we just discussed, Chevron never did a study with lower doses long term and looked to see whether there was paraquat in the brain, correct? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Never did? A No. Q And, sir, let me if you are looking at brain tissue and the amount of paraquat in the tissue sample is greater than the amount of paraquat in the blood, does that mean that the paraquat has gotten outside of the capillary and into the brain tissue? MS. REISMAN: Objection to form. A In those terminal cases? Q (By Mr. Kennedy) Yes. A Yes. Q Let's look to worker studies. Again, it is your belief that the worker studies and the one you talked about was the Malaysian study it was your 	 who's looking to see whether or not they have paraquating their urine? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) True? MS. REISMAN: Objection to form. A Yes. That was done. Q (By Mr. Kennedy) And indeed, they found paraquat in the urine of these applicators, did they not? MS. REISMAN: Objection to form. A Of some of them, at least. Q (By Mr. Kennedy) Well, they found it in 9 out of 19, do you remember that? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Sir, if a worker has paraquat in their urine, that means they have paraquat in their blood, true? A True. Q And blood circulates through the entire body, does it not? A It does. Q And it circulates through the entire body 	at t

26 (Pages 98 to 101)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 29 of 41 Page ID #2772

Richard Cavalli August 23, 2022

	Page 102	Page 104
1	Q (By Mr. Kennedy) Nów, you testified in this	1 True?
2	Malaysian study by Dr. Howard that examinations were	2 A That's what it says.
3	done, and these workers with paraquat in their blood	
4	circulating through their brains were were perfectly	3 Q It's a 1981 study, right? 4 A Published in '81.
5	fine, perfectly healthy on examination.	
6		
	Do you recall that testimony?	6 A It would have.
7	A Yes, sir.	7 Q Go to the next page, 36.
8	MS. REISMAN: Objection.	8 See in that right-hand column right above
9	Mr. Cavalli, I know it's been a while since	9 "Exposure to Paraquat"? Look right above that. I
10	we've been going this morning. You just need to give	10 think it indicates that this involved 27 paraquat
11	me a minute before you respond.	11 spraymen.
12	A I'm sorry.	12Do you see that right-hand column?
13	MS. REISMAN: Give me a moment to object	13 A Yes.
14	when I need to.	14 Q Right above "Exposure to Paraquat,"
15	Objection to form on that question.	15 27 workers, true?
16	Q (By Mr. Kennedy) Oh. Sir, do you have an	16 A Yes.
17	answer to my question?	17 Q All right. If you'll go to the next page,
18	A Can you repeat it?	18 37. You see where it says "Clinical Examination"?
19	Q Question: You testified in the Malaysian	19 Could you take a look at that?
20	study by Dr. Howard that examinations were done and	20 MR. KENNEDY: Could you pull that up,
21	these workers with paraquat in their blood circulating	21 please, and
22	through their brains were perfectly were perfectly	22 A Yes.
23	normal and healthy on examination?	23 MR. KENNEDY: highlight "Clinical
24	MS. REISMAN: Objection to form.	24 Examination."
25	Q (By Mr. Kennedy) Correct? Remember that	25 A Yes. I see it.
		Dama 105
1	Page 103	Page 105
1	testimony?	1 Q (By Mr. Kennedy) It says "Clinical
2	A Yes, I do.	2 Examination." Again, I'm trying to understand how you
3	Q And I think you testified that on	3 are drawing the conclusion there were no neurologic
4	examination that there were neurological or central	4 findings on on examination. All right?
5	nervous system findings. Do you recall that?	5 The paper says: "All workers were given a
6	A I do.	6 full clinical examination, particular attention being
7	Q And what I want to ask you about is how you	7 paid to the respiratory system and the skin."
8	arrived at this conclusion that there were no	8 Did I read that right?
9	neurologic findings and that they were perfectly	9 A You did.
10	healthy on exam. All right?	10 Q So they're paying closer attention to the
11	MR. KENNEDY: If you can give us	11 respiratory system in the skin, that seemed to be
12	Exhibit 111.	12 their primary focus.
	(Exhibit 111 has been marked and now	13 Would you agree?
13		14 MS. REISMAN: Objection to form.
13 14	identified for the record.	
	identified for the record. A Can I get a I'm supposed to look at it?	
14	A Can I get a I'm supposed to look at it?	15 A That's what the paper says.
14 15	A Can I get a I'm supposed to look at it?Q (By Mr. Kennedy) Yes.	15AThat's what the paper says.16Q(By Mr. Kennedy) No mention of a neurologic
14 15 16 17	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true?
14 15 16 17 18	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking 	 A That's what the paper says. Q (By Mr. Kennedy) No mention of a neurologic examination, true? MS. REISMAN: Objection to form.
14 15 16 17 18 19	A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right?	 A That's what the paper says. Q (By Mr. Kennedy) No mention of a neurologic examination, true? MS. REISMAN: Objection to form. A No mention here, yes.
14 15 16 17 18 19 20	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right? A Yes, it is. 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true? 18 MS. REISMAN: Objection to form. 19 A No mention here, yes. 20 Q (By Mr. Kennedy) And there's no mention
14 15 16 17 18 19 20 21	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right? A Yes, it is. Q It says it's by Dr. Howard. You see that? 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true? 18 MS. REISMAN: Objection to form. 19 A No mention here, yes. 20 Q (By Mr. Kennedy) And there's no mention 21 anywhere in this paper as to what examinations were
14 15 16 17 18 19 20 21 22	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right? A Yes, it is. Q It says it's by Dr. Howard. You see that? A Yes. 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true? 18 MS. REISMAN: Objection to form. 19 A No mention here, yes. 20 Q (By Mr. Kennedy) And there's no mention 21 anywhere in this paper as to what examinations were 22 actually done.
14 15 16 17 18 19 20 21 22 23	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right? A Yes, it is. Q It says it's by Dr. Howard. You see that? A Yes. Q And the study title: "A Study of the Health 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true? 18 MS. REISMAN: Objection to form. 19 A No mention here, yes. 20 Q (By Mr. Kennedy) And there's no mention 21 anywhere in this paper as to what examinations were 22 actually done. 23 Would that be right?
14 15 16 17 18 19 20 21 22	 A Can I get a I'm supposed to look at it? Q (By Mr. Kennedy) Yes. Now, Exhibit 111, this is a publication of the study, the Malaysia study that we've been talking about; is that right? A Yes, it is. Q It says it's by Dr. Howard. You see that? A Yes. 	 15 A That's what the paper says. 16 Q (By Mr. Kennedy) No mention of a neurologic 17 examination, true? 18 MS. REISMAN: Objection to form. 19 A No mention here, yes. 20 Q (By Mr. Kennedy) And there's no mention 21 anywhere in this paper as to what examinations were 22 actually done.

27 (Pages 102 to 105)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 30 of 41 Page ID #2773

Richard Cavalli August 23, 2022

	Page 106	ריד	Page 10
1	Q (By Mr. Kennedy) And there's no mention	$ \mathbf{L}_{1} $	upon any education or any training or ever the
2	anywhere in this paper as to what their finding were on	2	performance of such an examination, true?
3	examination.	3	MS. REISMAN: Objection to form.
4	Would that be true?	4	A Except for the examinations I underwent
5	MS. REISMAN: Objection to form.	5	myself.
6	A I'd have to read it.	6	Q (By Mr. Kennedy) All right. You continued
7	Q (By Mr. Kennedy) And, sir, the physician	7	and your testified also on on questioning from
8	that that did did these examinations was was	8	Chevron's counsel that this Howard study did not show
9	the physician even a neurologist? Do you know?	9	any signs of of Parkinson's disease amongst these
10	MS. REISMAN: Objection to form.	10	patients.
11	Foundation.	11	Do you recall that testimony?
12	A I don't believe either one was, but I don't	12	A I do.
13	remember.	13	
14		14	Q Do you know the early signs of Parkinson's disease?
15	Q (By Mr. Kennedy) And were you provided with with any kind of a data or documents at any	15	
15 16		16	MS. REISMAN: Objection to form.
17	time that would tell you what examinations were actually done and what the findings actually were?	17	A I know relatively little about Parkinson's
18		18	disease. O (By Mr Kennedy) Well let me ack you. These
18 19	A They the discussions that we had leading	19	Q (By Mr. Kennedy) Well, let me ask you. Thes examinations that were done, did did they look for
20	up to this study, the full clinical examination meant	20	•
	the kind of evaluation of the function of the nervous	20	orthostatic changes in blood pressure? Do you know?
21	system that you would get by looking at an intact		MS. REISMAN: Objection to form.
22	person. It's part of the clinical examination.	22	A No, I don't. I don't know that.
23	Q Was that anywhere in the were you	23	Q (By Mr. Kennedy) Do you know that that's an
24 25	provided with a protocol that told you specifically	24 25	early sign of Parkinson's disease?
20	and can you tell us here today what examinations were	25	MS. REISMAN: Objection to form.
	Page 107		Page 10
1	done and what the findings were?	1	Foundation.
2	MS. REISMAN: Objection to form.	2	A I do not.
3	A I don't recall the protocol as we sit here.	3	Q (By Mr. Kennedy) Did these examinations and
4	Q (By Mr. Kennedy) And I think when you when	4	evaluations look into dream enactment, do you know?
5	you testified in response to the to the questions	5	A Say that again.
6	asked by Chevron's counsel and I think here today	6	Q Dream enactment?
_	you you testified that a standard clinical exam		
7		7	MS. REISMAN: Objection. Form.
8	was was done?	8	MS. REISMAN: Objection. Form. Q (By Mr. Kennedy) Did they look into that
	was was done? A That correct.		-
8 9		8	Q (By Mr. Kennedy) Did they look into that
8	A That correct.	8 9	Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers?
8 9 10	A That correct.Q Well, you're not a medical doctor?	8 9 10	Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form.
8 9 10 11	 A That correct. Q Well, you're not a medical doctor? A I am not. 	8 9 10 11	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term.
8 9 10 11 12	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're 	8 9 10 11 12	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you
8 9 10 11 12 13	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at 	8 9 10 11 12 13	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct?
8 9 10 11 12 13 14	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? 	8 9 10 11 12 13 14	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of
8 9 10 11 12 13 14 15	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. 	8 9 10 11 12 13 14 15	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form.
8 9 10 11 12 13 14 15 16	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard 	8 9 10 11 12 13 14 15 16	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do
8 9 10 11 12 13 14 15 16 17	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? 	8 9 10 11 12 13 14 15 16 17 18	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know?
8 9 10 11 12 13 14 15 16 17 18	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? A I did not. 	8 9 10 11 12 13 14 15 16 17	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know? MS. REISMAN: Same objection.
8 9 10 11 12 13 14 15 16 17 18 19 20	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? A I did not. Q Were you ever trained as to what a standard 	8 9 10 11 12 13 14 15 16 17 18 19 20	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know? MS. REISMAN: Same objection. A I I can't say one way or another.
8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? A I did not. Q Were you ever trained as to what a standard clinical examination includes? 	8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know? MS. REISMAN: Same objection. A I I can't say one way or another. Q (By Mr. Kennedy) The ability to to smell
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? A I did not. Q Were you ever trained as to what a standard clinical examination includes? MS. REISMAN: Objection to form. 	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know? MS. REISMAN: Same objection. A I I I can't say one way or another. Q (By Mr. Kennedy) The ability to to smell an olfactory manifestation, did they look for that in
8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A That correct. Q Well, you're not a medical doctor? A I am not. Q Have you ever performed what what you're calling a standard clinical exam on any patients at all? A No. Q In in your training in biology, zoology, toxicology, did you take a course in what a standard clinical examination is for a patient? A I did not. Q Were you ever trained as to what a standard clinical examination includes? 	8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q (By Mr. Kennedy) Did they look into that during these valuation of these 27 Malaysian workers? MS. REISMAN: Objection to form. A I don't I don't understand the term. Q (By Mr. Kennedy) Then I would assume you don't understand that that's an early sign of Parkinson's disease also, correct? MS. REISMAN: Objection to form. Foundation. Q (By Mr. Kennedy) Did they look for that? Do you know? MS. REISMAN: Same objection. A I I can't say one way or another. Q (By Mr. Kennedy) The ability to to smell

28 (Pages 106 to 109)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 31 of 41 Page ID #2774

Richard Cavalli August 23, 2022

	Page 110		Page 112
1		Would th	
1	but I don't recall anything like that.		at be the extent of your experience?
2 3	Q What about retropulsion and propulsion? Was that evaluated?		SMAN: Objection to form.
4	MS. REISMAN: Objection to form.		ow, other than perhaps reading about
4 5	0		
6	 A I don't I don't recognize those terms. Q (By Mr. Kennedy) Those are early 		Kennedy) And, sir, the workers in
7	manifestations of Parkinson's disease. Did you		in this study, this Howard study,
8	understand that?	-	ined on a single occasion; is that true?
			SMAN: Objection. Form.
9 10	MS. REISMAN: Objection to form. Foundation.		e so. But again, I would have to
10			Konnady) I think you tastified to
11	A No. But everything you've mentioned can be		Kennedy) I think you testified to
12	caused by many things. But no, I don't I don't		a single examination? SMAN: Objection to form.
13	even know what you mean by those terms.		-
14	Q (By Mr. Kennedy) What about cogwheel		Kennedy) Does that refresh your
	rigidity? Was that evaluated in this study of the 27 workers?		
16			think it was a single exam.
17	A Again, I not familiar with the term.		ron ICI had no idea how these workers
18	Q That's an early or a manifestation of		e years later, ten years later,
19 20	Parkinson's disease. Did you understand that?	•	
-	MS. REISMAN: Objection to form.		SMAN: Objection. Form.
21	Foundation.		re they weren't followed up.
22	A No. I I don't.		Kennedy) And do you understand that
23	Q (By Mr. Kennedy) Other than the statement in		orkers were under 35 years of age when
24	the article that the exam focused on the lungs and the		ngle, one occasion examination.
25	skin, can you tell us anything about the specific exams	25 Do you u	nderstand that?
	Page 111		Page 113
1	-	1 MS PEIS	_
1	done and the specific findings done in any one of these		MAN: Objection to form.
2	done and the specific findings done in any one of these 27 workers?	2 A Yeah. A	MAN: Objection to form. gain, I would have to look.
2 3	done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form.	2 A Yeah. A 3 Q (By Mr. 1)	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's
2 3 4	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It 	 A Yeah. A Q (By Mr.) true and I read 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if
2 3 4 5	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a 	 A Yeah. A Q (By Mr.) true and I read half of them wer 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if re under 35, Chevron had no idea how any
2 3 4 5 6	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for 	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if
2 3 4 5 6 7	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them were6of these workers750, true?	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45,
2 3 4 5 6 7 8	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in 	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 50, true? MS. REIS 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form.
2 3 4 5 6 7 8 9	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? 	 A Yeah. A Q (By Mr. 1) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr. 1) 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no
2 3 4 5 6 7 8 9 10	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. 	 A Yeah. A Q (By Mr. 1) true and I read half of them wer of these workers 50, true? MS. REIS Q (By Mr. 1) follow-up? 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's It the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no
2 3 4 5 6 7 8 9 10 11	done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it	 A Yeah. A Q (By Mr.) true and I read half of them wer of these workers 50, true? MS. REIS Q (By Mr.) follow-up? MS. REIS 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if the under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12	done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination.	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr.) follow-up? MS. REIS A That is t 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if the under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue.
2 3 4 5 6 7 8 9 10 11 12 13	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you 	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr.) follow-up? MS. REIS A That is t Q (By Mr.) 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if re under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in
2 3 4 5 6 7 8 9 10 11 12 13 14	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? 	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr.) follow-up? MS. REIS A That is t Q (By Mr.) Response to the c 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if re under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in uestions by by Chevron's lawyer
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. 	 A Yeah. A Q (By Mr.) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr.) follow-up? MS. REIS A That is t Q (By Mr.) response to the q that you did not 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if re under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in juestions by by Chevron's lawyer believe that there was a need for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. 	 A Yeah. A Q (By Mr. 1) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr. 1) follow-up? MS. REIS A That is t Q (By Mr. 1) response to the c that you did not follow-up examination 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? 	 A Yeah. A Q (By Mr. 1) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr. 1) follow-up? MS. REIS Q (By Mr. 1) G (By Mr. 1) response to the constraint of the second constrai	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in juestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. 	 A Yeah. A Q (By Mr. 1) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr. 1) follow-up? MS. REIS Q (By Mr. 1) A That is t Q (By Mr. 1) that you did not follow-up examini eliminated from Do you re 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them 	 A Yeah. A Q (By Mr. 1) true and I read half of them were of these workers 50, true? MS. REIS Q (By Mr. 1) follow-up? MS. REIS Q (By Mr. 1) A That is t Q (By Mr. 1) that you did not follow-up examini follow-up examini eliminated from Do you rei why there was not 	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's It the article again this morning if re under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them performed on my children. I have had the experience 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them were6of these workers750, true?8MS. REIS9Q(By Mr. 1)10follow-up?11MS. REIS12AThat is t13Q(By Mr. 1)14response to the c15that you did not16follow-up examina17eliminated from18Do you re19why there was n20MS. REIS	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if re under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in juestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations? MAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them performed on my children. I have had the experience of having physical examinations myself, and they all 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them were6of these workers750, true?8MS. REIS9Q(By Mr. 1)10follow-up?11MS. REIS12AThat is t13Q(By Mr. 1)14response to the q15that you did not16follow-up examinant17eliminated from18Do you re19why there was n20MS. REIS21AYes. Th	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if e under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations? MAN: Objection to form. at was that was my belief and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them performed on my children. I have had the experience of having physical examinations myself, and they all included that. 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them wer6of these workers750, true?8MS. REIS9Q(By Mr. 1)10follow-up?11MS. REIS12AThat is t13Q(By Mr. 1)14response to the q15that you did not16follow-up examinant17eliminated from18Do you re19why there was n20MS. REIS21AYes. Th22opinion at the t	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if the under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations? MAN: Objection to form. at was that was my belief and ime.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. A g (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them performed on my children. I have had the experience of having physical examinations myself, and they all included that. Q (By Mr. Kennedy) So the extent of your 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them wer6of these workers750, true?8MS. REIS9Q9Q10follow-up?11MS. REIS12A13Q14response to the q15that you did not16follow-up examinated from17eliminated from18Do you re19why there was n20MS. REIS21AYes. Th23Q(By Mr. 1)	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if the under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in juestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations? MAN: Objection to form. at was that was my belief and ime. Kennedy) But, sir, the fact is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 done and the specific findings done in any one of these 27 workers? MS. REISMAN: Objection to form. A First of all, it doesn't say it focused. It just says particular attention was paid. And again, a clinical examination would include looking for neurologic signs and symptoms. Q (By Mr. Kennedy) Where does it say that in the paper? MS. REISMAN: Objection to form. A It's under the I mean, specifically it doesn't, but it would be part of clinical examination. Q (By Mr. Kennedy) Such an examination that you have never performed in your career, true? MS. REISMAN: Objection to form. Argumentative. Q (By Mr. Kennedy) True? MS. REISMAN: Same objection. A I have never performed one. I've seen them performed on my children. I have had the experience of having physical examinations myself, and they all included that. 	2AYeah. A3Q(By Mr. 1)4true and I read5half of them wer6of these workers750, true?8MS. REIS9Q9Q10follow-up?11MS. REIS12A13Q14response to the q15that you did not16follow-up examinated from17eliminated from18Do you re19why there was n20MS. REIS21AYes. Th23Q(By Mr. 1)	MAN: Objection to form. gain, I would have to look. Kennedy) Well, assuming that's I the article again this morning if the under 35, Chevron had no idea how any were doing at the age of of 40, 45, MAN: Objection to form. Kennedy) Because there's no MAN: Objection to form. rue. Kennedy) And you testified in puestions by by Chevron's lawyer believe that there was a need for nations because paraquat rapidly is the body. member stating that as the reason o need for follow-up examinations? MAN: Objection to form. at was that was my belief and ime.

Paszkiewicz Court Reporting (618) 307-9320 / Toll-Free (855) 595-3577

29 (Pages 110 to 113)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 32 of 41 Page ID #2775

Richard Cavalli August 23, 2022

		1	
	Page 114	FI	NTIAI Page 116
1	MS. REISMAN: Objection to form. And he's	╢┛┙	how long paraquat would stay in the brain of a dog?
2	testifying as in his individual capacity, not on	2	"ANSWER: I don't recall that a study like
3	behalf of Chevron.	3	that was done.
4	You can give your response to the extent you	4	"QUESTION: At any time between 1960 and
5	have personal knowledge subject to my objection to	5	1986, did ICI or Chevron do any studies to determine
6	form of the question.	6	how long paraquat would stay in the brain of a monkey?
7	A I I I don't specifically well,	7	"ANSWER: I don't recall seeing that
8	would you ask the question again. I'm sorry.	8	study a study like that.
9	Q (By Mr. Kennedy) Sir, you told us there was	9	"QUESTION: Between 1960 and 1986, with
10	no need for follow-up examinations because paraquat was	10	respect to any animal, did ICI or Chevron do a study
11	rapidly eliminated from the body, and my question is	11	to determine how long paraquat would stay in the brain
12	isn't it true that neither you nor anyone at Chevron	12	after exposure?
13	knew how long paraquat remained in the brain?	13	"ANSWER: I think we already discussed
14	MS. REISMAN: Objection to form.	14	earlier, we couldn't find a study where they analyzed
15	Foundation.	15	paraquat in the brain. So that so that it
16	A I I don't have a specific memory one way	16	stayed in the brain or that it was there. So far as I
17	or the other. There was a lot of information	17	know, there's no data about paraquat in the brain."
18	available how long paraquat stayed in the body.	18	Do you have any recollection, sir, that
19	MR. KENNEDY: Pull up the testimony of	19	would dispute the accuracy of the testimony of the
20		20	person representing Chevron on that issue?
20	McMillen taken on April 27, '22, if you could, please.	21	MS. REISMAN: Standing objection for pulling
	MS. REISMAN: Do you have a hard copy of	22	out portion of this testimony without all the
22	this, Mr. Kennedy?	23	testimony present to be able to see context for this
23	MR. KENNEDY: No.	1	
24	MS. REISMAN: I'm just going to object to	24	and other statements made during the deposition.
25	the extent you're going to pull out a single question	25	Object to form.
25	the extent you're going to pull out a single question Page 115	25	Object to form. Page 117
25		25	
	Page 115		Page 117
1	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing	1	Page 117 Subject to that, you can answer if you have an answer.
1 2	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here.	1 2	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please?
1 2 3	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of	1 2 3	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When
1 2 3 4	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by	1 2 3 4	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection
1 2 3 4 5 6	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues	1 2 3 4 5	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again.
1 2 3 4 5 6 7	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can	1 2 3 4 5 6 7	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand
1 2 3 4 5 6 7 8	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this	1 2 3 4 5 6 7 8	Page 11 ⁻⁷ Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days.
1 2 3 4 5 6 7 8 9	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics.	1 2 3 4 5 6 7 8 9	Page 11 ⁻⁷ Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an
1 2 3 4 5 6 7 8 9 10	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right?	1 2 3 4 5 6 7 8 9 10	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your
1 2 3 4 5 6 7 8 9 10 11	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an	1 2 3 4 5 6 7 8 9 10 11	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're
1 2 3 4 5 6 7 8 9 10 11 12	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement.	1 2 3 4 5 6 7 8 9 10 11 11 12	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're MR. KENNEDY: Completely inappropriate.
1 2 3 4 5 6 7 8 9 10 11 12 13	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258.	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at
1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron.	1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 11 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986,	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986, did ICI or Chevron do any rat studies where they	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of the representative of Chevron?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986, did ICI or Chevron do any rat studies where they determined how long paraquat would stay in the brain	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of the representative of Chevron? MS. REISMAN: Objection to form.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986, did ICI or Chevron do any rat studies where they determined how long paraquat would stay in the brain of a rat that was exposed to paraquat.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of the representative of Chevron? MS. REISMAN: Objection to form. A No.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986, did ICI or Chevron do any rat studies where they determined how long paraquat would stay in the brain of a rat that was exposed to paraquat. "ANSWER: I don't recall that that was done.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of the representative of Chevron? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Was there any reason any
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 115 and answer that there's context, I suspect, for everything. So we're going to have a standing objection on not having a full transcript here. Q (By Mr. Kennedy) This is the deposition of Sara McMillen. Sara McMillen was was chosen by Chevron to speak in their behalf about the issues certain issues in this case. All right? You can assume that, that she is representing Chevron in this case with respect to their position on various topics. All right? MS. REISMAN: Objection to foundation, an understatement. Q (By Mr. Kennedy) If you go to page 258. 258, line 2, McMillen representative of Chevron. "QUESTION: I'm not interested in the lungs. I'm trying to finish. "ANSWER: I have already said they did not analyze the brain. "QUESTION: Okay. Between 1960 and 1986, did ICI or Chevron do any rat studies where they determined how long paraquat would stay in the brain of a rat that was exposed to paraquat.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 117 Subject to that, you can answer if you have an answer. A Could you re-ask it, please? MR. KENNEDY: Your objection is noted. When I ask the question again, I don't want the objection again for five minutes so that I have to ask it again. This is completely inappropriate, and you understand it and know it, but you've been doing it for two days. MS. REISMAN: That's completely an inappropriate comment, and please don't point your finger at me as you're as you're MR. KENNEDY: Completely inappropriate. MS. REISMAN: It is not. If we were at trial, you would be required to have a full transcript there so we could check the the the portions that you're reading. Go ahead. I have a standing objection to this. Q (By Mr. Kennedy) Do you have any recollection that in any way would disagree with that testimony of the representative of Chevron? MS. REISMAN: Objection to form. A No.

30 (Pages 114 to 117)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 33 of 41 Page ID #2776

Richard Cavalli August 23, 2022

	1	
Page 118	E	Page 120
		follow-ups of those survivors, correct?
		MS. REISMAN: Objection to form.
		A We did not.
		Q (By Mr. Kennedy) And with respect to the
-		animal studies, Chevron never determined how long
-		paraquat stayed in the brain, correct?
		MS. REISMAN: Objection to form.
		A Yes.
-		Q (By Mr. Kennedy) And with respect to the
-		animal studies, the long-term chronic low-dose exposure
		studies, Chevron never did those type studies to see if
		paraquat got into the brain, correct?
-		MS. REISMAN: Objection to form.
		A Specifically, no. But we did do
•		observations during the lifetime of the animals, a
		determination that showed that accepted very, very
		high doses. The lung was compromised. There was no
		change in brain anatomy or function to the extent it
		could be noted.
-		MR. KENNEDY: I would move to strike.
		Q (By Mr. Kennedy) I'm going to ask you a
· · · · · · · · · · · · · · · · · · ·		question again. Would it be true that Chevron never
		did long-term low-dose studies to determine whether or
		not paraquat was in the brain?
safety?	25	MS. REISMAN: Objection to form. Asked and
Page 119		Page 121
MS. REISMAN: Objection. Form. Asked and	1	answer.
-	2	Q (By Mr. Kennedy) True? It never looked to
A You know, it would depend on the	3	see if it got into the brain in a rat, a mouse, a dog,
-	4	a monkey, a hen, a dog, or a goat, true?
	5	MS. REISMAN: Same objection.
	6	A I no. I don't believe we did.
	7	Q (By Mr. Kennedy) And Chevron never did an
U	8	epidemiology study in the United States of America, did
	9	they?
		MS. REISMAN: Objection to form.
-	11	A No.
		Q (By Mr. Kennedy) And Chevron never did an
		epidemiology that specifically looked to see whether or
· · · ·		not workers were developing early signs and symptoms
		with Parkinson's, correct?
		MS. REISMAN: Same objection. Form.
		A No.
-		Q (By Mr. Kennedy) And when you folks received
		brain tissue from from people that had been poisoned
		by paraquat and had died, when you received that brain
		tissue, you evaluated it to determine whether or not
		there was paraquat. But you never did detailed
A Yes.	22	histopathological examinations of that brain tissue,
A 103.		
Q With respect to the poisoning cases when the	24	correct?
	 Animal? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) A rat, a mouse, a dog, a fonkey. Any reason why they couldn't have done that for to 1986? MS. REISMAN: Objection to form. A net whole animal or in the brain? Q (By Mr. Kennedy) The brain. MS. REISMAN: Same objection. A No. There's no reason why. Q (By Mr. Kennedy) Had Chevron done studies and fom onkey for seven to ten months, would that have founderstand that paraquat stayed in the brain of a monkey for seven to ten months, would that have founderstand that paraquat stayed in the brain of a monkey for seven to ten months, would that have founderstand that paraquat stayed in the brain of a monkey for seven to ten months, would that have found that paraquat persisted for a minimum of seven to ten months in the brain of a monkey brain, they found that paraquat persisted for a minimum of seven to ten months in the brain of a monkey. You can assume that. Ma you known that back in 1980, 1985, would that have changed your your position with respect how paraquat needs to be evaluated to confirm its safety? 	animal? Generation of the second

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 34 of 41 Page ID #2777

Richard Cavalli August 23, 2022

	-		2022
	Page 122	יש	Page 124
1	certainly well, certainly probably would have	$ \mathbf{L}_{1} $	Mr. Kennedy, that he is free to tell you the documents
2	been done by the pathologist.	2	that he reviewed that refreshed his recollection. But
3	Q Chevron never did it, and you never retained	3	other than that, and if if he recalls specific
4	anybody to do it, true?	4	worker exposure studies or animal studies that he
5	A True.	5	reviewed or autopsy reports that he reviewed in the
6	Q And could we agree just in the general	6	context of his review, he can reveal those to you.
7	scientific sense, sir, if you don't look for	7	But past those specific limited materials,
8	something, you're not going to find it, true?	8	I'm going to instruct him not to answer.
9	MS. REISMAN: Objection to form.	9	MR. KENNEDY: Okay.
10	A Referring to paraquat in the brain, it	10	MS. REISMAN: And we are not waiving
11	didn't manifest itself as causing anything. So, you	11	privilege or work product even with respect to those
12	know, we we looked maybe we didn't look for it,	12	animal studies or autopsy reports or worker exposure
13	but we looked at it.	13	data that he does recall reviewing. But I'm fine with
14	MR. KENNEDY: I have nothing further.	14	he with Mr. Cavalli testifying with respect to the
15	MR. FLOWERS: Take a 2-minute break.	15	animal studies, the worker exposure studies, and the
16	MR. FLOWERS: Take a 2-minute break. MR. KENNEDY: Yeah. Take a 2-minute break.	16	human autopsy reports that he reviewed.
10	I probably missed something.	17	Q (By Mr. Kennedy) Okay. And so that I'm
18	VIDEOGRAPHER: We're going off the record at	18	clear, I'm asking you to identify any any documents,
19	11:58 a.m.	19	written or electronic, any medical literature, or any
20		20	other publication or any deposition testimony that you
20	(A break was taken.)		
	VIDEOGRAPHER: We're back on the record at	21	reviewed the totality of what you reviewed, whether
22	12:01 p.m.	22	it was provided to you by counsel or that you went and
23	MR. KENNEDY: Still Eric Kennedy. I'm	23	got it on your own. All right?
24	simply making a record with respect to materials that	24	Are you able to to give us that
25	Mr. Cavalli reviewed in preparation for his testimony	25	information?
	Page 123		Page 125
1	today.	1	MS. REISMAN: Without waiving privilege or
2	Q (By Mr. Kennedy) Mr. Cavalli, could you give	2	attorney work product, if you recall the animal
3	me a list and tell me the documents first, the	3	studies or the worker exposure studies, the human
4	documents, paper documents, that you reviewed in	4	autopsy reports that you reviewed in the context of
5	preparation for your deposition?	5	your preparation, you can testify as to those.
6	MS. REISMAN: And I'm going to assert an	6	As to the other materials, we are asserting
			As to the other materials, we are asserting
7	objection, and this was a discussion we've already had	7	
7 8	objection, and this was a discussion we've already had off the record. We're going to assert privilege over		privilege under work product, and we are not waiving
	objection, and this was a discussion we've already had off the record. We're going to assert privilege over the documents and work product over the documents	7	
8	off the record. We're going to assert privilege over	7 8	privilege under work product, and we are not waiving either of those with respect to the limited set of
8 9	off the record. We're going to assert privilege over the documents and work product over the documents	7 8 9	privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about.
8 9 10	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of	7 8 9 10	privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify
8 9 10 11 12	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli.	7 8 9 10 11 12	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at.
8 9 10 11	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the	7 8 9 10 11	privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about.A I cannot give you a list of the documents
8 9 10 11 12 13	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As	7 8 9 10 11 12 13	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum?
8 9 10 11 12 13 14	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of	7 8 9 10 11 12 13 14	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on
8 9 10 11 12 13 14 15	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As	7 8 9 10 11 12 13 14 15	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also
8 9 10 11 12 13 14 15 16	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection.	7 8 9 10 11 12 13 14 15 16	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to
8 9 10 11 12 13 14 15 16 17 18	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his	7 8 9 10 11 12 13 14 15 16 17	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation,
8 9 10 11 12 13 14 15 16 17 18 19	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure	7 8 9 10 11 12 13 14 15 16 17 18 19	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files.
8 9 10 11 12 13 14 15 16 17 18 19 20	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure data, and human autopsy data, all of which has been	7 8 9 10 11 12 13 14 15 16 17 18 19 20	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files. Q (By Mr. Kennedy) Did you review any medical
8 9 10 11 12 13 14 15 16 17 18 19 20 21	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure data, and human autopsy data, all of which has been produced to you. Subject to that disclosure, I'm not	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files. Q (By Mr. Kennedy) Did you review any medical literature?
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure data, and human autopsy data, all of which has been produced to you. Subject to that disclosure, I'm not going to permit Mr. Cavalli to talk about and reveal	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files. Q (By Mr. Kennedy) Did you review any medical literature? MS. REISMAN: Again, subject to my
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure data, and human autopsy data, all of which has been produced to you. Subject to that disclosure, I'm not going to permit Mr. Cavalli to talk about and reveal the documents that he reviewed in preparation for this	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files. Q (By Mr. Kennedy) Did you review any medical literature? MS. REISMAN: Again, subject to my objections, if you recall specific worker exposure or
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	off the record. We're going to assert privilege over the documents and work product over the documents that were shown to Mr. Cavalli. We have disclosed him out of an abundance of caution as a nonretained expert, and we have disclosed within there the materials that he reviewed and the context of his work at Chevron back in the '80s. As is clear from today, he doesn't have a recollection of that he's testified, that nothing refreshed his recollection. But we have disclosed to you that his opinions were based on animal data, worker exposure data, and human autopsy data, all of which has been produced to you. Subject to that disclosure, I'm not going to permit Mr. Cavalli to talk about and reveal	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 privilege under work product, and we are not waiving either of those with respect to the limited set of materials that I've described that you can testify about. A I cannot give you a list of the documents that or other material that I looked at. Q (By Mr. Kennedy) Did you review any summaries of materials or memorandum? MS. REISMAN: I'm going to object on privilege and work product basis, but I will also represent that the only materials that were shown to Mr. Cavalli were produced in this litigation, documents from Chevron's files. Q (By Mr. Kennedy) Did you review any medical literature? MS. REISMAN: Again, subject to my

32 (Pages 122 to 125)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 35 of 41 Page ID #2778

Richard Cavalli August 23, 2022

		1
	Page 126	ENTERIA T Page 128
1	with respect to those.	E ₁ N A Yes
2	Q (By Mr. Kennedy) And other than counsel, the	2 Q Do you still practice toxicology?
3	attorneys representing Chevron, did you speak with	3 A I do not.
4	anybody else in preparation for your deposition?	4 Q Have you practiced toxicology since you
5	A No.	5 retired in 1999?
6	MR. KENNEDY: I don't think I have any	6 A I have not. Excuse me.
7	further questions unless I missed something?	7 Q Have you kept abreast with the with the
8	MR. FLOWERS: No.	8 literature? Have you kept up with the scientific
9	MR. KENNEDY: All good here.	9 literature on any topic since 1999?
10	MS. REISMAN: Thank you.	10 A Not really.
11	Why don't we break for lunch and come back	11 Q And with respect to paraquat specifically,
12	at 1:00, 1:15? What do you think? Good? 1:15.	12 have you done anything to keep up with the literature
12	-	13 on paraquat since Chevron left the business in 1986?
13	VIDEOGRAPHER: Okay. We're going off the	13 on paraquat since Chevron left the business in 1980? 14 A I have not.
	record at 12:05 p.m.	
15 16	(A break was taken.)	
	VIDEOGRAPHER: Stand by. We're back on the	16 last couple of days that no document that you have
17	record at 1:27 p.m.	17 seen has refreshed your recollection.
18	[EXAMINATION]	18 So is it correct that your testimony here
19	QUESTIONS BY MS. REISMAN:	19 today and yesterday is based only on your
20	Q Good afternoon, Mr. Cavalli.	20 recollections of your understandings prior to when
21	A Good afternoon.	21 Chevron exited the paraquat business in 1986?
22	Q We're back from a break for lunch, and the	22 MR. KENNEDY: Objection. Form. Leading.
23	same rules apply to my questioning as those that apply	23 A That's correct.
24	to Mr. Kelly's, Mr. Kennedy's and my own yesterday.	24 Q (By Ms. Reisman) Now, you testified that you
25	Can you hear me, Mr. Cavalli?	25 believe that paraquat applicators had low-dose
	Doct 107	Dogo 120
	Page 127	Page 129
1	A I can.	1 exposures over several years. I believe that was
2	Q Are you having difficulty hearing me?	2 something that you testified to earlier today, and you
3	A Well, the air conditioner is competing with	3 agreed with Mr. Kennedy that the same that that was
4	you.	4 the same, that low-dose exposure over several years was
5	MS. REISMAN: Can we shut let's go off	5 the same as chronic low-dose exposure?
6	the record.	6 MR. KENNEDY: Objection. Leading.
7	VIDEOGRAPHER: Going off the record at	7 Q (By Ms. Reisman) Mr. Kelly, I'm just setting
8	1:27 p.m.	8 the stage and reminding him of testimony. I haven't
9	(A break was taken.)	9 even gotten to my question.
10	VIDEOGRAPHER: Stand by. We're back on the	10 MR. KENNEDY: I'm going to object to the
11	record at 1:28 p.m.	11 speeches prior to the question being asked.
12	Q (By Ms. Reisman) Good afternoon, Mr. Cavalli.	12 MS. REISMAN: I'm going to ask you to please
13	A Good afternoon.	13 hold your objections until there is a question on the
14	Q I was just saying we're back from lunch, and	14 table. I'm reminding the witness where we are.
15	I just wanted to remind you that the same rules apply	15 Q (By Ms. Reisman) You agreed with Mr. Kennedy
16	to my questioning as as as did apply when	16 earlier that low-dose exposures over several years was
17	Mr. Kelly, Mr. Kennedy were asking you questions.	17 the same as chronic low-dose exposure.
18	That is if you don't understand my question, just let	18 Do you recall that testimony?
19	me know. And if you get fatigued and are losing	19 MR. KENNEDY: Objection. Leading.
20	focus, let me know and we can take a quick break.	20 A Yeah, I think so.
21	A Okay.	21 Q (By Ms. Reisman) Did you have an
22	Q I want to talk to you, Mr. Cavalli, first	22 understanding as to how many times a year a field
23	about your appearances here today and the basis for	23 worker in the US would apply paraquat?
24	your testimony. I believe you testified yesterday	A My impression at at the time, I believe,
25	that you left Chevron in 1999; is that correct?	25 was that in the United States, paraquat was sprayed
1		

33 (Pages 126 to 129)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 36 of 41 Page ID #2779

Richard Cavalli August 23, 2022

	Page 130		Page 132
1	intermittently and only for short periods of time	$ \mathbf{L}_{1} $	yesterday about the central nervous system effects
2		2	listed in that study. So I want to talk to you about
2	during the year.	3	
	Q Do you recall how many times a year a		that study and those questions now.
4	paraquat a field worker would apply paraquat?	4	If you would turn to page 128 of that study,
5	A No, I don't.	5	Mr. Cavalli, which has Bates No. 879 on the bottom and
6	Q Do you remember if it was a few times or	6	tell me when you are with me.
7	many times during a year?	7	A We're getting there. Okay. Yes, I am.
8	A I really couldn't say.	8	Q In the left column of that page, there is a
9	Q To the best of your knowledge and	9	paragraph that begins "Signs of Poisoning after
10	understanding when you worked on paraquat issues, was	10	Intraperitoneal Dosing."
11	the frequency of a farmer/field worker's exposure more	11	Do you see that?
12	akin to I think you just called it a intermittent,	12	A I do.
13	sporadic exposure?	13	Q And Mr. Kelly read you several sentences
14	MR. KENNEDY: Objection. Leading.	14	from that paragraph. I recall him reading, I think,
15	Q (By Ms. Reisman) Would you characterize	15	through the first sentence, second sentence, third
16	farmer/field worker exposure as inter intermittent	16	sentence, and fourth sentence. And I want to read to
17	exposure?	17	you a sentence that follows the passage that Mr. Kelly
18	A That was my understanding.	18	read to you yesterday.
19	MR. KENNEDY: Objection. Leading.	19	Do you see a sentence that begins
20	Q (By Ms. Reisman) Did you understand did	20	"Additionally " in the middle of that two-thirds
21	did you have an understanding as to whether it was	21	of the way through that paragraph?
22	sporadic?	22	A Yes, I do.
23	MR. KENNEDY: Objection. Leading.	23	Q I'm going to begin reading there.
24	A That was my impression.	24	"Additionally, in the earlier stages breathing might
25	Q (By Ms. Reisman) Well, let me ask you. How	25	be gasping or, alternatively, deep and fast."
1	Page 131 would you describe farmer/field worker exposure to	1	Page 133 Do you see that?
2	paraquat in the US?	2	A Yes, I do.
3	A The my understanding is that it would be	3	Q What does that indicate to you as to what
4	used for weed control maybe once, maybe twice a year.	4	was occurring in these rats?
5	Q What type of animal study would that be most	5	A That indicates that the rats' pulmonary
6	similar to?	6	system, the lungs were not working well.
7	A Say probably a subacute study or, depending	7	Q Does that indicate some lung damage?
8	on the frequency, of just acute studies.	8	A Yes. That's better way to put it.
9	Q Would you liken the exposure that you just	9	Q Yesterday you said you mentioned that you
10	described that paraquat workers in the US had as akin	10	disagree with the author's statement of findings with
11	to chronic studies in animals?	11	respect to these CNS central nervous system effects
12	A Not exactly, no.	12	in this study. How so?
13	Q I want to switch gears now, Mr. Cavalli, and	13	A Well, again, the animals were having
14	talk to you about a an exhibit that was marked	14	difficulty exchanging oxygen, and it would be in a
15	by I actually think it was Mr. Kelly yesterday.	15	mildly to severe hypoxic state and a secondary effec
16	You should have it in front of you. It's Cavalli 40.	16	of that would occur in the nervous system.
17	(Exhibit 40 has been marked and now	17	Q In the next paragraph of that study,
18	identified for the record.	18	Mr. Cavalli, Mr. Kelly read you the first sentence of
19	A Yes, I have it.	19	that paragraph, and I'd like to read to you a sentence
20	Q (By Ms. Reisman) Cavalli 40 Cavalli 40 is	20	that follows.
21	an article entitled "The Toxicity of Paraquat," authors	21	"In animals which survived for a number of
22	Clark D.G. Clark, T.F. McElligott, and Weston Hurst.	22	days after the last of a series of ascending doses,
23	Are you with me, Mr. Cavalli?	23	the later signs of illness were chiefly difficulty
20	A Yes, I am.	24	breathing" and it goes on.
24			
24 25	Q Mr. Kelly asked you several questions	25	What does that passage indicate to you about

Paszkiewicz Court Reporting (618) 307-9320 / Toll-Free (855) 595-3577

34 (Pages 130 to 133)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 37 of 41 Page ID #2780

Richard Cavalli August 23, 2022

	August 2	T	
	Page 134	T	Page 136
1	the animals?	Lil	those the only animal studies that Chevron and you
2	A Again, pulmonary damage.	2	relied on in the early years?
3	Q Yesterday you testified that there were no	3	A I believe there were other – other animal
4	reports and it may have been this morning. It was	4	studies.
5	during Mr. Kelly's questioning. You testified that	5	Q Were the results of Dr. Calandra's studies
6	there were no reports of CNS effects, central nervous	6	on paraquat consistent with the other animal data that
7	system effects in the animal studies you reviewed.	7	you had at the time?
8	Did you mean that you didn't recall any	8	A Yes, they were.
9	studies reporting primary effects of paraquat in the	9	Q And were those studies conducted by IBT on
10	brain and central nervous system?	10	paraquat repeated at a later time?
11	MR. KENNEDY: Objection. Leading.	11	A They were.
12	A Yes.	12	Q Did the results of those studies that were
13	Q (By Ms. Reisman) Let me ask it this way:	13	repeated at a later time, that is, when those studies
14	What did you mean when you said you did not recall any	14	were done, did those studies change your understanding
15	studies reporting central nervous system effects in	15	of the toxicity of paraquat?
16	animal studies that you reviewed?	16	MR. KENNEDY: Objection. Leading.
17	A That I was not aware of any study that	17	A No, they did not.
18	showed a primary effect on the nervous system.	18	Q (By Ms. Reisman) Did you learn anything new
19	Q Okay. Switch gears with you again,	19	from those strike that.
20	Mr. Cavalli. Following up on another area of	20	You've testified several times the last
21	questions by the plaintiff's counsel.	21	couple days about a body of knowledge that you relied
22	Mr. Kelly asked you yesterday who you	22	on for your understanding as to the toxicity of
23	considered most knowledgeable about paraquat at	23	paraquat and your belief and understanding that could
24	Chevron when you became more involved in the 1973 and	24	be used safely when it was used in accordance with the
25	1974 time period, and you answered "no one."	25	label.
	Page 135		Page 137
1	Now, I understand you didn't think any one	1	Were there non-IBT animal studies and other
2	person was most knowledgeable. Were there people at	2	data that you relied on as part of that body of
3	Chevron who you believe had knowledge and understood	3	knowledge that
4	the toxicity of paraquat prior to your more focused	4	A There were certainly other other data,
5			
	involvement in 1973 and 1974?	5	some of which was from animal studies.
6	involvement in 1973 and 1974? A Yes, I do.		-
6 7		5	some of which was from animal studies.
	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren 	5 6	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers,
7	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the 	5 6 7	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was
7 8	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren 	5 6 7 8	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers,
7 8 9	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the 	5 6 7 8 9 10 11	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was
7 8 9 10	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. 	5 6 7 8 9 10	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question.
7 8 9 10 11	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday 	5 6 7 8 9 10 11	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a
7 8 9 10 11 12	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned 	5 6 7 8 9 10 11 12 13 14	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group
7 8 9 10 11 12 13	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the 	5 6 7 8 9 10 11 12 13	some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers?
7 8 9 10 11 12 13 14	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in 	5 6 7 8 9 10 11 12 13 14	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring
7 8 9 10 11 12 13 14 15	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. 	5 6 7 8 9 10 11 12 13 14 15 16 17	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of
7 8 9 10 11 12 13 14 15 16	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in 	5 6 7 8 9 10 11 12 13 14 15 16	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring
7 8 9 10 11 12 13 14 15 16 17	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We – we had – you know, if they followed the precautionary labels, it all added up to exposure would be very low.
7 8 9 10 11 12 13 14 15 16 17 18	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? A Specifically, no. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We – we had – you know, if they followed the precautionary labels, it all added up to exposure would be very low. Q And did you believe that you had sufficient
7 8 9 10 11 12 13 14 15 16 17 18 19	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? A Specifically, no. Q Do you know one way or the other? 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We – we had – you know, if they followed the precautionary labels, it all added up to exposure would be very low.
7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? A Specifically, no. Q Do you know one way or the other? A I don't know one way or the other. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We – we had – you know, if they followed the precautionary labels, it all added up to exposure would be very low. Q And did you believe that you had sufficient
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? A Specifically, no. Q Do you know one way or the other? A I don't know one way or the other. Q You also mentioned that you recall folks at 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We – we had – you know, if they followed the precautionary labels, it all added up to exposure would be very low. Q And did you believe that you had sufficient data to believe that if agricultural workers used
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A Yes, I do. Q And who were they? A That would have been Nils Ospenson, Lauren Stelzer, T.W. Reed, Dick Wessel. I think that's the list of people. Q During your testimony testimony yesterday or, again, may have been this morning, you mentioned that there was a more senior toxicologist at the company at that time. Who was that? A That was Dr. Duane Hallesy. Q Do you remember if he had any involvement in paraquat issues? A Specifically, no. Q Do you know one way or the other? A I don't know one way or the other. Q You also mentioned that you recall folks at Chevron working with Joe Calandra prior to 1973, 1974, 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 some of which was from animal studies. Q You were asked yesterday about whether you or your group conducted a formal study on the adverse health effects of paraquat in farm-related workers, and it may have been different words, but that was basically the gist of the question. And you said you had not conducted such a formal study. Why didn't you or anyone in your group conduct such a formal study of those workers? A Because over time we had a large body of knowledge about paraquat's toxicity. We had a lot of information on the exposure levels that were occurring among workers. We we had you know, if they followed the precautionary labels, it all added up to exposure would be very low. Q And did you believe that you had sufficient data to believe that if agricultural workers used paraquat according to the labels and instructions for

35 (Pages 134 to 137)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 38 of 41 Page ID #2781

Richard Cavalli August 23, 2022

	Page 138	ריד	Page 140
1	Q (By Ms. Reisman) Same question that I asked	$ \mathbf{L}_{1} $	uring that it was airculating in their blood, and you
		2	urine that it was circulating in their blood, and you
2	you about the study on the health effects of paraquat		answered "yes"
3	on farm-related workers. Mr. Kelly asked you the same	3	A Yes.
4	question as to agricultural workers in the US; that is,	4	Q is that correct?
5	you were asked yesterday about whether you or your	5	A Yes, I did.
6	group conducted a formal study of risks to	6	Q He then asked you if that blood circulated
7	US agricultural workers applying paraquat.	7	through the brain, and you said "yes."
8	Why didn't you or anyone in your group	8	Do you recall that?
9	conduct a formal study of those workers with respect	9	A Yes, I do.
10	to health risks	10	Q What part of the brain was that blood
11	A Well, there were	11	circulating through?
12	Q to those workers?	12	A It would have been in the major blood
13	A There were former there were formal	13	vessels and smaller blood vessels and the capillaries
14	studies available to us that had been done by others	14	Q Was it circulating through brain tissue
15	that showed, again, very low exposure to paraquat.	15	under those circumstances?
16	Q And what did that low exposure to paraquat	16	A I don't believe so.
17	tell you about the risk to those workers?	17	Q Switching gears once again, Mr. Cavalli,
18	A Low exposure, low risk.	18	bear with me. I want about training.
19	Q Did Chevron sponsor any of those US studies	19	You were asked a series of questions on
20	done on worker exposure in the US, if you recall?	20	whether you have ever trained paraquat applicators, or
20		21	field workers, or farmers, I think the question was.
22	A I believe we did one, at least.	22	And you said you had never personally done
	Q You were asked whether you or anyone in your	23	that training, but you mentioned that you had trained
23	group commissioned an epidemiologic survey to evaluate	1	
24 25	the safety of paraquat use, and you were also asked whether Chevron ever conducted such an epidemiologic	24 25	field representatives, and that's what I want to talk to you about today.
	Page 139		Page 14
1	-	1	Page 14 Do you recall doing training of field
1 2	survey, and you answered "no" to both questions.	1 2	_
	survey, and you answered "no" to both questions. Did you support such a study being done,		Do you recall doing training of field
2	survey, and you answered "no" to both questions.	2	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do.
2 3 4	survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it?	2 3 4	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on?
2 3 4 5	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. 	2 3 4 5	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity
2 3 4	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? 	2 3 4	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels.
2 3 4 5 6 7	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. 	2 3 4 5 6 7	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have received
2 3 4 5 6 7 8	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've 	2 3 4 5 6 7 8	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field.
2 4 5 6 7 8 9	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? 	2 3 4 5 6 7 8 9	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the
2 3 5 6 7 8 9	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. 	2 3 4 5 6 7 8 9 10	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean
2 3 5 6 7 8 9 10	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit 	2 3 4 5 6 7 8 9 10 11	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that?
2 3 4 5 6 7 8 9 10 11	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, 	2 3 4 5 6 7 8 9 10 11 12	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are
2 3 4 5 6 7 8 9 10 11 12 13	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I 	2 3 4 5 6 7 8 9 10 11 12 13	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk,
2 3 4 5 6 7 8 9 10 11 12 13 14	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. 	2 3 4 5 6 7 8 9 10 11 12 13 14	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low.
2 3 4 5 6 7 8 9 10 11 12 13 14	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and noted urine found in paraquat found in some of the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have received from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field representatives?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and noted urine found in paraquat found in some of the workers' urine. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have received from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field representatives? A These were what we what were called
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 221	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and noted urine found in paraquat found in some of the workers' urine. Do you remember that line of questioning? A Yes, I do. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receive from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field representatives? A These were what we what were called technical field representatives, and they they actually went out into fields. They they met with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 survey, and you answered "no" to both questions. Did you support such a study being done, even if Chevron itself did not technically commission or conduct it? A Yes. Q Was such an epidemiologic study ever done? A Yes. Q And was that the Howard study that you've testified about? A Yes. Q Mr. Cavalli, I'm jumping around quite a bit because I'm trying to hit various issues that came up, so bear with me. And if you need more background as I switch topics, please let me know. During Mr. Kennedy's questioning, he asked you whether if paraquat strike that. During Mr. Kennedy's questions questioning, he asked you about the Howard study and noted urine found in paraquat found in some of the workers' urine. Do you remember that line of questioning? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Do you recall doing training of field representatives with respect to paraquat? A Yes, I do. Q And what did you train them on? A We trained them on, of course, the toxicity of paraquat, the value of the precautionary labels. Tried to answer questions that they may have receiver from the field. Q When you said that you trained them on the value of the precautionary labels, what did you mean by that? A Just that if the precautionary labels are are followed, the exposure to paraquat, hence risk, would be very low. Q Did part of the training include discussing the labels and instructions for use? A I'm I'm pretty sure it did, yes. Q What was the purpose of training these field representatives? A These were what we what were called technical field representatives, and they they

36 (Pages 138 to 141)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 39 of 41 Page ID #2782

Richard Cavalli August 23, 2022

	Page 142	F	VITIAI Page 14
1	there are anymore and to essentially do what I did	Lil	portion that Mr. Kennedy asked you about, and I wan
2	for them.	2	to read the full question and answer into the record.
3	Q Did you have an understanding as to whether	3	The question was: "Doctor, can you answer
4	those field representatives went out in the field and	4	my question once again or can you answer it once? If
5	conveyed the information that you trained them on?	5	you put an ounce of paraquat on your skin, it will
6	A That is my understanding.	6	kill you, won't it? If you leave it on, if you don't
7	Q I want to go back to your role at Chevron as	7	wash it off.
8	a toxicologist. In general, Mr. Kelly asked you	8	"ANSWER: If you leave it on and if the skin
9	yesterday about other Chevron products that you worked	9	breaks down, I would guess that that might be a
10	on over time, and he named to you various petroleum	10	sufficient amount."
11	products and lubricants and solvents.	11	Was that your testimony your sworn
12	Did you also work on nonpetroleum products	12	testimony in the Ferebee case?
13	including specifically other pesticides and insecti-	13	A Yes, it was.
14	insecticides?	14	Q And is that consistent with your response
15	A Yes, I did.	15	here today that it depends on the circumstances to
16	Q And had you worked on those other	16	know whether such an amount would have any harmf
17	pesticides, insecticides, and herbicides before you	17	effect let alone kill you?
18	began your focus on paraquat in 1973, 1974 time frame?	18	A Yes.
19	A Yes.	19	MS. REISMAN: Let's go off the record for
20	Q Were any of those pesticides and,	20	one minute.
21	specifically, some of the insecticides known to be	21	VIDEOGRAPHER: Going off the record at
22	neurotoxic?	22	1:50 p.m.
23	A Yes.	23	(A break was taken.)
24	Q So did you and others at Chevron have some	23	VIDEOGRAPHER: We're back on the record
24	experience researching, identifying, evaluating	24	1:53 p.m.
	D 142		D 14
	Page 143		Page 14
1	neurotoxic substances prior to 1973 or 1974?	1	Q (By Ms. Reisman) Just one last question of
2	A Yes.	2	you, Mr. Cavalli. Mr. Kelly asked you yesterday abou
3	MS. REISMAN: Switching topics once again,	3	your undergraduate degree, and he asked you whether
	and I'm going to ask if our colleague here can pull up		
4		4	could have been in zoology as opposed to biology.
5	the Ferebee transcript. This was a transcript if	5	So I'm going to ask you to take a look at
5 6	the Ferebee transcript. This was a transcript if you just put up the front page first.	5 6	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a
5 6 7	the Ferebee transcript. This was a transcript ifyou just put up the front page first.Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy	5 6 7	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University
5 6 7 8	the Ferebee transcript. This was a transcript ifyou just put up the front page first.Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedyasked you some questions about your testimony in a case	5 6 7 8	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962.
5 6 7 8 9	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. 	5 6 7 8 9	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people
5 6 7 8 9 10	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some 	5 6 7 8 9 10	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is?
5 6 7 8 9 10 11	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? 	5 6 7 8 9 10 11	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is.
5 6 7 8 9 10 11 12	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. 	5 6 7 8 9 10 11 12	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D.
5 6 7 8 9 10 11 12 13	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is 	5 6 7 8 9 10 11 12 13	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli?
5 6 7 8 9 10 11 12 13 14	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? 	5 6 7 8 9 10 11 12 13 14	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes.
5 6 7 8 9 10 11 12 13 14 15	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. 	5 6 7 8 9 10 11 12 13 14 15	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually
5 6 7 8 9 10 11 12 13 14 15 16	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you 	5 6 7 8 9 10 11 12 13 14 15 16	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology?
5 6 7 8 9 10 11 12 13 14 15 16 17	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? 	5 6 7 8 9 10 11 12 13 14 15 16 17	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does.
5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes. Q Okay. Thank you.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, do you have any specific recollections about giving 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no further questions at this time.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, do you have any specific recollections about giving this testimony and the specifics of that testimony or 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, do you have any specific recollections about giving this testimony and the specifics of that testimony or only that you gave testimony? 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no further questions at this time. MR. KENNEDY: Yeah, I can ask I can ask them from here.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, do you have any specific recollections about giving this testimony and the specifics of that testimony or only that you gave testimony? A Onl basically, I gave testimony. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no further questions at this time. MR. KENNEDY: Yeah, I can ask I can ask them from here. [EXAMINATION]
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the Ferebee transcript. This was a transcript if you just put up the front page first. Q (By Ms. Reisman) Mr. Cavalli, Mr. Kennedy asked you some questions about your testimony in a case called Ferebee. Do you recall that you answered some questions on some testimony you gave in Ferebee? A Yes, I do. Q And that testimony was given in 1982; is that correct? A That's what the document says, yes. Q Do you have a specific recollection as you sit here today? A No. Not the exact date, no. Q And and with respect to your testimony, do you have any specific recollections about giving this testimony and the specifics of that testimony or only that you gave testimony? 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	So I'm going to ask you to take a look at at a document we'll pull up on the screen which is a yearbook picture we found of you from the University of San Francisco, year 1962. Is that you in the lower row, four people from the left, I guess it is? A I believe it is. Q Can you see? Is that you, Richard D. Cavalli? A Yes. Q Does this help remind you that you actually got your degree in biology? A Yes, it does. Q Okay. Thank you. MS. REISMAN: Pull that down. I have no further questions at this time. MR. KENNEDY: Yeah, I can ask I can ask them from here.

37 (Pages 142 to 145)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 40 of 41 Page ID #2783


Richard Cavalli August 23, 2022

	Page 146		Page 148
1	representing the plaintiffs in this case.	$ \mathbf{L} $	A- The as I understood it, the technical
2	You testified just now that it was your	2	field rep's job was to assist – assist understanding
3	understanding that paraquat applicators only applied	3	how to use paraquat, what it did, what it didn't do.
4	paraquat once or twice a year; is that your testimony?	4	They also did a lot of work on crops. But they were
5	MS. REISMAN: Objection. Form.	5	in contact with, as I said, the ag extension agents
6	A That was my did I specifically say once	6	and quite often with groups of farmers.
7	or twice a year?	7	Q (By Mr. Kennedy) Well, when you would meet
8	Q (By Mr. Kennedy) Yes.	8	with them, and knowing and understanding that they
9	A That was my understanding at the time, yes.	9	would be talking to farmers and applicators, did you
10	Q And so is it your testimony that the entire	10	ever tell them that every time Chevron or ICI did an
11	time that you were at Chevron and you were evaluating	11	animal study, whether it was rats, mice, dogs, pigs,
12	the risk of paraquat on applicators, you were always	12	goat, hens, or monkeys, every time they found paraquat
13	assuming that they would never apply paraquat more	13	in their brain, did you tell that to the to the
14	than once or twice a year?	14	field reps?
15	MS. REISMAN: Objection to form.	15	MS. REISMAN: Objection to form.
16	A No. That's not correct.	16	A No. I don't I don't remember that.
17	Q (By Mr. Kennedy) Then your testimony is you	17	Q (By Mr. Kennedy) Did you tell the field reps
18	don't know whether it's only once or twice a year?	18	that you folks had received brain tissue on autopsy and
19	MS. REISMAN: Objection to form.	19	26 times you found paraquat in the brains on autopsies?
20	Q (By Mr. Kennedy) Is that your testimony?	20	Did you tell the field reps that so they could
21	A My my testimony is that we had a large	21	communicate that to the farmers and applicators?
22	database which we were able to apply to paraquat	22	MS. REISMAN: Objection to form.
23	workers in the field without without consideration	23	A No.
24	of it being just once or twice a year.	24	Q (By Mr. Kennedy) Did you tell them at all
25	Q So you understand some apply 20 times a	25	about the the 1966 Clark study that we talked so
	Page 147		5 140
	Idge 147		Page 149
1	year, 30 times a year?	1	Page 149 much about where there were stated signs of brain
1 2		1 2	
	year, 30 times a year?		much about where there were stated signs of brain
2	year, 30 times a year? MS. REISMAN: Objection to form.	2	much about where there were stated signs of brain involvement, did you tell them about the '66 study?
2 3	year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that?	2 3	much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form.
2 3 4	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to 	2 3 4	much about where there were stated signs of braininvolvement, did you tell them about the '66 study?MS. REISMAN: Objection to form.A No.
2 3 4 5	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. 	2 3 4 5	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983,
2 3 4 5 6	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I – I don't. I don't have any reason to say either way. Q All right. Then you were talking about the 	2 3 4 5 6	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an
2 3 4 5 6 7	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many 	2 3 4 5 6 7 8 9	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides?
2 3 4 5 6 7 8	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat 	2 3 4 5 6 7 8	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an
2 3 4 5 6 7 8 9	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that 	2 3 4 5 6 7 8 9	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides?
2 3 4 5 6 7 8 9 10	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? 	2 3 4 5 6 7 8 9 10	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study?
2 3 4 5 6 7 8 9 10 11	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. 	2 3 4 5 6 7 8 9 10 11	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes
2 3 4 5 6 7 8 9 10 11 12	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker 	2 3 4 5 6 7 8 9 10 11 12	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence.
2 3 4 5 6 7 8 9 10 11 12 13	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically 	2 3 4 5 6 7 8 9 10 11 12 13	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who communicated with farmers, did you tell them that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. A In the abstract, no. Q (By Mr. Kennedy) And then just just 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who communicated with farmers, did you tell them that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. A In the abstract, no. Q (By Mr. Kennedy) And then just just finally, you I think you just testified that you 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who communicated with farmers, did you tell them that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. A In the abstract, no. Q (By Mr. Kennedy) And then just just finally, you I think you just testified that you would actually meet with field reps; is that correct? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who communicated with farmers, did you tell them that Chevron and ICI had never done a study to determine how long paraquat stays in the brain? Did you tell them
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 year, 30 times a year? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) You understand that? A I I don't. I don't have any reason to say either way. Q All right. Then you were talking about the difference between chronic and subacute. How many times a year does an applicator have to apply paraquat to be considered chronically exposed? What's that line? MS. REISMAN: Objection to form. Q (By Mr. Kennedy) Do you know? A No. No, I don't. Q And how many years does a paraquat worker have to apply paraquat to be considered a chronically exposed worker? Do you know where that line is? MS. REISMAN: Objection to form. Calls for expert opinion. A In the abstract, no. Q (By Mr. Kennedy) And then just just finally, you I think you just testified that you would actually meet with field reps; is that correct? A Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 much about where there were stated signs of brain involvement, did you tell them about the '66 study? MS. REISMAN: Objection to form. A No. Q (By Mr. Kennedy) Did you tell them in 1983, these field reps, knowing that they're going to be meeting with farmers and applicators, did you tell them about the 1983 Barbeau epidemiology study that found an association between Parkinson's disease and pesticides? Did you tell them about that study? MS. REISMAN: Objection to form. Assumes facts not in evidence. Q (By Mr. Kennedy) Did you tell them about that? MS. REISMAN: Objection to form. A You know, I was not meeting with them that late in the day. I can't answer for my colleagues. Q (By Mr. Kennedy) Let me ask you this. Then did you tell these field representatives who communicated with farmers, did you tell them that Chevron and ICI had never done a study to determine how long paraquat stays in the brain? Did you tell them

38 (Pages 146 to 149)

Case 3:21-md-03004-NJR Document 2407-3 Filed 09/20/22 Page 41 of 41 Page ID #2784

Richard Cavalli August 23, 2022



39 (Pages 150 to 152)